<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virus Res</journal-id><journal-id journal-id-type="iso-abbrev">Virus Res</journal-id><journal-title-group><journal-title>Virus Research</journal-title></journal-title-group><issn pub-type="ppub">0168-1702</issn><issn pub-type="epub">1872-7492</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7443330</article-id><article-id pub-id-type="publisher-id">S0168-1702(20)31048-0</article-id><article-id pub-id-type="doi">10.1016/j.virusres.2020.198141</article-id><article-id pub-id-type="publisher-id">198141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Samrat</surname><given-names>Subodh Kumar</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Tharappel</surname><given-names>Anil M.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Li</surname><given-names>Zhong</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Li</surname><given-names>Hongmin</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005"><label>a</label>Wadsworth Center, New York State Department of Health, 120 New Scotland Ave, Albany, NY 12208, USA</aff><aff id="aff0010"><label>b</label>Department of Biomedical Sciences, School of Public Health, University at Albany, 1 University Place, Rensselaer, NY 12144, USA</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Wadsworth Center, New York State Department of Health, 120 New Scotland Ave, Albany, NY 12208, USA.</corresp></author-notes><pub-date pub-type="pmc-release"><day>23</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>15</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>23</day><month>8</month><year>2020</year></pub-date><volume>288</volume><fpage>198141</fpage><lpage>198141</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>19</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">SARS-CoV-2 binds more strongly to ACE2 as compare to SARS-CoV.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">The viral Spike protein is most important target for vaccine design.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">Antibody dependent enhancement enhances the viral entry and replication in the host cell.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p id="par0020">Nanobody is alternative to avoid Antibody dependent enhancement.</p></list-item><list-item id="lsti0025"><label>&#x02022;</label><p id="par0025">Different strategies for vaccine development.</p></list-item><list-item id="lsti0030"><label>&#x02022;</label><p id="par0030">Spike protein-based vaccines.</p></list-item></list></p></abstract><abstract id="abs0010"><p>The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more strongly than SARS-CoV to the same host receptor, angiotensin-converting enzyme 2 (ACE2). Previously, several methods to develop a vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since SARS-CoV-2 uses the spike (S) protein for entry to the host cell, it is one of the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In this review, we have summarised the characteristics of the S protein, as well as the different approaches being used for the development of vaccines and/or therapeutics based on the S protein.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Therapeutic</kwd><kwd>SARS-CoV-2</kwd><kwd>Vaccine</kwd><kwd>Spike protein</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0035">In December 2019, Wuhan in the Hubei province of China became the center of an outbreak of pneumonia of unknown cause, which raised intense attention not only within China but internationally. Later, it was confirmed that the causative agent for this pneumonia-like disease is a coronavirus (CoV) belonging to the family <italic>Coronaviridae</italic> (<xref rid="bib0550" ref-type="bibr">Jiang et al., 2020a</xref>; C. <xref rid="bib0110" ref-type="bibr">C. Wang et al., 2020</xref>; <xref rid="bib0835" ref-type="bibr">Q. Wang et al., 2020</xref>; F. <xref rid="bib0285" ref-type="bibr">F. Wu et al., 2020</xref>; <xref rid="bib1165" ref-type="bibr">Y. Wu et al., 2020</xref>; <xref rid="bib1205" ref-type="bibr">Zhou et al., 2020</xref>). On February 11, 2020, the World Health Organization named the virus SARS-CoV-2 and renamed the syndrome from 2019-nCoV to COVID-19, short for coronavirus disease 2019 (&#x0201c;WHO. Novel Coronavirus(2019-nCoV) Situation Report &#x02013; 22. February 11, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/" id="intr0345">https://www.who.int/docs/default-source/coronaviruse/situation-reports/</ext-link>20,200,211<ext-link ext-link-type="uri" xlink:href="http://-sitrep-22-ncov.pdf" id="intr0350">-sitrep-22-ncov.pdf</ext-link>. Accessed May27, 2020.,&#x0201d; n.d.). COVID-19, a respiratory disease, has led to more than 22,140,472 confirmed cases and over 781,135 deaths globally as of August 19, 2020. In the USA alone, over 5,482,602 people are currently infected with SARS-CoV-2, which has caused more than 171,823 deaths (&#x0201c;Johns Hopkins University: <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html" id="intr0355">https://coronavirus.jhu.edu/map.html</ext-link>. Accessed on August 19, 2020.,&#x0201d; n.d.)</p><p id="par0040">The first coronavirus pandemic of the 21&#x02009;st century occurred in November 2002, when an infectious agent caused outbreaks of atypical pneumonia in Guangdong Province, southern China, and Southeast Asia, North America, and Europe. By the end of February 2003, the virus had spread to neighboring regions and countries. The disease caused by the virus was named severe acute respiratory syndrome (SARS), for which a global alert was issued by WHO on March 13, 2003 (<xref rid="bib0660" ref-type="bibr">Lee et al., 2003</xref>; <xref rid="bib1025" ref-type="bibr">Tsang et al., 2003</xref>; <xref rid="bib1200" ref-type="bibr">Zhong et al., 2003</xref>). SARS caused a global pandemic in 2002&#x02013;2003, with approximately 10 % (774/8098) case fatality rate (CFR) ((<xref rid="bib0550" ref-type="bibr">Jiang et al., 2020a</xref>; <xref rid="bib0660" ref-type="bibr">Lee et al., 2003</xref>). The SARS-causing coronavirus SARS-CoV has not circulated in humans since 2004.</p><p id="par0045">Another coronavirus, named MERS-CoV after the disease it causes (Middle East Respiratory Syndrome), was first reported in Saudi Arabia in 2012 and has continued to infect humans with restricted human-to-human transmission. WHO has reported a CFR of approximately 34.4 % (858/2494) in 27 countries for MERS-CoV (&#x0201c;WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). August 2, 2019. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intr0360">https://www.who.int/emergencies/mers-cov/en/</ext-link>. Accessed on May 27, 2020.,&#x0201d; n.d.).</p><p id="par0050">The coronavirus was first identified as a cause of the common cold in 1960 (<xref rid="bib0030" ref-type="bibr">Al-Osail and Al-Wazzah, 2017</xref>). Coronaviruses belong to the subfamily <italic>Coronavirinae</italic> in the family <italic>Coronaviridae</italic> and the order <italic>Nidovirales</italic> (International Committee on Taxonomy of Viruses). Based on phylogenetic and genome structure, this subfamily is further divided into four genera <italic>Alphacoronavirus</italic>, <italic>Betacoronavirus</italic>, <italic>Gammacoronavirus</italic>, and <italic>Deltacoronavirus</italic> (de Wilde et al., 2018). Alphacoronaviruses and betacoronaviruses usually cause respiratory illness in humans and gastroenteritis in animals. These two families include seven strains of human CoVs. The four viruses HCoV-NL63, HCoV-229E, HCoV&#x02212;OC43, and HKU1 induce only mild upper respiratory diseases in immunocompetent hosts; however, some of them may cause severe complications in infants, young children and older people (<xref rid="bib0190" ref-type="bibr">Cui et al., 2019</xref>; <xref rid="bib0950" ref-type="bibr">Su et al., 2016</xref>). The other three highly pathogenic viruses, SARS-CoV, MERS-CoV, and SARS-CoV-2, cause severe respiratory syndrome, pneumonia, bronchiolitis, rhinitis, pharyngitis, sinusitis, and other systemic symptoms such as occasional watery diarrhea in humans of all ages. Based on current sequence databases, all human coronaviruses have animal origins. Five of them, SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-NL63, and HCoV-229E, originated from a bat, and the remaining two, HCoV&#x02212;OC43 and HKU1, originated in rodents(<xref rid="bib0825" ref-type="bibr">Paules et al., 2020</xref>; <xref rid="bib0950" ref-type="bibr">Su et al., 2016</xref>).</p><p id="par0055">The coronavirus genome is a single-stranded RNA of about 30 Kb, the largest among the RNA viruses (<xref rid="bib0755" ref-type="bibr">Masters, 2006</xref>). Coronaviruses usually infect their hosts in a species&#x02010;specific manner, resulting in acute or persistent infections. The RNA genome contains a 5&#x02032; cap and 3&#x02032; poly-A tail, making it suitable for direct translation into a large size polyprotein. Structural protein occupies 10&#x02009;kb of the genome, whereas non-structural protein occupies two-third of the genome. The virus has a spherical shape with a diameter of approximately 125&#x02009;nm. The most striking feature of the coronavirus is the club-shaped spike protein projecting from the virion surface. These spike proteins serve as attachment proteins for the virus to enter host cells (<xref rid="bib0300" ref-type="bibr">Fehr and Perlman, 2015</xref>; <xref rid="bib0790" ref-type="bibr">Neuman et al., 2006</xref>).</p><p id="par0060">The viral genome of the coronavirus encodes four structural proteins named spike (S), envelope (E), membrane (M), and nucleocapsid (N), 16 non-structural proteins (nsp1&#x02013;16), and 8 accessory proteins (<xref rid="bib0555" ref-type="bibr">Jiang et al., 2020b</xref>; <xref rid="bib0940" ref-type="bibr">Siu et al., 2008</xref>). The S protein plays the most critical role in viral attachment, fusion, and entry into the target cell (D. E. <xref rid="bib0120" ref-type="bibr">C.J. Gordon et al., 2020</xref>;<xref rid="bib0200" ref-type="bibr">D.E. Gordon et al., 2020</xref>; <xref rid="bib0555" ref-type="bibr">Jiang et al., 2020b</xref>, <xref rid="bib0555" ref-type="bibr">2020b</xref>)). It is a trimeric class I fusion protein that exists in a metastable prefusion conformation following translation. A substantial structural rearrangement of the S protein is required to fuse the viral membrane with the host cell membrane (<xref rid="bib0100" ref-type="bibr">Bosch et al., 2003</xref>; <xref rid="bib0485" ref-type="bibr">Hulswit et al., 2016</xref>). The size of the densely glycosylated S protein ranges between CoV species from approximately 1100&#x02013;1600 amino acids length, with an estimated molecular mass of up to 220&#x02009;kDa (<xref rid="bib0485" ref-type="bibr">Hulswit et al., 2016</xref>; <xref rid="bib0675" ref-type="bibr">Li, 2016</xref>). CoV particles are decorated with the club-shaped trimers of the S protein, which is 8&#x02013;23-nm long (<xref rid="bib0455" ref-type="bibr">Hofmann et al., 2004</xref>). The S protein not only determines the host tropism but also is the crucial target for neutralizing antibodies produced by the immune system of the infected host (<xref rid="bib0455" ref-type="bibr">Hofmann et al., 2004</xref>; <xref rid="bib1095" ref-type="bibr">Walls et al., 2020</xref>).</p><p id="par0065">The S protein is divided into S1 and S2 subunits. The S1 subunit contains two domains termed the N-terminal domain (NTD) and the C-terminal domain (CTD). The receptor-binding domain (RBD) is in the CTD. The S2 subunit contains the necessary elements required for membrane fusion, including an internal membrane fusion peptide (FP), two 7-peptide repeats (HR), a membrane-proximal external region (MPER), and a transmembrane domain (TM) (<xref rid="bib0675" ref-type="bibr">Li, 2016</xref>). The S1 and S2 subunits are separated by a cleavage site that is recognized by host proteases and undergoes proteolytic cleavage (<xref rid="bib0450" ref-type="bibr">Hoffmann et al., 2020</xref>; <xref rid="bib0680" ref-type="bibr">Li et al., 2003</xref>; <xref rid="bib1155" ref-type="bibr">Wrapp et al., 2020b</xref>). The S protein is primed by cellular protease TMPRSS2 (<xref rid="bib0365" ref-type="bibr">Glowacka et al., 2011</xref>; <xref rid="bib0760" ref-type="bibr">Matsuyama et al., 2010</xref>; <xref rid="bib0765" ref-type="bibr">Meng et al., 2020</xref>; <xref rid="bib0935" ref-type="bibr">Shulla et al., 2011</xref>), which cleaves the S protein at the S1/S2 and S2&#x02032; sites, leading to conformational changes of the S2 unit to allow fusion between the virus and host cell membranes to release viral RNA into the cytoplasm (<xref rid="bib0450" ref-type="bibr">Hoffmann et al., 2020</xref>; <xref rid="bib0765" ref-type="bibr">Meng et al., 2020</xref>). The S protein is also an excellent target for the development of therapeutic entry inhibitors, vaccines, and therapeutic antibodies (<xref rid="bib0035" ref-type="bibr">Amanat and Krammer, 2020</xref>; &#x0201c;<xref rid="bib0040" ref-type="bibr">An updated guide to the coronavirus drugs and vaccines in development,&#x0201d; 2020</xref>; <xref rid="bib0235" ref-type="bibr">Du et al., 2009a</xref>; <xref rid="bib0595" ref-type="bibr">Kim et al., 2020</xref>; <xref rid="bib1195" ref-type="bibr">Zhao et al., 2018</xref>).</p><p id="par0070">The S proteins of different coronaviruses are so unique that some phylogenetically similar spike proteins bind to different receptors. In contrast, some phylogenetically different spike proteins can bind to a similar receptor (<xref rid="bib0670" ref-type="bibr">Li, 2015</xref>). MERS-CoV requires dipeptidyl peptidase 4 (DPP4) as its receptor (<xref rid="bib0680" ref-type="bibr">Li et al., 2003</xref>; <xref rid="bib0840" ref-type="bibr">Raj et al., 2013</xref>). Murine hepatitis virus (MHV), a &#x003b2;-coronavirus, uses carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) for entry (<xref rid="bib0255" ref-type="bibr">Dveksler et al., 1991</xref>; <xref rid="bib1145" ref-type="bibr">Williams et al., 1991</xref>). A few coronaviruses, including bovine coronavirus, recognize sugar for attachment and entry (<xref rid="bib0905" ref-type="bibr">Schultze et al., 1991</xref>). Some CoVs, including porcine respiratory coronavirus (PRCV), require recognition of aminopeptidase N (APN) (<xref rid="bib0370" ref-type="bibr">Godet et al., 1994</xref>), whereas transmissible gastroenteritis virus (TGEV) requires recognition of APN in addition to sugar for virus entry (<xref rid="bib0215" ref-type="bibr">Delmas et al., 1992</xref>; <xref rid="bib0620" ref-type="bibr">Krempl et al., 1997</xref>). The human angiotensin-converting enzyme 2 (ACE2) is the common receptor for SARS-CoV, SARS-CoV-2, and NL63, although the NL63 RBD has a structure significantly different from those of SARS-CoV and CoV-2 (<xref rid="bib0460" ref-type="bibr">Hofmann et al., 2005</xref>, p. 63; <xref rid="bib0665" ref-type="bibr">Letko et al., 2020</xref>; <xref rid="bib0680" ref-type="bibr">Li et al., 2003</xref>, p. 2; <xref rid="bib0700" ref-type="bibr">Lin et al., 2008</xref>; <xref rid="bib0970" ref-type="bibr">Tai et al., 2020</xref>). It has been shown that the receptor-binding domain of SARS-CoV-2 binds more strongly to the ACE2 receptor than that of SARS-CoV, making it a more suitable target for the development of virus attachment inhibitors, neutralizing antibodies, and vaccines (<xref rid="bib0970" ref-type="bibr">Tai et al., 2020</xref>; Q. <xref rid="bib0110" ref-type="bibr">C. Wang et al., 2020</xref>; <xref rid="bib0835" ref-type="bibr">Q. Wang et al., 2020</xref>). Strong binding of SARS-CoV-2 RBD to the ACE2 receptor is also a key reason for the higher infection rate in SARS-CoV-2 as compared to SARS-CoV and MERS-CoV ((<xref rid="bib0970" ref-type="bibr">Tai et al., 2020</xref>; <xref rid="bib1150" ref-type="bibr">Wrapp et al., 2020a</xref>) However, a recent paper by Shang and colleagues suggests that the full-length spike protein of SARS-CoV-2 has similar or lower affinity to hACE2 than SARS-CoV. This suggests that SARS-CoV-2 RBD is less exposed than SARS-CoV-RBD, and it is also less dependent on target cell protease since it is preactivated by proprotein convertase furin (<xref rid="bib0920" ref-type="bibr">Shang et al., 2020</xref>).</p></sec><sec id="sec0010"><label>2</label><title>SARS-CoV-2 and the S protein as a potential vaccine target</title><p id="par0075">The recent outbreak of SARS-CoV-2 is much more challenging to control because of its long incubation period. Recent studies have shown that the incubation time could range from 2 to 14 days with the median incubation period of 6.4 days (<xref rid="bib0055" ref-type="bibr">Backer et al., 2020</xref>; <xref rid="bib0645" ref-type="bibr">Lauer et al., 2020</xref>; <xref rid="bib0705" ref-type="bibr">Linton et al., 2020</xref>). It is estimated that only around 101 of every 10,000 people who contract SARS-CoV-2 are likely to develop symptoms after 14 days (<xref rid="bib0645" ref-type="bibr">Lauer et al., 2020</xref>). Therefore, most regulatory agencies suggest quarantine for at least 14 days. Some virus-carrying individuals do not develop any disease symptoms, but they can transmit the virus. One investigation in China suggested that the R0 of SARS-CoV-2 was as high as 4.7&#x02013;6.6 before any infection control measures were applied (<xref rid="bib0880" ref-type="bibr">Sanche et al., 2020</xref>), suggesting that SARS-CoV-2 is highly contagious and more infectious than previously estimated. These findings are also supported by the fact that the SARS-CoV-2-RBD demonstrates 10&#x02013;20 fold higher affinity to the human ACE2 receptor than SARS-CoV (<xref rid="bib0970" ref-type="bibr">Tai et al., 2020</xref>; <xref rid="bib1150" ref-type="bibr">Wrapp et al., 2020a</xref>).</p><p id="par0080">To date, there is no approved drug for treatment of COVID-19, but an experimental antiviral drug with a known safety profile is currently being used for treatment of COVID-19 patients. It has been shown that the nucleotide analog Remdesivir can inhibit SARS-CoV and MERS-CoV in tissue culture and nonhuman animal models (<xref rid="bib0750" ref-type="bibr">Martinez, 2020</xref>). A clinical trial of Remdesivir is underway for treatment of Ebola virus infection. Recently clinical trials for Remdesivir have been started for SARS-CoV-2 as well (<xref rid="bib0125" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="bib0355" ref-type="bibr">George Sakoulas, 2020</xref>; C. J. <xref rid="bib0120" ref-type="bibr">C.J. Gordon et al., 2020</xref>; <xref rid="bib0200" ref-type="bibr">D.E. Gordon et al., 2020</xref>). Despite much research and effort, there is no vaccine available for SARS-CoV-2 or any other coronaviruses. The diversity of the S-protein also renders any vaccines and nAbs unlikely to be cross-protective between existing and emerging CoVs.</p></sec><sec id="sec0015"><label>3</label><title>Structure of the SARS-CoV-2 spike protein RBD bound with ACE2</title><p id="par0085">The role of the S protein in binding with host receptors makes it a perfect target for vaccine and antiviral therapeutic development. Previous studies on SARS-CoV and MESR-CoV have revealed that vaccines based on the S protein can induce antibodies to block virus binding and fusion or neutralize virus infection ((<xref rid="bib0235" ref-type="bibr">Du et al., 2009a</xref>). Since the S protein plays a role in both virus entry and viral RNA release into the cytoplasm, a vaccine against the S protein should induce antibodies to block viral entry (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>
). Previous reports suggest that immunization of mice with a trimeric form of MERS-CoV S protein RBD domain elicits potent neutralizing antibodies against MERS CoV (<xref rid="bib0175" ref-type="bibr">Coleman et al., 2017</xref>; <xref rid="bib0245" ref-type="bibr">Du et al., 2013</xref>; <xref rid="bib0785" ref-type="bibr">Mou et al., 2013</xref>; <xref rid="bib0965" ref-type="bibr">Tai et al., 2016</xref>);. Other studies show that immunization of rabbits with an RBD-Fc fusion protein elicits robust antibody responses, and the antisera can completely block SARS-CoV infection at different serum dilution (<xref rid="bib0145" ref-type="bibr">Chen et al., 2014</xref>; <xref rid="bib0170" ref-type="bibr">Coleman et al., 2014</xref>; <xref rid="bib0240" ref-type="bibr">Du et al., 2009b</xref>; <xref rid="bib0440" ref-type="bibr">He et al., 2004</xref>). Another study showed that immunization of mice with the S1 subunit of MERS-CoV actively induces neutralizing antibody production. Using the same strategy, the S1 subunit of SARS-CoV-2 can also induce S1-specific IgG in mice. However, further studies are required to verify the potency of the antibodies (<xref rid="bib0595" ref-type="bibr">Kim et al., 2020</xref>). Also, development of a vaccine targeting the S protein is always challenging, as a vaccine based on neutralizing antibodies may lead to antibody-dependent enhancement of secondary virus infection and vaccine-enhanced disease.<fig id="fig0005"><label>Fig. 1</label><caption><p><bold>Structure of SARS-CoV-2 Spike protein RBD bound with ACE2A</bold>. Schematic representation of SARS-CoV-2 Spike protein. Linear representation of the SARS-CoV-2 spike monomer. Its S1 subunit contains the N-terminal domain (NTD; 14&#x02013;305 aa), receptor binding domain (RBD; 319&#x02013;541 aa), and receptor binding motif (RBM; 437&#x02013;508 aa). Its S2 subunit contains fusion peptide (FP; 788&#x02013;806 aa), heptad repeat 1 (HR1;12&#x02013;984 aa), heptad repeat 2 (HR2;1163&#x02013;1213 aa), transmembrane domain (TM;1214&#x02013;1237 aa), and cytoplasmic domain (CP; 1238&#x02013;1273). The predicted glycosylation sites are indicated above the domain bars. <bold>B</bold>. Overall structure of the SARS-CoV-2 RBD bound to ACE2. ACE2 is shown in lime green. The SARS-CoV-2 RBD core is shown in purple and RBM in tint colour. The N-terminal helix of ACE2 responsible for binding is labelled (<xref rid="bib0640" ref-type="bibr">Lan et al., 2020</xref>).</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="sec0020"><label>4</label><title>Antibody-dependent enhancement</title><p id="par0090">It has been observed that COVID-19 pandemic intensity is different among regions. A country or region suffering the most may have been primed by exposure to one or more coronaviruses and encountered the effects of antibody-dependent enhancement (ADE) due to antigenic epitope heterogeneity (<xref rid="bib1005" ref-type="bibr">Tetro, 2020</xref>). ADE is a phenomenon in which pre-existing non- or poorly neutralizing antibodies enhance the viral entry and replication in the host cell. ADE is more common in flaviviruses, especially in the dengue virus, which has four serotypes. It has been shown that when patients are infected with dengue virus for first time, specific neutralizing antibodies are produced. However, if they are later infected with a different serotype of dengue virus, the pre-existing antibodies from the previous infection do not have enough potency to neutralize the new virus, even though they can bind with the virus. These partially neutralizing antibodies help the virus to enter cells via an Fc-receptor (FcR)-mediated mechanism in addition to their natural entry route (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>
A). The antibody-bound viruses bind via the antibody Fc-domain to FcR expressed on the surface of several immune cells, leading to enhancement of the virus entry and replication (<xref rid="bib0575" ref-type="bibr">Katzelnick et al., 2017</xref>; <xref rid="bib0585" ref-type="bibr">Khandia et al., 2018</xref>). ADE has also been reported in other viruses like HIV, Ebola, HCV, and Zika ((<xref rid="bib0375" ref-type="bibr">Gorlani and Forthal, 2013</xref>; <xref rid="bib0770" ref-type="bibr">Meyer et al., 2008</xref>; <xref rid="bib0975" ref-type="bibr">Takada et al., 2001</xref>; <xref rid="bib1140" ref-type="bibr">Willey et al., 2011</xref>). Vaccine-induced enhancement was first reported during the vaccine trial of RSV in 1969. In this trial, the administration of the formalin-inactivated vaccine RSV (FI-RSV) to na&#x000ef;ve infants resulted in a much higher incidence rate of severe illness. It led to increased hospitalization in 80 % among vaccinated infants, compared to only 5% of the non-immunized infants (<xref rid="bib0590" ref-type="bibr">Kim et al., 1969</xref>). Unfortunately, two vaccinated infants also died because of enhanced RSV infections (<xref rid="bib0590" ref-type="bibr">Kim et al., 1969</xref>).<fig id="fig0010"><label>Fig. 2</label><caption><p><bold>Schematic representation of antibody-dependent enhancement and protection through nanobodies</bold>. <bold>A</bold>. Virus particles are detected by heterotypic antibodies from previous infection. This complex then binds to the Fc&#x003b3; receptor on the surface of immune cells and is internalized. Further virus replication leads to an increased viral load. <bold>B</bold>. The nanobody lacks an Fc portion and is unable to bind to the Fc&#x003b3; receptor, which protects the cell from antibody-dependent enhancement (created with BioRender.com).</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="par0095">ADE has also been reported in SARS-CoV and MERS-CoV. It has been shown that anti-spike sera, which can neutralize SARS-CoV pseudo viral particles, can initiate virus entry in cells that do not express the ACE2 receptor for SARS-CoV. ADE is based on the expression of FcR on cells (<xref rid="bib0535" ref-type="bibr">Jaume et al., 2011</xref>; <xref rid="bib1110" ref-type="bibr">Wang et al., 2014</xref>). Another report suggests that ADE occurs through FcR in macrophages, but there are no changes in gene profiling, and virus replication has been shown to be abortive (<xref rid="bib1175" ref-type="bibr">Yip et al., 2016</xref>). A recent study has shown that MERS-CoV RBD-specific MAb and the SARS-CoV RBD-specific MAb can mediate the entry of their respective coronaviruses into FcR-expressing human cells. This study also suggests that a fully neutralizing antibody can also mediate ADE by functionally mimicking viral receptors from host cells (<xref rid="bib1105" ref-type="bibr">Wan et al., 2019</xref>). It has also been shown that passive transfer of anti-S IgG or serum from previously infected animals caused more severe lung injury in animal models (<xref rid="bib0720" ref-type="bibr">Liu et al., 2019a</xref>,<xref rid="bib0725" ref-type="bibr">b</xref>).</p><p id="par0100">There are huge theoretical concerns of vaccine-induced ADE which can occur in several scenarios. It is possible that vaccine-induced antibodies against SARS-CoV-2 may bind to the virus without neutralizing it. Currently mutations on the viral Spike protein have been found in circulating clinical SARS-CoV-2 strains (<xref rid="bib0615" ref-type="bibr">Korber et al., 2020</xref>; <xref rid="bib0735" ref-type="bibr">Lu et al., 2020</xref>). If this happen, the non-neutralizing antibodies could produce ADE effect and enhance the viral entry into cells (<xref rid="bib0340" ref-type="bibr">Garber, 2020</xref>; <xref rid="bib0520" ref-type="bibr">Iwasaki and Yang, 2020</xref>; <xref rid="bib1005" ref-type="bibr">Tetro, 2020</xref>; <xref rid="bib1035" ref-type="bibr">Ulrich et al., 2020</xref>). In addition, significant sequence variations between the spike proteins of SARS-CoV and SARS-CoV-2 may cause ADE (<xref rid="bib1005" ref-type="bibr">Tetro, 2020</xref>). Moreover, it is also possible that a future SARS-related (SARSr)-CoV causes ADE in patients vaccinated with SARS-CoV-2, if the future SARSr-CoV shows significant sequence variations from SARS-CoV-2. Furthermore, insufficient concentration of neutralizing Ab may also cause ADE (<xref rid="bib0860" ref-type="bibr">Renner et al., 2018</xref>; <xref rid="bib1105" ref-type="bibr">Wan et al., 2019</xref>). Given the fact that neutralizing antibodies declined rapidly in some of COVID-19 patients (<xref rid="bib0730" ref-type="bibr">Long et al., 2020</xref>; <xref rid="bib0915" ref-type="bibr">Seow et al., 2020</xref>), this latter scenario is more troublesome. Nevertheless, based on the knowledge from research on SARS-CoV, several vaccine trials are ongoing for SARS-CoV-2.</p></sec><sec id="sec0025"><label>5</label><title>Use of nanobodies against coronaviruses</title><p id="par0105">Soon after the discovery of the nanobody in the camelid family by C. Hamers-Casterman and colleagues in 1993 (<xref rid="bib0410" ref-type="bibr">Hamers-Casterman et al., 1993</xref>), it became a potent tool as a neutralizing antibody. Several nanobodies have been screened and validated for binding against different targets ranging from human melanoma cells to viruses. A nanobody against human melanoma cells targeting endothelin receptor type B has been recently identified, which will be helpful in the future to treat human melanoma (<xref rid="bib0545" ref-type="bibr">Ji et al., 2020</xref>). Besides, several nanobodies have been identified to block the ligand-receptor binding for primary immune cells. For example, nanobodies inhibiting PD1-PDL1 interaction, LIN28:let-7 interaction, and T cell marker CD3 are all promising candidates for targeting and activating cytotoxic T lymphocytes (CTLs) to induce anti-tumor responses. GRP78, CD38, and GPC3 expression on cancer cells have also been targeted for nanobody expression and purification, which provide useful cancer cell markers and potential therapeutic markers (<xref rid="bib0015" ref-type="bibr">Aghamollaei et al., 2020</xref>, p. 78; <xref rid="bib0405" ref-type="bibr">Hambach et al., 2020</xref>; <xref rid="bib0695" ref-type="bibr">Li et al., 2020</xref>; <xref rid="bib0780" ref-type="bibr">Moradi-Kalbolandi et al., 2020</xref>; L. <xref rid="bib0625" ref-type="bibr">L. Xia et al., 2020</xref>; <xref rid="bib0865" ref-type="bibr">S. Xia et al., 2020</xref>; C. <xref rid="bib0525" ref-type="bibr">J. Yu et al., 2020</xref>;<xref rid="bib0115" ref-type="bibr">C. Yu et al., 2020</xref>).</p><p id="par0110">One drawback of use of nanobody is the absence of antibody-dependent cellular cytotoxicity (ADCC). Since nanobody lacks the Fc portion so it is unable to bind to immune cells to provide ADCC effect. It has been shown that non protective antibodies help in protection from HIV (<xref rid="bib0315" ref-type="bibr">Forthal et al., 2001</xref>; <xref rid="bib0435" ref-type="bibr">Haynes et al., 2012</xref>), herpes simplex virus (<xref rid="bib0610" ref-type="bibr">Kohl et al., 2000</xref>; <xref rid="bib0605" ref-type="bibr">Kohl and Loo, 1982</xref>, <xref rid="bib0605" ref-type="bibr">1982</xref>), Ebola virus (<xref rid="bib0400" ref-type="bibr">Gunn et al., 2018</xref>; <xref rid="bib0890" ref-type="bibr">Saphire et al., 2018</xref>), and influenza virus (<xref rid="bib0380" ref-type="bibr">Greenberg et al., 1977</xref>; <xref rid="bib0540" ref-type="bibr">Jegaskanda et al., 2014</xref>), and SARS-CoV (<xref rid="bib1170" ref-type="bibr">Yasui et al., 2014</xref>) by mechanism of ADCC. Therefore, the use of nanobody has both benefits and drawbacks. Nanobody provides protection against ADE, however, it lacks ADCC. It is very important to balance the adverse effect of ADE and beneficial effect of ADCC. To this end, it is important to note that nanobody can be easily engineered to add different effector function such as Fc regions, toxins, liposomes, and other ligand binding scaffolds (<xref rid="bib0430" ref-type="bibr">Harmsen et al., 2005</xref>; <xref rid="bib0650" ref-type="bibr">Laursen et al., 2018</xref>; <xref rid="bib0900" ref-type="bibr">Schriewer et al., 2020</xref>). Recently, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved a bivalent nanobody, caplacizumab, for treatment of patients with thrombotic thrombocytopenic purpura (<xref rid="bib0420" ref-type="bibr">Hanlon and Metjian, 2020</xref>; <xref rid="bib0910" ref-type="bibr">Scully et al., 2019</xref>).</p><p id="par0115">Several nanobodies have been reported to act as potential therapeutic agents against different viruses. Nanobodies against viruses work on the principle of inhibiting the ligand-receptor interaction (<xref rid="fig0010" ref-type="fig">Fig. 2</xref> A&#x00026;B). A nanobody against HCV has been reported which blocks the E2-CD81 interaction and stops the virus-cell to cell transmission (<xref rid="bib0990" ref-type="bibr">Tarr et al., 2013</xref>). A replication-inhibiting nanobody against porcine reproductive and respiratory syndrome virus (PRRSV), which is a significant threat to the swine industry, has been identified and provides a novel antiviral drug for inhibition of PRRSV replication and controlling PRRSV disease (<xref rid="bib0250" ref-type="bibr">Duan et al., 2020</xref>; <xref rid="bib1120" ref-type="bibr">Wang et al., 2019</xref>). Another intracellular antibody directed towards human papillomavirus (HPV) oncoprotein E7 has shown great potential for therapy of HPV16-associated disease (<xref rid="bib0690" ref-type="bibr">Li et al., 2019</xref>). Nanobodies have also exhibited good antiviral effects against bovine viral diarrhea virus (<xref rid="bib0685" ref-type="bibr">Li et al., 2017</xref>).</p><p id="par0120">Only limited studies have been performed on nanobodies against coronaviruses. A few groups investigated nanobody activity against the MERS-CoV S protein and successfully found nanobodies that could neutralize MERS-CoV in pseudo-viral particles and in a mouse model (<xref rid="bib0845" ref-type="bibr">Raj et al., 2018</xref>; <xref rid="bib1195" ref-type="bibr">Zhao et al., 2018</xref>). Recently, nanobodies against SARS-CoV have also been identified which have shown cross-neutralization activity, and therefore have excellent therapeutic potential against the SARS-CoV-2 virus (<xref rid="bib1150" ref-type="bibr">Wrapp et al., 2020a</xref>). Several other nanobodies have been identified recently that act against the SARS-CoV-2 receptor-binding domain (<xref rid="bib0155" ref-type="bibr">Chi et al., 2020</xref>; <xref rid="bib1100" ref-type="bibr">Walter et al., 2020</xref>; Y. <xref rid="bib0285" ref-type="bibr">F. Wu et al., 2020</xref>; <xref rid="bib1165" ref-type="bibr">Y. Wu et al., 2020</xref>).</p></sec><sec id="sec0030"><label>6</label><title>Different vaccine strategies using the S protein against SARS-CoV-2</title><p id="par0125">Protein-based subunit vaccines are probably one of the safest formats of vaccine, but immune responses generated with this kind of vaccine are heavily dependent on the adjuvant used. The S protein in different form including full-length S Protein, S1 RBD, RBD-Fc, and N-terminal, have shown nAb responses and protection in multiple animal models and nonhuman primates (<xref rid="bib0220" ref-type="bibr">Deng et al., 2018</xref>; <xref rid="bib0635" ref-type="bibr">Lan et al., 2015</xref>; <xref rid="bib1030" ref-type="bibr">Tse et al., 2020</xref>; <xref rid="bib1115" ref-type="bibr">Wang et al., 2017</xref>; <xref rid="bib1185" ref-type="bibr">Zhang et al., 2016</xref>).</p></sec><sec id="sec0035"><label>7</label><title>DNA vaccines</title><p id="par0130">DNA vaccines are composed of plasmid DNA molecules encoding one or more immunogens. A DNA vaccine is better than an mRNA vaccine in terms of the formulation required for its stability and ease of delivery. However, there is a risk that integration of the vaccine into the host genome may create mutations(<xref rid="bib0655" ref-type="bibr">Ledwith et al., 2000</xref>; <xref rid="bib0710" ref-type="bibr">Liu, 2019</xref>). Passive transfer of sera from mice immunized with DNA encoding the MERS-CoV S domain has been shown to protect na&#x000ef;ve mice from MERS-CoV infection (<xref rid="bib0150" ref-type="bibr">Chi et al., 2017</xref>). Other research showed that the DNA encoding the S1 domain is superior to that with full length S protein in eliciting antibody and Th1/Th2 responses. Both DNAs encoding the S1 and S proteins were shown to induce cross-neutralizing Abs against multiple strains of MERS-CoV from human and camel origins (<xref rid="bib0025" ref-type="bibr">Al-amri et al., 2017</xref>). Another study showed that sera from mice immunized with S protein-encoding DNA detects SARS-CoV S protein (<xref rid="bib1190" ref-type="bibr">Zhao et al., 2004</xref>). Mice immunized with S protein-encoding DNA and booted with CD4+ and CD8&#x02009;+&#x02009;T cell-specific peptides improves the expression of several cytokines (<xref rid="bib0475" ref-type="bibr">Huang et al., 2007</xref>). Another report shows that DNA encoding the S protein from SARS-CoV elicits neutralizing antibodies, as measured by a Pseudotyped lentiviral vector reporter neutralization assay and S protein-specific CD4+ and CD8&#x02009;+&#x02009;T-cell responses in all immunized volunteer (<xref rid="bib0745" ref-type="bibr">Martin et al., 2008</xref>). Recently, Yu and colleagues reported that DNA vaccine encoding the SARS-CoV-2 S protein can protect rhesus macaques after challenge with SARS-CoV-2 (J. <xref rid="bib0525" ref-type="bibr">J. Yu et al., 2020</xref>; <xref rid="bib0115" ref-type="bibr">C. Yu et al., 2020</xref>). Currently, two SARS-CoV-2 DNA vaccines are under development. Inovio Pharmaceuticals developed a DNA vaccine NCT043364, which is undergoing Phase 1 clinical trial. Several other companies are involved in the development of DNA vaccines, which is mentioned S protein-based DNA vaccine (<xref rid="tbl0005" ref-type="table">Table 1</xref>
).<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>S protein-based DNA vaccines.</p></caption><alt-text id="at0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Manufacturer</th><th align="left">Strategy</th><th align="left">Vaccine Name/Stage</th><th align="left">Ref</th></tr></thead><tbody><tr><td align="left">Inovio Pharmaceuticals/International Vaccine Institute</td><td align="left">DNA plasmid vaccine injected by intradermal (ID) injection followed by electroporation (EP) using a CELLECTRA&#x000ae; 2000 device in healthy adult volunteers</td><td align="left">INO-4800/<break/>Phase 1/2<break/>NCT04336410<break/>NCT04447781</td><td align="left">(&#x0201c;Inovio Pharmaceuticals/International Vaccine Institute. <ext-link ext-link-type="uri" xlink:href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-and-IVI-Partner-with-Seoul-National-University-Hospital-to-Start-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-INO-4800-in-South-Korea/default.aspx" id="intr0005">http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-and-IVI-Partner-with-Seoul-National-University-Hospital-to-Start-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-INO-4800-in-South-Korea/default.aspx</ext-link>. Accessed July 29, 2020,&#x0201d; n.d.)</td></tr><tr><td align="left">Osaka University/AnGes/Takara Bio</td><td align="left">DNA plasmid vaccine&#x02009;+&#x02009;adjuvant</td><td align="left">Phase 1/2<break/>NCT04463472</td><td align="left">(&#x0201c;Osaka University/AnGes/Takara Bio. <ext-link ext-link-type="uri" xlink:href="https://www.takarabio.com/about/bioview-blog/current-events/dethroning-king-coronavirus-with-novel-vaccines" id="intr0010">https://www.takarabio.com/about/bioview-blog/current-events/dethroning-king-coronavirus-with-novel-vaccines</ext-link>. Accessed July 29, 2020,&#x0201d; n.d.)</td></tr><tr><td align="left">Karolinska Institute / Cobra Biologics (OPENCORONA Project)</td><td align="left">DNA vaccine delivered to patient&#x02019;s muscle by electroporation to generate a viral antigen on which the immune system then reacts</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Cobra Biologics. Cobra Biologics and the Karolinska Institute collaborate to develop COVID-19 vaccine. 30th Mar 2020. <ext-link ext-link-type="uri" xlink:href="https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine" id="intr0015">https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine</ext-link>. Accessed May 21, 2020,&#x0201d; n.d.)</td></tr><tr><td align="left">Takis/Applied DNA Sciences/Evvivax</td><td align="left">DNA vaccine candidates created using the structure of the S protein</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Takis. Takis, a biotech company in Castel Romano, Rome, announces that it is ready to test its Covid-19 vaccine on pre-clinical models. 17 March 2020. <ext-link ext-link-type="uri" xlink:href="http://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-announces-that-it-is-ready-to-test-its-covid-19-vaccine-on-pre-clinical-models" id="intr0020">http://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-announces-that-it-is-ready-to-test-its-covid-19-vaccine-on-pre-clinical-models</ext-link>. Accessed on May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet, Inc.</td><td align="left">Plasmid DNA delivered via PharmaJet&#x02019;s Tropis Needle-free Injection System, which precisely targets delivery of vaccine to the intradermal tissue depth</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Pharmajet: Pharmajet partner with ITI and EpiVax to develop and deliver COVID-10 Vaccine. April 15, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.immunomix.com/pharmajet-partners-with-iti-and-epivax-to-develop-and-deliver-covid-19-vaccine/" id="intr0025">https://www.immunomix.com/pharmajet-partners-with-iti-and-epivax-to-develop-and-deliver-covid-19-vaccine/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Zydus Cadila</td><td align="left">DNA plasmid vaccine against the major viral membrane protein responsible for the cell entry of the novel coronavirus</td><td align="left">Phase 1/2<break/>CTRI/2020/07/026,352</td><td align="left">(&#x0201c;Zydus Cadila. Zydus Cadila accelerates COVID-19 vaccine research. 8 April 2020 <ext-link ext-link-type="uri" xlink:href="https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research" id="intr0030">https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research</ext-link>. Accessed on May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Genexine Consortium</td><td align="left">DNA VVaccine (GX-19)</td><td align="left">Phase 1/2<break/>NCT04445389</td><td align="left">(&#x0201c;Genexine Consortium. <ext-link ext-link-type="uri" xlink:href="https://pharmashots.com/press-releases/korean-biotech-firm-genexines-covid-19-deoxyribonucleic-acid-vaccine-pipeline-gx-19-is-ready-for-clinical-testing-as-soon-as-it-applies-to-the-drug-ministry-for-human-testing/" id="intr0035">https://pharmashots.com/press-releases/korean-biotech-firm-genexines-covid-19-deoxyribonucleic-acid-vaccine-pipeline-gx-19-is-ready-for-clinical-testing-as-soon-as-it-applies-to-the-drug-ministry-for-human-testing/</ext-link>. Accessed July 29, 2020,&#x0201d; n.d.)</td></tr><tr><td align="left">BioNet Asia</td><td align="left">GENE-based vaccine (COVIGEN) encoding the SARS-CoV-2 S protein</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;BioNet. BioNet in Thailand is developing a COVID-19 GENE-based vaccine (COVIGEN) encoding the S (Spike) protein of SARS-CoV-2. <ext-link ext-link-type="uri" xlink:href="http://www.bionet-asia.com/media/news-events/" id="intr0040">http://www.bionet-asia.com/media/news-events/</ext-link>. Accessed on May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">University of Waterloo</td><td align="left">DNA vaccine using a bacteriophage-based approach allowing it to replicate within bacteria already present in the body, delivering the vaccine to cells in targeted tissues and triggering production of a virus-like particle (VLP) that will induce an immune response</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;University of Waterloo. University of Waterloo developing DNA-based COVID-19 vaccine. April 16, 2020. <ext-link ext-link-type="uri" xlink:href="https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine" id="intr0045">https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Symvivo Corporation</td><td align="left">bacTRL-Spike contains different concentrations of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2</td><td align="left">bacTRL-Spike/<break/>Phase 1 (NCT04334980)<break/></td><td align="left">(&#x0201c;Symvivo Corporation. Evaluating the Safety, Tolerability, and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. April 6, 2020. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04334980" id="intr0050">https://clinicaltrials.gov/ct2/show/NCT04334980</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0040"><label>8</label><title>Viral vector-based vaccines</title><p id="par0135">Viral vector-based vaccines depend on the delivery of one or more antigens encoded by a modified viral vector. This technique has several advantages over other techniques in use. This technology uses replicating or non-replicating vectors. Upon delivery, antigens are expressed in the host cells, and host cells generate both humoral and cell-based immune responses against the targeted pathogen (<xref rid="bib0105" ref-type="bibr">Bouard et al., 2009</xref>; <xref rid="bib0850" ref-type="bibr">Rauch et al., 2018</xref>). Viral vectors that can tolerate a large fragment insertion in their genome can be manipulated to encode any antigen of choice. Several viral vectors have been used recently in the generation of vaccine candidates against SARS-CoV. Also, a rabies virus-based vaccine expressing the SARS-CoV S protein has been found to induce the production of high levels of SARS-CoV-neutralizing antibodies in mice in a single vaccination (<xref rid="bib0290" ref-type="bibr">Faber et al., 2005</xref>).</p><p id="par0140">A live attenuated Modified Vaccinia Ankara (MVA) vector encoding a full-length S glycoprotein has been shown to generate a potent neutralizing antibody in mice, rabbit, and monkey (<xref rid="bib0140" ref-type="bibr">Chen et al., 2005</xref>). Other studies show that immunization of mice with recombinant adenovirus containing the S protein induces both neutralizing antibodies in serum as well as CD8&#x02009;+&#x02009;T cells in lungs (<xref rid="bib0225" ref-type="bibr">Du et al., 2006</xref>, p.; <xref rid="bib0600" ref-type="bibr">Kobinger et al., 2007</xref>; <xref rid="bib0715" ref-type="bibr">Liu et al., 2005</xref>; <xref rid="bib0925" ref-type="bibr">Shim et al., 2012</xref>). Currently, different companies are involved in making replicating and non-replicating viral vector-based vaccines (<xref rid="tbl0010" ref-type="table">Table 2</xref>, <xref rid="tbl0015" ref-type="table">Table 3</xref>
, respectively). The University of Oxford&#x02019;s non-replicating adenovirus-based ChAdOx1 nCoV-19 vaccine has shown protection in rhesus macaques after challenge with SARS-CoV-2(van Doremalen et al., 2020).<table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>Replicating viral vector-based vaccines that encode for the S protein.</p></caption><alt-text id="at0020">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Manufacturer</th><th align="left">Strategy</th><th align="left">Vaccine Name/Stage</th><th align="left">Ref.</th></tr></thead><tbody><tr><td align="left">Zydus Cadila</td><td align="left">Codon-optimised proteins of the new coronavirus, expressed by replicating measles viral vector, will use reverse genetics to stimulate long-term neutralizing antibodies that protect against the infection</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Zydus Cadila. Zydus Cadila looks to expedite Covid-19 vaccine development February 17, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.pharmaceutical-technology.com/news/zydus-cadila-covid-19-vaccine/" id="intr0055">https://www.pharmaceutical-technology.com/news/zydus-cadila-covid-19-vaccine/</ext-link>, May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Institute Pasteur/Themis/<break/>Univ. of Pittsburgh Center for Vaccine Research</td><td align="left">The vaccine candidate consists of a replicating measles viral vector</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;CEPI. CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine. March 19, 2020. <ext-link ext-link-type="uri" xlink:href="https://cepi.net/news" id="intr0060">https://cepi.net/news</ext-link>_cepi/cepi-collaborates-withthe- institut-pasteur-in-a-consortium-to-develop-covid-19- vaccine/. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Tonix Pharma/ Southern Research</td><td align="left">Horsepox vector expressing S protein</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Tonix Pharma. TNX-1800 Horsepox vector for S protein. April 26, 2020. <ext-link ext-link-type="uri" xlink:href="https://covidvax.org/covid19-vaccine/Tonix/TNX-1800-Horsepox-vector-for-S-protein-Tonix-Pharma-Southern-Research" id="intr0065">https://covidvax.org/covid19-vaccine/Tonix/TNX-1800-Horsepox-vector-for-S-protein-Tonix-Pharma-Southern-Research</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">BiOCAD and IEM</td><td align="left">This viral vector vaccine based on attenuated influenza virus backbone (intranasal)</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;<xref rid="bib0080" ref-type="bibr">BIOCAD, 2020</xref>. <ext-link ext-link-type="uri" xlink:href="https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/" id="intr0070">https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/</ext-link>. Accessed May21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">University of Hong Kong</td><td align="left">Influenza vector expressing RBD on its surface to induce immunogenicity against the SARS-CoV-2 virus; notably, can be administered as a nasal spray</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;University of Hong Kong. CEPI partners with University of Hong Kong to develop COVID-19 vaccine. March 18, 2020. <ext-link ext-link-type="uri" xlink:href="https://cepi.net/news" id="intr0075">https://cepi.net/news</ext-link>_cepi/cepi-partners-with-university-of-hong-kong-to-develop-covid-19-vaccine/. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">IAVI/Batavia</td><td align="left">Replication-competent VSV chimeric virus technology (VSV&#x00394;G) delivering the SARS-CoV-2 Spike (S) glycoprotein</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines: <ext-link ext-link-type="uri" xlink:href="https://www.iavi.org/newsroom/press-releases/2020/iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines" id="intr0080">https://www.iavi.org/newsroom/press-releases/2020/iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines</ext-link>. March 5, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">University of Western Ontario</td><td align="left">VSV-S (Vesicular Stomatitis Virus-S) previously successfully used for the development of a vaccine for MERS</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;University of Ontario. Ontario Leading COVID-19 Research in Canada Province Announces First Phase of Research Projects to Fight COVID-19. May 21, 2020. <ext-link ext-link-type="uri" xlink:href="https://news.ontario.ca/opo/en/2020/05/ontario-leading-covid-19-research-in-canada.html" id="intr0085">https://news.ontario.ca/opo/en/2020/05/ontario-leading-covid-19-research-in-canada.html</ext-link>. Accessed May 21, 2020,&#x0201d; n.d.)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl0015"><label>Table 3</label><caption><p>Non-replicating viral vector-based vaccines that encode for the S protein.</p></caption><alt-text id="at0025">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Manufacturer</th><th align="left">Strategy</th><th align="left">Vaccine Name/ Stage</th><th align="left">Ref.</th></tr></thead><tbody><tr><td align="left">CanSino Biological Inc./<break/>Beijing Institute of Biotechnology</td><td align="left">The Phase 2 clinical trial will evaluate immunogenicity and safety of Ad5-nCoV, which encodes for a full-length S protein of SARS-CoV-2</td><td align="left">Phase1 ChiCTR2000030906<break/>Phase 2<break/>NCT04313127<break/>ChiCTR2000031781<break/></td><td align="left">(<xref rid="bib1215" ref-type="bibr">Zhu et al., 2020</xref>)</td></tr><tr><td align="left">University of Oxford<break/></td><td align="left">The ChAdOx1 platform consists of a transgenic nonreplicating chimp adenovirus-based vaccine that expresses, leading to host cell expression and display of the antigenic coronavirus spike protein upon immunization, thus prompting an immune response</td><td align="left">COV001/ <break/>Phase 1/2<break/>NCT04324606<break/>Phase 2<break/>2020-001,228-32<break/>Phase 3<break/>ISRCTN89951424<break/></td><td align="left">(<xref rid="bib0310" ref-type="bibr">Folegatti et al., 2020</xref>)</td></tr><tr><td align="left">Gamaleya Research Institute</td><td align="left">Adeno-based</td><td align="left">Phase 1<break/>NCT04436471<break/>NCT04437875</td><td align="left">(&#x0201c;Gamaleya Research Institute. <ext-link ext-link-type="uri" xlink:href="https://www.trialsitenews.com/gamaleya-research-institute-developed-covid-19-vaccine-clinical-trial-commences-across-russia/" id="intr0090">https://www.trialsitenews.com/gamaleya-research-institute-developed-covid-19-vaccine-clinical-trial-commences-across-russia/</ext-link>. Accessed on JUly 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">GeoVax/BravoVax<break/></td><td align="left">The aim of this vaccine is prevention/ control of SARS-CoV-2, using its GV-MVA-VLPTM vaccine platform</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;GeoVax. GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program. March 18, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.globenewswire.com/news-" id="intr0095">https://www.globenewswire.com/news-</ext-link> release/2020/03/18/2,002,611/0/en/GeoVax-Progresses-in-Coronavirus-COVID-19-Vaccine-Development-Program.html. Accessed May21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Janssen Pharmaceutical Companies<break/></td><td align="left">Ad26 (alone or with MVA boost); leverages Janssen&#x02019;s AdVac&#x000ae; and PER.C6&#x000ae; technology, which provide the ability to rapidly upscale production of the optimal vaccine candidate</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;Johnson &#x00026; Johnson. Johnson &#x00026; Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health &#x00026; Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. March 30, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use" id="intr0100">https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use</ext-link>. Accessed on May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">ReiThera<break/></td><td align="left">This vaccine targets the spike protein of SARS-CoV-2. The vaccine technology is based on a novel ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;ReiThera, LEUKOCARE and Univercells. ReiThera, Leukocare and Univercells announce fast-track development of a COVID-19 vaccine. APRIL 23, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/" id="intr0105">https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/</ext-link>. Accessed on May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">DZIF &#x02013; German Center for Infection Research</td><td align="left">This vaccine will combine the spike protein with the MVA vector&#x02019;s genetic information, resulting in a viral vector able to penetrate human cells and consequently produce spike proteins</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;SARS-CoV-2: DZIF scientists and the development of vaccines <ext-link ext-link-type="uri" xlink:href="https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines" id="intr0110">https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines</ext-link> Mar 9 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Altimmune<break/></td><td align="left">The new intranasal vaccine is based on NasoVAX, the company&#x02019;s influenza vaccine candidate. Like NasoVAX, single intranasal dose would provide systemic immunity</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Hannah Balfour: Biotech and academia collaborate on intranasal COVID-19 vaccine development:<ext-link ext-link-type="uri" xlink:href="https://www.drugtargetreview.com/news/59182/biotech-and-academia-collaborate-on-intranasal-covid-19-vaccine-development/" id="intr0115">https://www.drugtargetreview.com/news/59182/biotech-and-academia-collaborate-on-intranasal-covid-19-vaccine-development/</ext-link> 2 April 2020,&#x0201d; n.d.)</td></tr><tr><td align="left">Greffex<break/></td><td align="left">This genetically modified adenovirus-based vector vaccine will exploit GreVac(TM) Plug-And-Play technology to expedite the production of vaccine candidates</td><td align="left">AdCOVID/<break/>Pre-Clinical<break/></td><td align="left">(&#x0201c;Greffex. Greffex completes COVID-19 vaccine, prepares for FDA animal testing. March 12, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.innovationews.com/Greffex-completes-COVID-19-vaccine-prepares-for-FDA-testing/" id="intr0120">https://www.innovationews.com/Greffex-completes-COVID-19-vaccine-prepares-for-FDA-testing/</ext-link> Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Vaxart<break/></td><td align="left">The candidate is based on the company&#x02019;s VAASTT oral vaccines platform, which uses adenovirus type 5 (Ad5) as a delivery system for its treatment. Vaccine candidates will generate mucosal immune responses in addition to serum antibody responses</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;Vaxart. Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program. April 30, 2020. <ext-link ext-link-type="uri" xlink:href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-additional-positive-pre-clinical-data-its-oral/" id="intr0125">https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-additional-positive-pre-clinical-data-its-oral/</ext-link> Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Centro Nacional Biotecnolog&#x000ed;a (CNB-CSIC), Spain</td><td align="left">MVA poxvirus vectors expressing S protein</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;Luis Enjuanes, Isabel Sola y Sonia Z&#x000fa;&#x000f1;iga. NOVEL HUMAN PATHOGENIC CORONAVIRUS: SARS-CoV-2. March 26, 2020. Centro Nacional de Biotecnolog&#x000ed;a (CNB-CSIC), Madrid (Spain),&#x0201d; n.d.)</td></tr><tr><td align="left">University of Manitoba</td><td align="left">Dendritic cell-based vaccine</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;COVID-19 vaccine: Dendritic cell-based vaccine. <ext-link ext-link-type="uri" xlink:href="https://covidvax.org/covid19-vaccine/ManitobaUni/Dendritic-cell-based-vaccine-University-of-Manitoba" id="intr0130">https://covidvax.org/covid19-vaccine/ManitobaUni/Dendritic-cell-based-vaccine-University-of-Manitoba</ext-link>. Accessed May 26, 2020,&#x0201d; n.d.)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0045"><label>9</label><title>Subunit vaccines</title><p id="par0145">Subunit vaccines use one or more antigens suitable for eliciting a robust immune response. In theory, the subunit vaccine is a very easy and safe vaccine, but in practice, it requires a suitable adjuvant to stimulate the host immune response. Several previous attempts were partially successful with SARS-CoV. Immunization of animals with the S1 RBD domain fused with the IgG1 FC portion (RBD-FC) induced highly potent antibodies which could bind with the RBD domain of the S1 domain, completely neutralize SARS-CoV, and inhibit SARS-CoV entry into Vero E6 cells (<xref rid="bib0240" ref-type="bibr">Du et al., 2009b</xref>, <xref rid="bib0230" ref-type="bibr">2007</xref>; <xref rid="bib0440" ref-type="bibr">He et al., 2004</xref>). A similar approach is being used to develop a vaccine against the SARS-CoV-2 virus. Several companies, including the University of Queensland, are developing subunit vaccines based on the &#x0201c;molecular clamp&#x0201d; technology (<xref rid="bib0980" ref-type="bibr">Takashima et al., 2011</xref>). Trimer-tag technology is being used by Clover Biopharmaceuticals, Inc. to develop a vaccine against SARS-CoV-2 using mammalian cell-expressed Trimeric S protein (&#x0201c;Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo. - PubMed - NCBI,&#x0201d; n.d.). Novavax, Inc. has several S protein-based nanoparticle vaccines which needs to be tested for its efficacy in the animal model. Johnson &#x00026; Johnson, Pasteur Institute, and Chongqing Zhifei Biological Products Co., Ltd. have also started subunit vaccine development against SARS-CoV-2. Other companies involved in making subunit vaccines are listed in <xref rid="tbl0020" ref-type="table">Table 4</xref>
.<table-wrap position="float" id="tbl0020"><label>Table 4</label><caption><p>Vaccines based on protein subunits.</p></caption><alt-text id="at0030">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Manufacturer</th><th align="left">Strategy</th><th align="left">Vaccine Name/Stage</th><th align="left">Ref.</th></tr></thead><tbody><tr><td align="left">Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences</td><td align="left">Adjuvant recombinant protein (RBD-Dimer</td><td align="left">Phase 1<break/>NCT04445194<break/>Phase 2<break/>NCT04466085</td><td align="left">(&#x0201c;<xref rid="bib0045" ref-type="bibr">Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences. 2020</xref><ext-link ext-link-type="uri" xlink:href="https://covidvax.org/covid19-vaccine/AnhuiZhifei/Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad" id="intr0135">https://covidvax.org/covid19-vaccine/AnhuiZhifei/Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Vaxine Pty Ltd/Medytox</td><td align="left">Recombinant spike protein with Advax adjuvant</td><td align="left">Phase 1<break/>NCT04453852</td><td align="left">(&#x0201c;Vaxine Pty Ltd/Medytox. <ext-link ext-link-type="uri" xlink:href="https://www.biospectrumasia.com/news/37/16000/vaxine-announces-covid-19-vaccine-collaboration-with-medytox.html" id="intr0140">https://www.biospectrumasia.com/news/37/16000/vaxine-announces-covid-19-vaccine-collaboration-with-medytox.html</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Kentucky Bioprocessing, Inc</td><td align="left">RBD-Based</td><td align="left">Phase 1<break/>NCT04473690</td><td align="left">(&#x0201c;Kentucky Bioprocessing, Inc. <ext-link ext-link-type="uri" xlink:href="https://www.kentucky.com/news/coronavirus/article241709386.html" id="intr0145">https://www.kentucky.com/news/coronavirus/article241709386.html</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">AdaptVac (PREVENT-nCoV consortium)<break/></td><td align="left">AdaptVac&#x02019;s universal viral Capsid-Like Particle (CLP) will be employed to deliver an optimal vaccine against the SARS-CoV-2 virus (COVID-19)</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;<xref rid="bib0010" ref-type="bibr">ADPVAC, 2020</xref>. <ext-link ext-link-type="uri" xlink:href="https://www.adaptvac.com/news" id="intr0150">https://www.adaptvac.com/news</ext-link>. Accesses May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">ExpreS2ion<break/></td><td align="left">Drosophila S2 insect cell expression system VLPs. This vaccine uses AdaptVac&#x02019;s capsid VLP technology and ExpreS2ion&#x02019;s ExpreS2 technology, which has the potential to mimic a virus to the body&#x02019;s immune system, giving the optimal stimulus to generate a fast, long-lasting immune response that offers a highly efficacious protection</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;ExpreS2ion. ExpreS2ion Announces Bavarian Nordic Enters Agreement with AdaptVac to Advance the COVID-19 Vaccine. May 06 2020. <ext-link ext-link-type="uri" xlink:href="https://expres2ionbio.com/investor/international-press-releases/" id="intr0155">https://expres2ionbio.com/investor/international-press-releases/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">IMV Inc<break/></td><td align="left">DPX-COVID-19 is a formulation of the DPX platform with peptide epitopes from S proteins of the novel coronavirus (SARS-CoV-2)</td><td align="left">DPX-COVID-19/<break/>Pre-Clinical</td><td align="left">(&#x0201c;IMV. DPX-COVID-19 at a glance. April 15, 2020:<ext-link ext-link-type="uri" xlink:href="https://imv-inc.com/clinical-trials/dpx-covid-19/" id="intr0160">https://imv-inc.com/clinical-trials/dpx-covid-19/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">WRAIR/USAMRIID</td><td align="left">Ferritin nanoparticle from H. pylori are used to attach a small part of the coronavirus S protein binding receptor onto the ferritin nanoparticle shell which is surrounded by proprietary lipid ring around the shell that acts as an accelerant or booster</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Eric Niiler: The US Army&#x02019;s Virus Research Lab Gears Up to Fight Covid-19. April 01, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/" id="intr0165">https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/</ext-link> Accessed on May21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">National Institute of Infectious Disease, Japan</td><td align="left">Vaccines rely on genetic engineering to create recombinant proteins that will serve as an antibody against the virus</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Shionogi Inc. Shionogi Accelerates Development of Potential COVID-19 Treatments and Vaccine. April 28, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.shionogi.com/us/en/news/2020/4/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine.html" id="intr0170">https://www.shionogi.com/us/en/news/2020/4/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine.html</ext-link>. Accessed May21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan</td><td align="left">VLP-recombinant protein&#x02009;+&#x02009;Adjuvant</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;<xref rid="bib0075" ref-type="bibr">BIKEN foundation, 2020</xref>. <ext-link ext-link-type="uri" xlink:href="https://www.osaka-u.ac.jp/en/news/info/corona/corona" id="intr0175">https://www.osaka-u.ac.jp/en/news/info/corona/corona</ext-link>_info/cooperation. Accesses May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Clover Biopharmaceuticals Inc./GSK/Dynavax</td><td align="left">Clover uses Trimer-Tag&#x000a9; technology to produce an S-Trimer subunit vaccine (resembling the native trimeric viral spike via a rapid mammalian cell culture-based expression system) which will be combined with GSK&#x02019;s pandemic adjuvant system to check vaccine efficacy</td><td align="left">COVID-19 S-Trimer/ <break/>Phase 1<break/>NCT04405908</td><td align="left">(&#x0201c;Clover Biopharmaceuticals Inc./GSK/Dynavax. <ext-link ext-link-type="uri" xlink:href="https://www.fiercebiotech.com/biotech/using-gsk-dynavax-tech-clover-kickstarts-covid-vax-trial-data-drop-august" id="intr0180">https://www.fiercebiotech.com/biotech/using-gsk-dynavax-tech-clover-kickstarts-covid-vax-trial-data-drop-august</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Univ. of Pittsburgh</td><td align="left">The vaccine candidate is based on unique and patent protected signal peptide technology utilizing Vaxil&#x02019;s proprietary VaxHit&#x02122; bioinformatics platform</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;COVID-19 Vaccine Candidate Shows Promise: April 02, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.upmc.com/media/news/" id="intr0185">https://www.upmc.com/media/news/</ext-link>040,220<ext-link ext-link-type="uri" xlink:href="http://-falo-gambotto-sars-cov2-vaccine" id="intr0190">-falo-gambotto-sars-cov2-vaccine</ext-link>. Accessed May21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Vaxil Bio<break/></td><td align="left">The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil&#x02019;s proprietary VaxHit&#x02122; bioinformatics platform.<break/></td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Vaxil. Vaxil commences preclinical COVID-19 vaccine trial and files an additional COVD-19 patent. March 27, 2020. <ext-link ext-link-type="uri" xlink:href="https://vaxil-bio.com/vaxil-commences-preclinical-covid-19-vaccine-trial-and-files-an-additional-covid-19-patent/" id="intr0195">https://vaxil-bio.com/vaxil-commences-preclinical-covid-19-vaccine-trial-and-files-an-additional-covid-19-patent/</ext-link> Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Biological E Ltd.</td><td align="left">Adjuvanted protein subunit (RBD)</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;<xref rid="bib0085" ref-type="bibr">Biological E Ltd, 2020</xref>. <ext-link ext-link-type="uri" xlink:href="https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html" id="intr0200">https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html</ext-link>. Accessed May 27, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Flow Pharma Inc</td><td align="left">FlowVax vaccines utilize Flow Pharma's patented Size Exclusion Antigen Presentation Control (SEAPAC(TM)) technology based on the benefits of making vaccine microspheres the same size as human white blood cells. This vaccine relies on killer T-cells rather than antibodies to fight virus infections</td><td align="left">FlowVax Covid-19/ Pre-Clinical</td><td align="left">(&#x0201c;Flow Pharma: Flow Pharma Announces Strategic Partnership with Oakwood Labs for GMP Manufacturing of FlowVax COVID-19 Vaccine. April 15, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.accesswire.com/585181/Flow-Pharma-Announces-Strategic-Partnership-with-Oakwood-Labs-for-GMP-Manufacturing-of-FlowVax-COVID-19-Vaccine" id="intr0205">https://www.accesswire.com/585181/Flow-Pharma-Announces-Strategic-Partnership-with-Oakwood-Labs-for-GMP-Manufacturing-of-FlowVax-COVID-19-Vaccine</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">AJ Vaccines<break/></td><td align="left">The vaccine candidate will use technology to raise strong immune responses while being well tolerated and to meet potential global demand in 2021</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;<xref rid="bib0020" ref-type="bibr">AJ Vaccines, 2020</xref>. <ext-link ext-link-type="uri" xlink:href="https://ajvaccines.com/news/" id="intr0210">https://ajvaccines.com/news/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Generex/EpiVax</td><td align="left">Generex Biotechnology Corporation will use EpiVax expertise and computational tools to predict epitopes that can be used to generate peptide vaccines against SARS-CoV-2 using the patented NuGenerex Immuno-Oncology (NGIO &#x02013; Formerly Antigen Express) Ii-Key technology</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Generex. Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic. March 04, 202. <ext-link ext-link-type="uri" xlink:href="https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic" id="intr0215">https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">EpiVax/Univ. of Georgia</td><td align="left">Sequence will be predicted based on EpiVax computational tool</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;EpiVax. EpiVax Accelerates COVID-19 Vaccine Development with UGA&#x02019;s Center for Vaccines and Immunology. May 04, 2020. <ext-link ext-link-type="uri" xlink:href="https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology" id="intr0220">https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Sanofi Pasteur/GSK<break/></td><td align="left">Sanofi will contribute its recombinant DNA technology-based S-protein COVID-19 antigen expressed using baculovirus expression platform, and GSK will contribute its proven pandemic adjuvant technology</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Sanofi and GSK. Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19. April 14, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00" id="intr0225">https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Novavax<break/></td><td align="left">Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M</td><td align="left">NVX-CoV2373/<break/>Phase 1/2<break/>NCT04368988</td><td align="left">(&#x0201c;Novavax. <ext-link ext-link-type="uri" xlink:href="https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine" id="intr0230">https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Heat Biologics/<break/>Univ. Of Miami<break/></td><td align="left">Heat's gp96 vaccine platform activates CD8 T cells, antigen presenting cells and natural killer cells, and induces mucosal immunity, which could make it an ideal vaccine for COVID-19</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Heat Biologics. Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus. Match 05, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.heatbio.com/news-media/news-releases/detail/649/heat-biologics-announces-research-collaboration-with" id="intr0235">https://www.heatbio.com/news-media/news-releases/detail/649/heat-biologics-announces-research-collaboration-with</ext-link>. May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">University of Queensland<break/>/GSK/Dynavax</td><td align="left">Subunit vaccine consisting of a SARS-CoV-2 spike protein stabilized with a protein &#x0201c;molecular clam&#x0201d;</td><td align="left"><break/>ACTRN12620000674932p</td><td align="left">(&#x0201c;University of Queensland /GSK/Dynavax. <ext-link ext-link-type="uri" xlink:href="https://advance.qld.gov.au/covid-19-fast-facts" id="intr0240">https://advance.qld.gov.au/covid-19-fast-facts</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Baylor College of Medicine/Texas Children's Hospital/Path</td><td align="left">Based on RBD of Spike protein</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;<xref rid="bib0060" ref-type="bibr">Baylor College of Medicine, 2020</xref><ext-link ext-link-type="uri" xlink:href="https://www.bcm.edu/coronavirus-preparedness/covid-19-research" id="intr0245">https://www.bcm.edu/coronavirus-preparedness/covid-19-research</ext-link>. May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">iBio/CC-Pharming</td><td align="left">Subunit protein is produced in a plant. The aim of this company is to deliver vaccine candidates for rapid production at iBio&#x02019;s FastPharming manufacturing facility</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Fast-Farming Pharma. How plants could speed up vaccine manufacture to tackle the COVID-19 pandemic? April 17, 2020. <ext-link ext-link-type="uri" xlink:href="https://themedicinemaker.com/manufacture/fast-farming-pharma" id="intr0250">https://themedicinemaker.com/manufacture/fast-farming-pharma</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Saint-Petersburg scientific research institute of vaccines and serums</td><td align="left">Recombinant protein, nanoparticles (based on S-protein and other epitopes)</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;Saint-Petersburg scientific research institute of vaccines and serums. May22, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" id="intr0255">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</ext-link>. Accessed May 25, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Innovax/Xiamen Univ./GSK<break/></td><td align="left">COVID-19&#x02032;s series of truncated S will be screened during the preclinical testing process; ultimate lead candidate will be determined by immunogenicity data</td><td align="left">COVID-19 XWG-03/<break/>Pre-Clinical</td><td align="left">(&#x0201c;GSK. GSK Joins Xiamen Innovax Biotech to Support COVID-19 Vaccine Development &#x00026; Expands Activity to Fight War against Pandemic. April 06, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.trialsitenews.com/gsk-joins-xiamen-innovax-biotech-to-support-covid-19-vaccine-development-expands-activity-to-fight-war-against-pandemic/" id="intr0260">https://www.trialsitenews.com/gsk-joins-xiamen-innovax-biotech-to-support-covid-19-vaccine-development-expands-activity-to-fight-war-against-pandemic/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">VIDO-InterVac,<break/>University of Saskatchewan</td><td align="left">Adjuvanted microsphere peptide-based vaccine</td><td align="left">Pre-Clinical<break/></td><td align="left">(&#x0201c;USask. USask VIDO-InterVac awarded $23&#x02009;M for COVID-19 vaccine research. April 23, 2020. <ext-link ext-link-type="uri" xlink:href="https://news.usask.ca/articles/research/2020/usask-vido-intervac-awarded-23m-for-covid-19-vaccine-research.php" id="intr0265">https://news.usask.ca/articles/research/2020/usask-vido-intervac-awarded-23m-for-covid-19-vaccine-research.php</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">OncoGen<break/></td><td align="left">Concept of personalized vaccination. Multiepitope peptide vaccine candidates were identified against nCov that can potentially trigger both CD4+ and CD8&#x02009;+&#x02009;T cell immune response</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;OncoGen. OncoGen researchers propose personalized vaccinomics strategy for the novel China coronavirus: <ext-link ext-link-type="uri" xlink:href="https://oncogen.ro/oncogen-vaccine-design-for-coronavirus/" id="intr0270">https://oncogen.ro/oncogen-vaccine-design-for-coronavirus/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">MIGAL Galilee Research Institute</td><td align="left">Oral, <italic>E. coli</italic>-based protein expression system of S and N proteins</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;MIGAL&#x02019;s Coronavirus Vaccine Project:<ext-link ext-link-type="uri" xlink:href="https://www.migal.org.il/en/node/7010" id="intr0275">https://www.migal.org.il/en/node/7010</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">University of Alberta</td><td align="left">Spike-based</td><td align="left">Pre-Clinical</td><td align="left">(&#x0201c;WHO. Draft landscape of COVID-19 candidate vaccines. May 30, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" id="intr0280">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</ext-link>. Accessed May 30, 2020.,&#x0201d; n.d.)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0050"><label>10</label><title>RNA vaccines</title><p id="par0150">mRNA has been used as a template for endogenous expression of proteins selected as a vaccine candidate. An mRNA vaccine is a promising alternative because of its high potency, short production cycle, and low manufacturing cost. (<xref rid="bib0815" ref-type="bibr">Pardi et al., 2018</xref>; <xref rid="bib1180" ref-type="bibr">Yun et al., 2020</xref>). Currently, there is no mRNA vaccine in the market, so it will be challenging to pass the quality control and safety evaluation. Currently, mRNA-1273, a potential vaccine against</p><p id="par0155">SARS-CoV-2 based on encoding for a prefusion stabilized form of the S protein, has been selected for evaluation by Moderna in collaboration with investigators at the NIAID Vaccine Research Center (VRC). This vaccine is currently the focus of a Phase 1 clinical trial (NCT04283461). Several other companies are also developing mRNA vaccines against SARS-CoV-2 (<xref rid="tbl0025" ref-type="table">Table 5</xref>
).<table-wrap position="float" id="tbl0025"><label>Table 5</label><caption><p>S protein-based RNA vaccines.</p></caption><alt-text id="at0035">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Manufacturer</th><th align="left">Strategy</th><th align="left">Vaccine Name/ Stage</th><th align="left">Ref</th></tr></thead><tbody><tr><td align="left">Fudan University<break/>/Shanghai JiaoTong University/RNACure Biopharma<break/></td><td align="left">LNP-encapsulated mRNA cocktail encoding VLP for induction of neutralizing antibodies, as well as producing virus-like particles similar to SARS-CoV-2</td><td align="left">Pre-clinical</td><td align="left">(&#x0201c;Fudan University. Towards an effective mRNA vaccine against 2019-nCoV: March 7, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.fudan.edu.cn/en/2020/0307/c1092a104281/page.htm" id="intr0285">https://www.fudan.edu.cn/en/2020/0307/c1092a104281/page.htm</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Moderna/NIAID</td><td align="left">Lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine encoding a full-length, prefusion stabilized S protein of SARS-CoV-2</td><td align="left">mRNA-1273/<break/>Phase 1<break/>NCT04283461<break/>Phase 2 NCT04405076<break/>Phase 3 NCT04470427</td><td align="left">(<xref rid="bib0530" ref-type="bibr">Jackson et al., 2020</xref>)</td></tr><tr><td align="left">Centro Nacional Biotecnolog&#x000ed;a (CNB-CSIC), Spain</td><td align="left">Replicating defective SARS-CoV-2- derived RNAs</td><td align="left">Pre-clinical</td><td align="left">(&#x0201c;Centro Nacional Biotecnolog&#x000ed;a (CNB-CSIC). TYPE: RNA vaccine:<ext-link ext-link-type="uri" xlink:href="https://www.lykeo.com/" id="intr0290">https://www.lykeo.com/</ext-link> replicating-defective-sarscov-2-derived-rnas-centro-nacional-biotecnologia-cnb-csic-spain. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">University of Tokyo / Daiichi-Sankyo</td><td align="left">LNP-encapsulated mRNA</td><td align="left">Pre-clinical</td><td align="left">(&#x0201c;University of Tokoyo and Daiichi Sankyo. Our Company&#x02019;s Efforts to Limit the Spread of the Virus that Causes COVID-19 Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">BIOCAD<break/></td><td align="left">Liposome-encapsulated mRNA to produce disease-specific antigens and trigger a regular immune response</td><td align="left">Pre-clinical</td><td align="left">(&#x0201c;BIOCAD, 2020. <ext-link ext-link-type="uri" xlink:href="https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/" id="intr0295">https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/</ext-link>. Accessed May21, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">China CDC/Tongji University/Stermina</td><td align="left">mRNA</td><td align="left">Pre-clinical</td><td align="left"/></tr><tr><td align="left">Arcturus/Duke-NUS</td><td align="left">Self replication of mRNA with LUNAR&#x000ae;, a leading nanoparticle non-viral delivery system, to produce proteins inside the human body. Provokes a vaccine response at much lower doses compared to traditional mRNA vaccines</td><td align="left"><break/>Phase 1/2<break/>NCT0448057</td><td align="left">(&#x0201c;<xref rid="bib0050" ref-type="bibr">Arcturus/Duke-NUS, 2020</xref><ext-link ext-link-type="uri" xlink:href="https://www.duke-nus.edu.sg/about/media/media-releases/media-releases/arcturus-therapeutics-duke-nus-clinical-trials-for-covid-19-vaccine-candidate-approved-to-proceed" id="intr0300">https://www.duke-nus.edu.sg/about/media/media-releases/media-releases/arcturus-therapeutics-duke-nus-clinical-trials-for-covid-19-vaccine-candidate-approved-to-proceed</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">BioNTech/Fosun Pharma/Pfizer</td><td align="left">This includes four vaccine candidates, each representing a different combination of mRNA format and target antigen</td><td align="left">Phase 1/22020&#x02212;001038-36 ChiCTR2000034825<break/>Phase 3<break/>NCT04368728</td><td align="left">(&#x0201c;BioNTech/Fosun Pharma/Pfizer. <ext-link ext-link-type="uri" xlink:href="https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/" id="intr0305">https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Imperial College London</td><td align="left">Self-amplifying RNA vaccine will deliver genetic instructions to muscle cells to make the &#x02018;S&#x02019; protein on the surface of the coronavirus. This should provoke an immune response and create immunity to COVID-19</td><td align="left">Phase 1<break/>ISRCTN17072692</td><td align="left">(&#x0201c;Imperial College London. <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsarena.com/news/imperial-college-covid-vaccine/" id="intr0310">https://www.clinicaltrialsarena.com/news/imperial-college-covid-vaccine/</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Curevac</td><td align="left">mRNA</td><td align="left">NCT04449276</td><td align="left">(&#x0201c;Curevac. <ext-link ext-link-type="uri" xlink:href="https://www.curevac.com/news/curevac-receives-regulatory-approval-from-german-and-belgian-authorities-to-initiate-phase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate" id="intr0315">https://www.curevac.com/news/curevac-receives-regulatory-approval-from-german-and-belgian-authorities-to-initiate-phase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Saiba GmbH</td><td align="left">Virus-like particle, based on RBD displayed on virus-like particles of plant virus Cucumber Mosaic Virus (CMV)</td><td align="left">Pre-clinical</td><td align="left">(&#x0201c;Saiba Biotech. Saiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept. <ext-link ext-link-type="uri" xlink:href="https://www.saiba-biotech.com/" id="intr0320">https://www.saiba-biotech.com/</ext-link>. Accessed May 21, 2020.,&#x0201d; n.d.)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0055"><label>11</label><title>Spike protein-based therapeutics</title><p id="par0160">Two S-protein-based methods that show promise as therapeutics for SARS-CoV-2 include those facilitating peptide interference with RBD-ACE2 interaction, as well as those using mAbs that target the S-protein. A previous study has shown that hexapeptide <sup>438</sup>YKYRYL<sup>443</sup> from the S protein of SARS-CoV virus binds to ACE2 with a binding affinity of K<sub>D</sub> =46&#x02009;&#x003bc;M and blocks the entry of SARS-CoV into Vero E6 cells (<xref rid="bib0945" ref-type="bibr">Struck et al., 2012</xref>). A peptide from the RBD domain of the S protein (aa 471&#x02013;503) can inhibit the binding of ACE2 to SARS-CoV RBD and block SARS-CoV entry into Vero cells with an EC50 of 41.6&#x02009;&#x003bc;M (<xref rid="bib0470" ref-type="bibr">Hu et al., 2005</xref>). Similarly, a combination of two peptides from ACE2 motif aa 22&#x02013;44 and 351&#x02013;357 linked together by glycine blocks entry of SARS pseudoparticles in HeLa cells expressing ACE2 protein with EC<sub>50</sub> of 100&#x02009;&#x003bc;M (<xref rid="bib0415" ref-type="bibr">Han et al., 2006</xref>). Recently it has been shown that a 23-mer spike binding peptide 1 (IEEQAKTFLDKFNHEAEDLFYQS) derived from human ACE2 a1 helix binds SARS-CoV-2-RBD with low nanomolar affinity (dissociation constant, KD&#x02009;=&#x02009;47&#x02009;nM), potentially inhibiting the entry of the virus into human cells (G. <xref rid="bib0630" ref-type="bibr">L. Zhang et al., 2020</xref>; <xref rid="bib0325" ref-type="bibr">G. Zhang et al., 2020</xref>). Another study showed that the lapidated form of peptide EK1, EK1C inhibits SARS-CoV-2 mediated cell-cell fusion at the concentration of 2.5&#x02009;&#x003bc;M and with an IC<sub>50</sub> of 48.1&#x02009;nM. This study also suggests that lipidation, as well as linker length, plays an essential role in the overall activity of lipopeptides. (S. <xref rid="bib0625" ref-type="bibr">L. Xia et al., 2020</xref>; <xref rid="bib0865" ref-type="bibr">S. Xia et al., 2020</xref>). This would be a potential candidate for therapeutic development. However, its efficacy against SARS-CoV-2 still needs to be validated using an <italic>in vivo</italic> model (<xref rid="tbl0030" ref-type="table">Table 6</xref>
).<table-wrap position="float" id="tbl0030"><label>Table 6</label><caption><p>Inactivated Virus based vaccines.</p></caption><alt-text id="at0040">Table 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Manufacturer</th><th align="left">Strategy</th><th align="left">Vaccine Name/ Stage</th><th align="left">Ref</th></tr></thead><tbody><tr><td align="left">Sinovac</td><td align="left">Inactivated</td><td align="left">Phase 3<break/>NCT04456595<break/>Phase 1<break/>NCT04383574<break/>NCT04352608</td><td align="left">(<xref rid="bib0335" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left">Wuhan Institue of Biological Products/Snopharm</td><td align="left">Inactivated</td><td align="left">Phase 3<break/>ChiCTR2000034780<break/>Phase1<break/>ChiCTR2000031809</td><td align="left">(&#x0201c;Wuhan Institue of Biological Products/Snopharm. <ext-link ext-link-type="uri" xlink:href="https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts100-antibody-response-for-covid-19-vaccine-it-s-already-giving" id="intr0325">https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts100-antibody-response-for-covid-19-vaccine-it-s-already-giving</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">BEJING Institute of Biological Products/Sinopharma</td><td align="left">Inactivated</td><td align="left">Phase 3<break/>ChiCTR2000034780<break/>Phase1<break/>ChiCTR2000032459</td><td align="left">(&#x0201c;<xref rid="bib0065" ref-type="bibr">BEJING Institute of Biological Products/Sinopharma, 2020</xref><ext-link ext-link-type="uri" xlink:href="https://www.fiercebiotech.com/research/inactivated-covid-19-vaccine-by-china-s-sinopharm-clears-animal-tests" id="intr0330">https://www.fiercebiotech.com/research/inactivated-covid-19-vaccine-by-china-s-sinopharm-clears-animal-tests</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Institute of Medical Biology, Chinesee Academy of Medical Sciences</td><td align="left">Inactivated</td><td align="left">Phase 1/2<break/>NCT04470609<break/>Phase 1<break/>NCT04412538</td><td align="left">(&#x0201c;Institute of Medical Biology, Chinesee Academy of Medical Sciences. <ext-link ext-link-type="uri" xlink:href="http://english.nmpa.gov.cn/2020-06/22/c" id="intr0335">http://english.nmpa.gov.cn/2020-06/22/c</ext-link>_502093.htm. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr><tr><td align="left">Bharat Biotech</td><td align="left">Inactivated (Whole- Virion Inactivated</td><td align="left"/><td align="left">(&#x0201c;<xref rid="bib0070" ref-type="bibr">Bharat Biotech, 2020</xref><ext-link ext-link-type="uri" xlink:href="https://www.deccanchronicle.com/lifestyle/health-and-wellbeing/270720/bharat-biotechs-covaxin-shows-encouraging-results-in-phase-i.html" id="intr0340">https://www.deccanchronicle.com/lifestyle/health-and-wellbeing/270720/bharat-biotechs-covaxin-shows-encouraging-results-in-phase-i.html</ext-link>. Accessed on July 29, 2020.,&#x0201d; n.d.)</td></tr></tbody></table></table-wrap></p><p id="par0165">Several monoclonal antibodies targeting the S protein against SARS-CoV have been identified that inhibit the virus entry to cells (<xref rid="bib0955" ref-type="bibr">Sui et al., 2004</xref>; <xref rid="bib1000" ref-type="bibr">ter Meulen et al., 2006</xref>, 2004; <xref rid="bib1020" ref-type="bibr">Traggiai et al., 2004</xref>; <xref rid="bib1210" ref-type="bibr">Zhu et al., 2007</xref>). Although RBD of the S protein is the prime target for neutralizing antibodies, antibodies can recognize different epitopes on RBD and work synergistically. The SARS-CoV neutralizing antibodies CR3014 and CR3022 bind noncompetitively to the SARS-CoV RBD and synergistically neutralize the virus (<xref rid="bib1000" ref-type="bibr">ter Meulen et al., 2006</xref>). A recent report revealed that although a SARS-CoV-neutralizing antibody m396 showed promising binding with SARS-CoV-2 RBD in computational modeling, it only showed slight binding at the highest measured concentration (2.0&#x02009;&#x003bc;M) in an experimental condition. Another study found that plasma samples from SARS-CoV-convalescent patients can neutralize SARS-CoV, but cannot cross-neutralize SARS-CoV-2, even though they can bind SARS-CoV-2 (<xref rid="bib0740" ref-type="bibr">Lv et al., 2020</xref>). These results suggest that monoclonal antibodies that bind with SARS-CoV S protein are unable to bind SARS-CoV-2. These results suggest an urgent need to develop novel monoclonal antibodies that could bind specifically to SARS-CoV-2 (<xref rid="bib1010" ref-type="bibr">Tian et al., 2020</xref>).</p><sec id="sec0060"><label>11.1</label><title>Small molecule inhibitor</title><p id="par0170">Another area of research which can provide immediate control of SARS-CoV-2 spreads is the small molecule inhibitors. Several previous reports have suggested that small molecule compound can successfully inhibit the interaction between SARS-CoV spike protein and ACE2, leading to block the virus entry into the cells (<xref rid="bib0005" ref-type="bibr">Adedeji et al., 2013</xref>; Huentelman Matthew J. et al., 2004; <xref rid="bib0570" ref-type="bibr">Kao et al., 2004</xref>). Similar study in SARS-CoV-2 suggest that small molecule can inhibit the interaction between SARS-CoV-2 and ACE2. Hanson et. al., have performed a drug repurposing screen against 3384 small molecule drugs using a proximity -based assay which measure the binding of SARS-CoV2 spike protein Domain (RBD) and ACE2, and found 25 high quality small molecule hits that can be evaluated for its efficacy in future (<xref rid="bib0425" ref-type="bibr">Hanson et al., 2020</xref>). Even though druggable pockets are absent in spike protein and ACE2 in their unbound states, bound states have well defined pockets for drug development. Using computer modeling, Patil et al. has shown that several antiviral compound against HCV and HIV viruses e.g. Atazanavir, Grazoprevir, Saquinavir, Simeprevir, Telaprevir and Tipranavir could be potential candidate inhibitors for immediate future investigation (<xref rid="bib0820" ref-type="bibr">Patil et al., 2020</xref>).</p></sec></sec><sec id="sec0065"><label>12</label><title>Conclusions and futures perspectives</title><p id="par0175">The emergence of the COVID-19 pandemic has underscored the necessity to find therapeutics and/or vaccines to control the spread of infection and save infected people. From recent and previous studies of SARS-CoV, MERS-CoV, and SARS-CoV-2, it is well known that the S protein plays a vital role in virus-host interaction and its entry into human cells. Still, we need to know more about the fundamental nature of SARS-CoV-2, for example, mechanisms of pathogenesis, cellular and humoral immune response in the host after virus infection, etc., to make a successful therapeutics and/or vaccine.</p><p id="par0180">In this review, we summarised different approaches using the S protein to generate a vaccine, therapeutics, or neutralizing antibodies targeting SARS-CoV-2. Several neutralizing antibodies have been detected that act against SARS-CoV or MERS-CoV, but with limited success. Many of the neutralizing antibodies or vaccines identified cause ADE or vaccine-enhanced disease, respectively. There is a rising concern about ADE effect by sub-optimal antibody generated by vaccine under development against SARS-CoV-2. Because of these risks, it is crucial to perform large-scale clinical trials to assess vaccine or therapeutic efficacy and safety before approving any for widespread use. It is also essential to find a neutralizing antibody which can neutralize different strain of viruses and yet not cause antibody-induced enhancement. Use of nanobodies is one of the options that can successfully avoid the ADE effect. Since the virus is still spreading globally, a vaccine is the preferred means to control COVID-19. Development, testing, and clinical trials are ongoing with a focus on identifying a potential drug/vaccine to prevent or treat SARS-CoV-2-associated disease.</p><p id="par0185">Recent studies have shown that SARS-CoV-2 is actively evolving. Recently, it was found that a clinical strain of SARS-CoV-2 containing a D614&#x02009;G mutation within the viral spike protein is now dominant in many countries (<xref rid="bib0615" ref-type="bibr">Korber et al., 2020</xref>). It has been reported in several studies that this mutation is not causing patient sicker but has higher rate of infectivity than the wild-type virus (<xref rid="bib0205" ref-type="bibr">Daniloski et al., 2020</xref>; <xref rid="bib0260" ref-type="bibr">Eaaswarkhanth et al., 2020</xref>; <xref rid="bib0800" ref-type="bibr">Ogawa et al., 2020</xref>;). D614&#x02009;G did not alter the virus&#x02019;s response to antibodies from patients infected with the wild-type virus, which suggests that vaccines currently under development based on the original viral spike protein will be still effective against the new strain (<xref rid="bib0390" ref-type="bibr">Grubaugh et al., 2020</xref>; L. <xref rid="bib0630" ref-type="bibr">L. Zhang et al., 2020</xref>; <xref rid="bib0325" ref-type="bibr">G. Zhang et al., 2020</xref>). However, in order to fully establish the safety, cross-challenging studies of the new strain in vaccinated animals should be performed to evaluate the biosafety of vaccines.</p></sec><sec id="sec0070"><title>references</title><p id="par0190">
<xref rid="bib0090" ref-type="bibr">BioNet (2020)</xref>, <xref rid="bib0095" ref-type="bibr">BioNTech/Fosun Pharma/Pfizer (2020)</xref>, <xref rid="bib0130" ref-type="bibr">Centro Nacional Biotecnolog&#x000ed;a (CNB-CSIC). (2020)</xref>, <xref rid="bib0135" ref-type="bibr">CEPI (2020)</xref>, <xref rid="bib0160" ref-type="bibr">Clover Biopharmaceuticals Inc (2020)</xref>, <xref rid="bib0165" ref-type="bibr">Cobra Biologics (2020)</xref>, <xref rid="bib0180" ref-type="bibr">COVID-19 Vaccine Candidate Shows Promise (2020)</xref>, <xref rid="bib0185" ref-type="bibr">COVID-19 vaccine: Dendritic cell-based vaccine (2020)</xref>, <xref rid="bib0195" ref-type="bibr">Curevac (2020)</xref>, <xref rid="bib0210" ref-type="bibr">de Wilde et al. (2018d)</xref>, <xref rid="bib0270" ref-type="bibr">EpiVax (2020)</xref>, <xref rid="bib0275" ref-type="bibr">Eric Niiler (2020)</xref>, <xref rid="bib0280" ref-type="bibr">ExpreS2ion (2020)</xref>, <xref rid="bib0295" ref-type="bibr">Fast-Farming Pharma (2020)</xref>, <xref rid="bib0305" ref-type="bibr">Flow Pharma (2020)</xref>, <xref rid="bib0320" ref-type="bibr">Fudan University (2020)</xref>, <xref rid="bib0330" ref-type="bibr">Gamaleya Research Institute (2020)</xref>, <xref rid="bib0345" ref-type="bibr">Generex (2020)</xref>, <xref rid="bib0350" ref-type="bibr">Genexine Consortium (2020)</xref>, <xref rid="bib0360" ref-type="bibr">GeoVax et al. (2020)</xref>, <xref rid="bib0120" ref-type="bibr">C.J. Gordon et al., 2020</xref>; <xref rid="bib0200" ref-type="bibr">D.E. Gordon et al., 2020</xref>, <xref rid="bib0385" ref-type="bibr">Greffex (2020)</xref>, <xref rid="bib0395" ref-type="bibr">GSK (2020)</xref>, <xref rid="bib1230" ref-type="bibr">ZZZZZ (2020)</xref>, <xref rid="bib0445" ref-type="bibr">Heat Biologics (2020)</xref>, <xref rid="bib0480" ref-type="bibr">Huentelman Matthew et al. (2004)</xref>, <xref rid="bib0490" ref-type="bibr">IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines (2020)</xref>, <xref rid="bib0495" ref-type="bibr">Imperial College London (2020)</xref>, <xref rid="bib0500" ref-type="bibr">Improvement of Pharmacokinetic (2020)</xref>, <xref rid="bib0505" ref-type="bibr">IMV (2020)</xref>, <xref rid="bib0510" ref-type="bibr">Inovio Pharmaceuticals/International Vaccine Institute (2020)</xref>, <xref rid="bib0515" ref-type="bibr">Institute of Medical Biology and Chinesee Academy of Medical Sciences (2020)</xref>, <xref rid="bib0560" ref-type="bibr">Johns Hopkins University (2020)</xref>, <xref rid="bib0565" ref-type="bibr">Johnson and Johnson (2020)</xref>, <xref rid="bib0580" ref-type="bibr">Kentucky Bioprocessing, Inc (2020)</xref>, <xref rid="bib0265" ref-type="bibr">Enjuanes and Z&#x000fa;&#x000f1;iga (2020)</xref>, <xref rid="bib0775" ref-type="bibr">MIGAL&#x02019;s Coronavirus Vaccine (2020)</xref>, <xref rid="bib0795" ref-type="bibr">Novavax (2020)</xref>, <xref rid="bib0805" ref-type="bibr">OncoGen (2020)</xref>, <xref rid="bib0810" ref-type="bibr">Osaka University/AnGes/Takara Bio (2020)</xref>, <xref rid="bib0830" ref-type="bibr">Pharmajet et al., il 15 (2020)</xref>, <xref rid="bib0855" ref-type="bibr">ReiThera (2020)</xref>, <xref rid="bib0870" ref-type="bibr">Saiba Biotech (2020)</xref>, <xref rid="bib0875" ref-type="bibr">Saint-Petersburg scientific research institute of vaccines and serums (2020)</xref>, <xref rid="bib0885" ref-type="bibr">Sanofi and GSK (2020)</xref>, <xref rid="bib0895" ref-type="bibr">SARS-CoV-2: DZIF, 9 2020</xref>, <xref rid="bib0930" ref-type="bibr">Shionogi Inc (2020)</xref>, <xref rid="bib0960" ref-type="bibr">Symvivo Corporation (2020)</xref>, <xref rid="bib0985" ref-type="bibr">Takis (2020)</xref>, <xref rid="bib0995" ref-type="bibr">ter Meulen et al. (2004t)</xref>, <xref rid="bib1015" ref-type="bibr">Tonix Pharma (2020)</xref>, <xref rid="bib1040" ref-type="bibr">University of Hong Kong (2020)</xref>, <xref rid="bib1045" ref-type="bibr">University of Ontario (2020)</xref>, <xref rid="bib1050" ref-type="bibr">University of Queensland /GSK/Dynavax (2020)</xref>, <xref rid="bib1055" ref-type="bibr">University of Tokoyo and Daiichi Sankyo (2020)</xref>, <xref rid="bib1060" ref-type="bibr">University of Waterloo (2020)</xref>, <xref rid="bib1065" ref-type="bibr">USask (2020)</xref>, <xref rid="bib1070" ref-type="bibr">van Doremalen et al. (2020v)</xref>, <xref rid="bib1075" ref-type="bibr">Vaxart (2020)</xref>, <xref rid="bib1080" ref-type="bibr">Vaxil (2020)</xref>, <xref rid="bib1085" ref-type="bibr">Vaxine Pty Ltd/Medytox (2020)</xref>, <xref rid="bib0110" ref-type="bibr">C. Wang et al., 2020</xref>; <xref rid="bib0835" ref-type="bibr">Q. Wang et al., 2020</xref>, <xref rid="bib1130" ref-type="bibr">WHO, 2020a</xref>,<xref rid="bib1135" ref-type="bibr">b</xref>, <xref rid="bib1125" ref-type="bibr">2019</xref>, <xref rid="bib1130" ref-type="bibr">WHO, 2020a</xref>,<xref rid="bib1135" ref-type="bibr">b</xref>, <xref rid="bib0285" ref-type="bibr">F. Wu et al., 2020</xref>; <xref rid="bib1165" ref-type="bibr">Y. Wu et al., 2020</xref>, <xref rid="bib1160" ref-type="bibr">Wuhan Institue of Biological Products/Snopharm (2020)</xref>, <xref rid="bib0625" ref-type="bibr">L. Xia et al., 2020</xref>; <xref rid="bib0865" ref-type="bibr">S. Xia et al., 2020</xref>, <xref rid="bib0525" ref-type="bibr">J. Yu et al., 2020</xref>; <xref rid="bib0115" ref-type="bibr">C. Yu et al., 2020</xref>, <xref rid="bib0630" ref-type="bibr">L. Zhang et al., 2020</xref>; <xref rid="bib0325" ref-type="bibr">G. Zhang et al., 2020</xref>, <xref rid="bib1220" ref-type="bibr">Zydus Cadila, 2020a</xref>,<xref rid="bib1225" ref-type="bibr">b</xref>, <xref rid="bib1220" ref-type="bibr">Zydus Cadila, 2020a</xref>,<xref rid="bib1225" ref-type="bibr">b</xref>, <xref rid="bib0720" ref-type="bibr">Liu et al., 2019a</xref>,<xref rid="bib0725" ref-type="bibr">b</xref>, <xref rid="bib1090" ref-type="bibr">Walls et al. (2019)</xref> and <xref rid="bib0465" ref-type="bibr">Houser et al. (2017)</xref>.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A.O.</given-names></name><name><surname>Severson</surname><given-names>W.</given-names></name><name><surname>Jonsson</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Weiss</surname><given-names>S.R.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms</article-title><source>J. Virol.</source><volume>87</volume><year>2013</year><fpage>8017</fpage><lpage>8028</lpage><pub-id pub-id-type="doi">10.1128/JVI.00998-13</pub-id><pub-id pub-id-type="pmid">23678171</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="other" id="sbref0010"><person-group person-group-type="author"><name><surname>ADPVAC</surname></name></person-group><article-title>BARBARIAN NORDIC Enters Agreement With ADAPVAC to Advance COVID-19 Vaccine Program. May 6</article-title><ext-link ext-link-type="uri" xlink:href="https://www.adaptvac.com/news" id="intr0365">https://www.adaptvac.com/news</ext-link><year>2020</year><comment>Accesses May 21, 2020., n.d.</comment></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Aghamollaei</surname><given-names>H.</given-names></name><name><surname>Ghanei</surname><given-names>M.</given-names></name><name><surname>Rasaee</surname><given-names>M.J.</given-names></name><name><surname>Latifi</surname><given-names>A.M.</given-names></name><name><surname>Bakherad</surname><given-names>H.</given-names></name><name><surname>Fasihi-Ramandi</surname><given-names>M.</given-names></name><name><surname>Taheri</surname><given-names>R.A.</given-names></name><name><surname>Gargari</surname><given-names>S.L.M.</given-names></name></person-group><article-title>Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells</article-title><source>Biotechnol. Appl. Biochem.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/bab.1916</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="other" id="sbref0020"><person-group person-group-type="author"><name><surname>AJ Vaccines</surname></name></person-group><article-title>AJ Vaccines to Develop Vaccine for COVID-19. March 06</article-title><ext-link ext-link-type="uri" xlink:href="https://ajvaccines.com/news/" id="intr0370">https://ajvaccines.com/news/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Al-amri</surname><given-names>S.S.</given-names></name><name><surname>Abbas</surname><given-names>A.T.</given-names></name><name><surname>Siddiq</surname><given-names>L.A.</given-names></name><name><surname>Alghamdi</surname><given-names>A.</given-names></name><name><surname>Sanki</surname><given-names>M.A.</given-names></name><name><surname>Al-Muhanna</surname><given-names>M.K.</given-names></name><name><surname>Alhabbab</surname><given-names>R.Y.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Hashem</surname><given-names>A.M.</given-names></name></person-group><article-title>Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><pub-id pub-id-type="doi">10.1038/srep44875</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Al-Osail</surname><given-names>A.M.</given-names></name><name><surname>Al-Wazzah</surname><given-names>M.J.</given-names></name></person-group><article-title>The history and epidemiology of Middle East respiratory syndrome corona virus</article-title><source>Multidiscip. Respir. Med.</source><volume>12</volume><year>2017</year><pub-id pub-id-type="doi">10.1186/s40248-017-0101-8</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines: status report</article-title><source>Immunity.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id></element-citation></ref><ref id="bib0040"><element-citation publication-type="book" id="sbref0040"><chapter-title>2020an updated guide to the coronavirus drugs and vaccines in development</chapter-title><source>Stat</source><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.statnews.com/2020/03/19/" id="intr0375">https://www.statnews.com/2020/03/19/</ext-link><comment>an-updated-guide-to-the-coronavirus-drugs-and-vaccines-in-development/ URL (accessed 4.15.20).</comment></element-citation></ref><ref id="bib0045"><mixed-citation publication-type="other" id="oref0005">Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences. <ext-link ext-link-type="uri" xlink:href="https://covidvax.org/covid19-vaccine/AnhuiZhifei/" id="intr0380">https://covidvax.org/covid19-vaccine/AnhuiZhifei/</ext-link>Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0050"><mixed-citation publication-type="other" id="oref0010">Arcturus/Duke-NUS. <ext-link ext-link-type="uri" xlink:href="https://www.duke-nus.edu.sg/about/media/media-releases/media-releases/" id="intr0385">https://www.duke-nus.edu.sg/about/media/media-releases/media-releases/</ext-link>arcturus-therapeutics-duke-nus-clinical-trials-for-covid-19-vaccine-candidate-approved-to-proceed. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Backer</surname><given-names>J.A.</given-names></name><name><surname>Klinkenberg</surname><given-names>D.</given-names></name><name><surname>Wallinga</surname><given-names>J.</given-names></name></person-group><article-title>Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020</article-title><source>Euro Surveill.</source><volume>25</volume><year>2020</year><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.5.2000062</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="other" id="sbref0050"><person-group person-group-type="author"><name><surname>Baylor College of Medicine</surname></name></person-group><article-title>New Partnership to Accelerate Research of COVID-19 Vaccine. May 5</article-title><ext-link ext-link-type="uri" xlink:href="https://www.bcm.edu/coronavirus-preparedness/covid-19-research" id="intr0390">https://www.bcm.edu/coronavirus-preparedness/covid-19-research</ext-link><year>2020</year><comment>May 21, 2020., n.d.</comment></element-citation></ref><ref id="bib0065"><mixed-citation publication-type="other" id="oref0015">BEJING Institute of Biological <ext-link ext-link-type="uri" xlink:href="http://Products/Sinopharma.https://www.fiercebiotech.com/research/" id="intr0395">Products/Sinopharma.https://www.fiercebiotech.com/research/</ext-link>inactivated-covid-19-vaccine-by-china-s-sinopharm-clears-animal-tests. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0070"><mixed-citation publication-type="other" id="oref0020">Bharat Biotech. <ext-link ext-link-type="uri" xlink:href="https://www.deccanchronicle.com/lifestyle/health-andwellbeing/270720/" id="intr0400">https://www.deccanchronicle.com/lifestyle/health-andwellbeing/270720/</ext-link>bharat-biotechs-covaxin-shows-encouraging-results-in-phase-i.html. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0075"><element-citation publication-type="other" id="sbref0055"><person-group person-group-type="author"><name><surname>BIKEN foundation</surname></name></person-group><article-title>RIMD, And NIBIOHN: Joint Development of Drugs and Inspection Techniques for COVID-19. March 18</article-title><ext-link ext-link-type="uri" xlink:href="https://www.osaka-u.ac.jp/en/news/info/corona/corona_info/cooperation" id="intr0405">https://www.osaka-u.ac.jp/en/news/info/corona/corona_info/cooperation</ext-link><year>2020</year><comment>Accesses May 21, 2020., n.d.</comment></element-citation></ref><ref id="bib0080"><element-citation publication-type="other" id="sbref0060"><person-group person-group-type="author"><name><surname>BIOCAD</surname></name></person-group><article-title>BIOCAD. Begins Developing COVID-19 Vaccine. March 19</article-title><ext-link ext-link-type="uri" xlink:href="https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/" id="intr0410">https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/</ext-link><year>2020</year><comment>Accessed May21, 2020., n.d</comment></element-citation></ref><ref id="bib0085"><element-citation publication-type="other" id="sbref0065"><person-group person-group-type="author"><name><surname>Biological E Ltd</surname></name></person-group><article-title>Covid 19: Six Indian Companies Working on Coronavirus Vaccine. April 16</article-title><ext-link ext-link-type="uri" xlink:href="https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html" id="intr0415">https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html</ext-link><year>2020</year><comment>Accessed May 27, 2020., n.d</comment></element-citation></ref><ref id="bib0090"><element-citation publication-type="other" id="sbref0070"><person-group person-group-type="author"><name><surname>BioNet</surname></name></person-group><article-title>BioNet In Thailand Is Developing a COVID-19 GENE-based Vaccine (COVIGEN) Encoding the S (Spike) Protein of SARS-CoV-2</article-title><ext-link ext-link-type="uri" xlink:href="http://www.bionet-asia.com/media/news-events/" id="intr0420">http://www.bionet-asia.com/media/news-events/</ext-link><comment>Accessed on May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0095"><mixed-citation publication-type="other" id="oref0025">BioNTech/Fosun Pharma/Pfizer. <ext-link ext-link-type="uri" xlink:href="https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/" id="intr0425">https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/</ext-link>. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>van der Zee</surname><given-names>R.</given-names></name><name><surname>de Haan</surname><given-names>C.A.M.</given-names></name><name><surname>Rottier</surname><given-names>P.J.M.</given-names></name></person-group><article-title>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</article-title><source>J. Virol.</source><volume>77</volume><year>2003</year><fpage>8801</fpage><lpage>8811</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.16.8801-8811.2003</pub-id><pub-id pub-id-type="pmid">12885899</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Bouard</surname><given-names>D.</given-names></name><name><surname>Alazard&#x02010;Dany</surname><given-names>N.</given-names></name><name><surname>Cosset</surname><given-names>F.-L.</given-names></name></person-group><article-title>Viral vectors: from virology to transgene expression</article-title><source>Br. J. Pharmacol.</source><volume>157</volume><year>2009</year><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.349</pub-id><pub-id pub-id-type="pmid">18776913</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Rowe</surname><given-names>R.G.</given-names></name><name><surname>Han</surname><given-names>A.</given-names></name><name><surname>Ji</surname><given-names>W.</given-names></name><name><surname>McMahon</surname><given-names>C.</given-names></name><name><surname>Baier</surname><given-names>A.S.</given-names></name><name><surname>Huang</surname><given-names>Y.-C.</given-names></name><name><surname>Marion</surname><given-names>W.</given-names></name><name><surname>Pearson</surname><given-names>D.S.</given-names></name><name><surname>Kruse</surname><given-names>A.C.</given-names></name><name><surname>Daley</surname><given-names>G.Q.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Sliz</surname><given-names>P.</given-names></name></person-group><article-title>A nanobody targeting the LIN28:let-7 interaction fragment of TUT4 blocks uridylation of let-7</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>117</volume><year>2020</year><fpage>4653</fpage><lpage>4663</lpage><pub-id pub-id-type="doi">10.1073/pnas.1919409117</pub-id><pub-id pub-id-type="pmid">32060122</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>C.J.</given-names></name><name><surname>Tchesnokov</surname><given-names>E.P.</given-names></name><name><surname>Woolner</surname><given-names>E.</given-names></name><name><surname>Perry</surname><given-names>J.K.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Porter</surname><given-names>D.P.</given-names></name><name><surname>Gotte</surname><given-names>M.</given-names></name></person-group><article-title>Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</article-title><source>J. Biol. Chem. jbc.RA120.013679.</source><year>2020</year><pub-id pub-id-type="doi">10.1074/jbc.RA120.013679</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Q.</given-names></name><name><surname>Dai</surname><given-names>S.</given-names></name></person-group><article-title>Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence</article-title><source>Travel Med. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101647</pub-id></element-citation></ref><ref id="bib0130"><mixed-citation publication-type="other" id="oref0030">Centro Nacional Biotecnolog&#x000ed;a (CNB-CSIC). TYPE: RNA vaccine:<ext-link ext-link-type="uri" xlink:href="https://www.lykeo.com/" id="intr0430">https://www.lykeo.com/</ext-link>replicating-defective-sarscov-2-derived-rnas-centro-nacional-biotecnologia-cnb-csic-spain. Accessed May 21, 2020., n.d.</mixed-citation></ref><ref id="bib0135"><element-citation publication-type="other" id="sbref0105"><person-group person-group-type="author"><name><surname>CEPI</surname></name></person-group><article-title>CEPI Collaborates With the Institut Pasteur in a Consortium to Develop COVID-19 Vaccine. March 19</article-title><ext-link ext-link-type="uri" xlink:href="https://cepi.net/news_cepi/cepi-collaborates-withthe-" id="intr0435">https://cepi.net/news_cepi/cepi-collaborates-withthe-</ext-link><year>2020</year><comment>institut-pasteur-in-a-consortium-to-develop-covid-19- vaccine/. Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0140"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Ba</surname><given-names>L.</given-names></name><name><surname>Yi</surname><given-names>C.E.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Tu</surname><given-names>X.</given-names></name><name><surname>Gettie</surname><given-names>A.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name><name><surname>Ho</surname><given-names>D.D.</given-names></name></person-group><article-title>Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>2678</fpage><lpage>2688</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.5.2678-2688.2005</pub-id><pub-id pub-id-type="pmid">15708987</pub-id></element-citation></ref><ref id="bib0145"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.-H.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Chag</surname><given-names>S.M.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Tricoche</surname><given-names>N.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Seid</surname><given-names>C.A.</given-names></name><name><surname>Hudspeth</surname><given-names>E.M.</given-names></name><name><surname>Lustigman</surname><given-names>S.</given-names></name><name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name><surname>Bottazzi</surname><given-names>M.E.</given-names></name><name><surname>Hotez</surname><given-names>P.J.</given-names></name><name><surname>Zhan</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate</article-title><source>Hum. Vaccin. Immunother.</source><volume>10</volume><year>2014</year><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.4161/hv.27464</pub-id><pub-id pub-id-type="pmid">24355931</pub-id></element-citation></ref><ref id="bib0150"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Gai</surname><given-names>W.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name></person-group><article-title>DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>2069</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.063</pub-id><pub-id pub-id-type="pmid">28314561</pub-id></element-citation></ref><ref id="bib0155"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Humanized single domain antibodies neutralize SARS-CoV-2 by targeting spike receptor binding domain (preprint)</article-title><source>Microbiology.</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.14.042010</pub-id></element-citation></ref><ref id="bib0160"><mixed-citation publication-type="other" id="oref0035">Clover Biopharmaceuticals Inc./GSK/Dynavax. <ext-link ext-link-type="uri" xlink:href="https://www.fiercebiotech.com/biotech/" id="intr0440">https://www.fiercebiotech.com/biotech/</ext-link>using-gsk-dynavax-tech-clover-kickstarts-covid-vax-trial-data-drop-august. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0165"><element-citation publication-type="other" id="sbref0130"><person-group person-group-type="author"><name><surname>Cobra Biologics</surname></name></person-group><article-title>Cobra Biologics and the Karolinska Institute Collaborate to Develop COVID-19 Vaccine. 30th Mar</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine" id="intr0445">https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine</ext-link><year>2020</year><comment>Accessed May 21, 2020, n.d</comment></element-citation></ref><ref id="bib0170"><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Mu</surname><given-names>H.</given-names></name><name><surname>Taylor</surname><given-names>J.K.</given-names></name><name><surname>Massare</surname><given-names>M.</given-names></name><name><surname>Flyer</surname><given-names>D.C.</given-names></name><name><surname>Glenn</surname><given-names>G.M.</given-names></name><name><surname>Smith</surname><given-names>G.E.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmid">24736006</pub-id></element-citation></ref><ref id="bib0175"><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Venkataraman</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Glenn</surname><given-names>G.M.</given-names></name><name><surname>Smith</surname><given-names>G.E.</given-names></name><name><surname>Flyer</surname><given-names>D.C.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>1586</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.012</pub-id><pub-id pub-id-type="pmid">28237499</pub-id></element-citation></ref><ref id="bib0180"><element-citation publication-type="book" id="sbref0145"><source>COVID-19 Vaccine Candidate Shows Promise: April 02,</source><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.upmc.com/media/news/040220-falo-gambotto-sars-cov2-vaccine" id="intr0450">https://www.upmc.com/media/news/040220-falo-gambotto-sars-cov2-vaccine</ext-link><comment>Accessed May21, 2020., n.d</comment></element-citation></ref><ref id="bib0185"><mixed-citation publication-type="other" id="oref0040">COVID-19 vaccine: Dendritic cell-based vaccine. https<ext-link ext-link-type="uri" xlink:href="http://://covidvax.org/covid19-vaccine/ManitobaUni/" id="intr0455">://covidvax.org/covid19-vaccine/ManitobaUni/</ext-link>Dendritic-cell-based-vaccine-University-of-Manitoba. Accessed May 26, 2020, n.d.</mixed-citation></ref><ref id="bib0190"><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="bib0195"><mixed-citation publication-type="other" id="oref0045">Curevac. <ext-link ext-link-type="uri" xlink:href="https://www.curevac.com/news/" id="intr0460">https://www.curevac.com/news/</ext-link>curevac-receives-regulatory-approval-from-german-and-belgian-authorities-to-initiate-phase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0200"><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D.E.</given-names></name><name><surname>Jang</surname><given-names>G.M.</given-names></name><name><surname>Bouhaddou</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Obernier</surname><given-names>K.</given-names></name><name><surname>O&#x02019;Meara</surname><given-names>M.J.</given-names></name></person-group><article-title>A SARS-CoV-2-Human protein-Protein interaction map reveals drug targets and potential drug-repurposing (preprint)</article-title><source>Syst. Biol. (Stevenage)</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.22.002386</pub-id></element-citation></ref><ref id="bib0205"><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Daniloski</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Sanjana</surname><given-names>N.E.</given-names></name></person-group><article-title>The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types</article-title><source>bioRxiv</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.14.151357</pub-id></element-citation></ref><ref id="bib0210"><element-citation publication-type="book" id="sbref0165"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A.H.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Kikkert</surname><given-names>M.</given-names></name><name><surname>van Hemert</surname><given-names>M.J.</given-names></name></person-group><chapter-title>Host factors in coronavirus replication</chapter-title><person-group person-group-type="editor"><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Tompkins</surname><given-names>S.M.</given-names></name></person-group><source>Roles of Host Gene and Non-Coding RNA Expression in Virus Infection, Current Topics in Microbiology and Immunology</source><year>2018</year><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc><fpage>1</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/82_2017_25</pub-id></element-citation></ref><ref id="bib0215"><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Delmas</surname><given-names>B.</given-names></name><name><surname>Gelfi</surname><given-names>J.</given-names></name><name><surname>L&#x02019;Haridon</surname><given-names>R.</given-names></name><name><surname>Vogel</surname><given-names>L.K.</given-names></name><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>H.</given-names></name><name><surname>Nor&#x000e9;n</surname><given-names>O.</given-names></name><name><surname>Laude</surname><given-names>H.</given-names></name></person-group><article-title>Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV</article-title><source>Nature</source><volume>357</volume><year>1992</year><fpage>417</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/357417a0</pub-id><pub-id pub-id-type="pmid">1350661</pub-id></element-citation></ref><ref id="bib0220"><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus</article-title><source>Emerg. Microbes Infect.</source><volume>7</volume><year>2018</year><fpage>60</fpage><pub-id pub-id-type="doi">10.1038/s41426-018-0056-7</pub-id><pub-id pub-id-type="pmid">29618723</pub-id></element-citation></ref><ref id="bib0225"><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>C.K.L.</given-names></name><name><surname>Wu</surname><given-names>S.H.W.</given-names></name><name><surname>Ng</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>J.-D.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name></person-group><article-title>Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines</article-title><source>Virology</source><volume>353</volume><year>2006</year><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.03.049</pub-id><pub-id pub-id-type="pmid">16793110</pub-id></element-citation></ref><ref id="bib0230"><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.10.031</pub-id><pub-id pub-id-type="pmid">17092615</pub-id></element-citation></ref><ref id="bib0235"><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The spike protein of SARS-CoV &#x02014; a target for vaccine and therapeutic development</article-title><source>Nat. Rev. Microbiol.</source><volume>7</volume><year>2009</year><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmid">19198616</pub-id></element-citation></ref><ref id="bib0240"><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Chan</surname><given-names>C.C.S.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. Coli cells elicits potent neutralizing antibody and protective immunity</article-title><source>Virology</source><volume>393</volume><year>2009</year><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.07.018</pub-id><pub-id pub-id-type="pmid">19683779</pub-id></element-citation></ref><ref id="bib0245"><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Kou</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e81587</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0081587</pub-id></element-citation></ref><ref id="bib0250"><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name></person-group><article-title>A novel intracellularly expressed NS5B-specific nanobody suppresses bovine viral diarrhea virus replication</article-title><source>Vet. Microbiol.</source><volume>240</volume><year>2020</year><object-id pub-id-type="publisher-id">108449</object-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2019.108449</pub-id></element-citation></ref><ref id="bib0255"><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Dveksler</surname><given-names>G.S.</given-names></name><name><surname>Pensiero</surname><given-names>M.N.</given-names></name><name><surname>Cardellichio</surname><given-names>C.B.</given-names></name><name><surname>Williams</surname><given-names>R.K.</given-names></name><name><surname>Jiang</surname><given-names>G.S.</given-names></name><name><surname>Holmes</surname><given-names>K.V.</given-names></name><name><surname>Dieffenbach</surname><given-names>C.W.</given-names></name></person-group><article-title>Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV</article-title><source>J. Virol.</source><volume>65</volume><year>1991</year><fpage>6881</fpage><lpage>6891</lpage><pub-id pub-id-type="pmid">1719235</pub-id></element-citation></ref><ref id="bib0260"><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Eaaswarkhanth</surname><given-names>M.</given-names></name><name><surname>Al Madhoun</surname><given-names>A.</given-names></name><name><surname>Al-Mulla</surname><given-names>F.</given-names></name></person-group><article-title>Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?</article-title><source>Int. J. Infect. Dis.</source><volume>96</volume><year>2020</year><fpage>459</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.071</pub-id><pub-id pub-id-type="pmid">32464271</pub-id></element-citation></ref><ref id="bib0265"><element-citation publication-type="book" id="sbref0220"><person-group person-group-type="author"><name><surname>Enjuanes</surname><given-names>Luis</given-names></name><name><surname>Z&#x000fa;&#x000f1;iga</surname><given-names>Isabel Solay Sonia</given-names></name></person-group><chapter-title>NOVEL HUMAN PATHOGENIC CORONAVIRUS: SARS-CoV-2. March 26</chapter-title><year>2020</year><publisher-name>Centro Nacional de Biotecnolog&#x000ed;a (CNB-CSIC)</publisher-name><publisher-loc>Madrid (Spain)</publisher-loc><comment>n.d.</comment></element-citation></ref><ref id="bib0270"><element-citation publication-type="other" id="sbref0225"><person-group person-group-type="author"><name><surname>EpiVax</surname></name></person-group><article-title>EpiVax Accelerates COVID-19 Vaccine Development With UGA&#x02019;s Center for Vaccines and Immunology. May 04</article-title><ext-link ext-link-type="uri" xlink:href="https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology" id="intr0465">https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0275"><element-citation publication-type="other" id="sbref0230"><person-group person-group-type="author"><name><surname>Eric Niiler</surname></name></person-group><article-title>The US Army&#x02019;s Virus Research Lab Gears Up to Fight Covid-19. April 01</article-title><ext-link ext-link-type="uri" xlink:href="https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/" id="intr0470">https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/</ext-link><year>2020</year><comment>Accessed on May21, 2020., n.d</comment></element-citation></ref><ref id="bib0280"><element-citation publication-type="other" id="sbref0235"><person-group person-group-type="author"><name><surname>ExpreS2ion</surname></name></person-group><article-title>ExpreS2ion Announces Bavarian Nordic Enters Agreement With AdaptVac to Advance the COVID-19 Vaccine. May 06</article-title><ext-link ext-link-type="uri" xlink:href="https://expres2ionbio.com/investor/international-press-releases/" id="intr0475">https://expres2ionbio.com/investor/international-press-releases/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0285"><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.-M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.-G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>Z.-W.</given-names></name><name><surname>Tian</surname><given-names>J.-H.</given-names></name><name><surname>Pei</surname><given-names>Y.-Y.</given-names></name><name><surname>Yuan</surname><given-names>M.-L.</given-names></name><name><surname>Zhang</surname><given-names>Y.-L.</given-names></name><name><surname>Dai</surname><given-names>F.-H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.-M.</given-names></name><name><surname>Zheng</surname><given-names>J.-J.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Holmes</surname><given-names>E.C.</given-names></name><name><surname>Zhang</surname><given-names>Y.-Z.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bib0290"><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>M.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Rice</surname><given-names>A.B.</given-names></name><name><surname>Koprowski</surname><given-names>H.</given-names></name><name><surname>Dietzschold</surname><given-names>B.</given-names></name><name><surname>Schnell</surname><given-names>M.J.</given-names></name></person-group><article-title>A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</article-title><source>J. Gen. Virol.</source><volume>86</volume><year>2005</year><fpage>1435</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1099/vir.0.80844-0</pub-id><pub-id pub-id-type="pmid">15831955</pub-id></element-citation></ref><ref id="bib0295"><element-citation publication-type="other" id="sbref0250"><person-group person-group-type="author"><name><surname>Fast-Farming Pharma</surname></name></person-group><article-title>How Plants Could Speed up Vaccine Manufacture to Tackle the COVID-19 Pandemic? April 17</article-title><ext-link ext-link-type="uri" xlink:href="https://themedicinemaker.com/manufacture/fast-farming-pharma" id="intr0480">https://themedicinemaker.com/manufacture/fast-farming-pharma</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0300"><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Coronaviruses</source><volume>1282</volume><year>2015</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id></element-citation></ref><ref id="bib0305"><element-citation publication-type="other" id="sbref0260"><person-group person-group-type="author"><name><surname>Flow Pharma</surname></name></person-group><article-title>Flow Pharma Announces Strategic Partnership With Oakwood Labs for GMP Manufacturing of FlowVax COVID-19 Vaccine. April 15</article-title><ext-link ext-link-type="uri" xlink:href="https://www.accesswire.com/585181/Flow-Pharma-Announces-Strategic-Partnership-with-Oakwood-Labs-for-GMP-Manufacturing-of-FlowVax-COVID-19-Vaccine" id="intr0485">https://www.accesswire.com/585181/Flow-Pharma-Announces-Strategic-Partnership-with-Oakwood-Labs-for-GMP-Manufacturing-of-FlowVax-COVID-19-Vaccine</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0310"><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Folegatti</surname><given-names>P.M.</given-names></name><name><surname>Ewer</surname><given-names>K.J.</given-names></name><name><surname>Aley</surname><given-names>P.K.</given-names></name><name><surname>Angus</surname><given-names>B.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><volume>0</volume><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id></element-citation></ref><ref id="bib0315"><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Forthal</surname><given-names>D.N.</given-names></name><name><surname>Landucci</surname><given-names>G.</given-names></name><name><surname>Daar</surname><given-names>E.S.</given-names></name></person-group><article-title>Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells</article-title><source>J. Virol.</source><volume>75</volume><year>2001</year><fpage>6953</fpage><lpage>6961</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.15.6953-6961.2001</pub-id><pub-id pub-id-type="pmid">11435575</pub-id></element-citation></ref><ref id="bib0320"><element-citation publication-type="other" id="sbref0275"><person-group person-group-type="author"><name><surname>Fudan University</surname></name></person-group><article-title>Towards an Effective mRNA Vaccine Against 2019-nCoV: March 7</article-title><ext-link ext-link-type="uri" xlink:href="https://www.fudan.edu.cn/en/2020/0307/c1092a104281/page.htm" id="intr0490">https://www.fudan.edu.cn/en/2020/0307/c1092a104281/page.htm</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0325"><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Pomplun</surname><given-names>S.</given-names></name><name><surname>Loftis</surname><given-names>A.R.</given-names></name><name><surname>Loas</surname><given-names>A.</given-names></name><name><surname>Pentelute</surname><given-names>B.L.</given-names></name></person-group><article-title>The first-in-class peptide binder to the SARS-CoV-2 spike protein (preprint)</article-title><source>Bioengineering.</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.19.999318</pub-id></element-citation></ref><ref id="bib0330"><mixed-citation publication-type="other" id="oref0050">Gamaleya Research Institute. <ext-link ext-link-type="uri" xlink:href="https://www.trialsitenews.com/" id="intr0495">https://www.trialsitenews.com/</ext-link>gamaleya-research-institute-developed-covid-19-vaccine-clinical-trial-commences-across-russia/. Accessed on JUly 29, 2020., n.d.</mixed-citation></ref><ref id="bib0335"><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Mao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><volume>369</volume><year>2020</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></element-citation></ref><ref id="bib0340"><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>K.</given-names></name></person-group><article-title>Coronavirus vaccine developers wary of errant antibodies</article-title><source>Nat. Biotechnol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/d41587-020-00016-w</pub-id></element-citation></ref><ref id="bib0345"><element-citation publication-type="other" id="sbref0295"><person-group person-group-type="author"><name><surname>Generex</surname></name></person-group><article-title>Generex Signs Contract With EpiVax to Develop Ii-key Peptide Vaccines to Address the Coronavirus Pandemic. March 04, 202</article-title><ext-link ext-link-type="uri" xlink:href="https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic" id="intr0500">https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic</ext-link><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0350"><mixed-citation publication-type="other" id="oref0055">Genexine Consortium. <ext-link ext-link-type="uri" xlink:href="https://pharmashots.com/press-releases/korean-biotech-firm-genexines-covid-19-deoxyribonucleic-acid-vaccine-pipeline-gx-19-is-ready-for-clinical-testing-as-soon-as-it-applies-to-the-drug-ministry-for-human-testing/" id="intr0505">https://pharmashots.com/press-releases/korean-biotech-firm-genexines-covid-19-deoxyribonucleic-acid-vaccine-pipeline-gx-19-is-ready-for-clinical-testing-as-soon-as-it-applies-to-the-drug-ministry-for-human-testing/</ext-link>. Accessed July 29, 2020, n.d.</mixed-citation></ref><ref id="bib0355"><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>George Sakoulas</surname><given-names>M.D.</given-names></name></person-group><article-title>Remdesivir: a promising antiviral against coronaviruses</article-title><source>NEJM Journal Watch</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1056/nejm-jw.NA50889</pub-id></element-citation></ref><ref id="bib0360"><element-citation publication-type="other" id="sbref0305"><person-group person-group-type="author"><name><surname>GeoVax</surname></name></person-group><article-title>GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program. March 18</article-title><ext-link ext-link-type="uri" xlink:href="https://www.globenewswire.com/news-" id="intr0510">https://www.globenewswire.com/news-</ext-link><year>2020</year><comment>release/2020/03/18/2002611/0/en/ GeoVax-Progresses-in-Coronavirus-COVID-19-Vaccine-Development-Program.html. Accessed May21, 2020., n.d</comment></element-citation></ref><ref id="bib0365"><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Glowacka</surname><given-names>I.</given-names></name><name><surname>Bertram</surname><given-names>S.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Allen</surname><given-names>P.</given-names></name><name><surname>Soilleux</surname><given-names>E.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Steffen</surname><given-names>I.</given-names></name><name><surname>Tsegaye</surname><given-names>T.S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Gnirss</surname><given-names>K.</given-names></name><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>Schneider</surname><given-names>H.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response</article-title><source>J. Virol.</source><volume>85</volume><year>2011</year><fpage>4122</fpage><lpage>4134</lpage><pub-id pub-id-type="doi">10.1128/JVI.02232-10</pub-id><pub-id pub-id-type="pmid">21325420</pub-id></element-citation></ref><ref id="bib0370"><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Godet</surname><given-names>M.</given-names></name><name><surname>Grosclaude</surname><given-names>J.</given-names></name><name><surname>Delmas</surname><given-names>B.</given-names></name><name><surname>Laude</surname><given-names>H.</given-names></name></person-group><article-title>Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein</article-title><source>J. Virol.</source><volume>68</volume><year>1994</year><fpage>8008</fpage><lpage>8016</lpage><pub-id pub-id-type="pmid">7525985</pub-id></element-citation></ref><ref id="bib0375"><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>Gorlani</surname><given-names>A.</given-names></name><name><surname>Forthal</surname><given-names>D.N.</given-names></name></person-group><article-title>Antibody-dependent enhancement and the risk of HIV infection</article-title><source>Curr. HIV Res.</source><volume>11</volume><year>2013</year><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.2174/1570162x113116660062</pub-id><pub-id pub-id-type="pmid">24191936</pub-id></element-citation></ref><ref id="bib0380"><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>S.B.</given-names></name><name><surname>Criswell</surname><given-names>B.S.</given-names></name><name><surname>Six</surname><given-names>H.R.</given-names></name><name><surname>Couch</surname><given-names>R.B.</given-names></name></person-group><article-title>Lymphocyte cytotoxicity to influenza virus-infected cells. II. Requirement for antibody and non-T lymphocytes</article-title><source>J. Immunol.</source><volume>119</volume><year>1977</year><fpage>2100</fpage><lpage>2106</lpage><pub-id pub-id-type="pmid">334984</pub-id></element-citation></ref><ref id="bib0385"><element-citation publication-type="other" id="sbref0330"><person-group person-group-type="author"><name><surname>Greffex</surname></name></person-group><article-title>Greffex Completes COVID-19 Vaccine, Prepares for FDA Animal Testing. March 12</article-title><ext-link ext-link-type="uri" xlink:href="https://www.innovationews.com/Greffex-completes-COVID-19-vaccine-prepares-for-FDA-testing/" id="intr0515">https://www.innovationews.com/Greffex-completes-COVID-19-vaccine-prepares-for-FDA-testing/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0390"><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>Grubaugh</surname><given-names>N.D.</given-names></name><name><surname>Hanage</surname><given-names>W.P.</given-names></name><name><surname>Rasmussen</surname><given-names>A.L.</given-names></name></person-group><article-title>Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.040</pub-id><comment>S0092867420308175.</comment></element-citation></ref><ref id="bib0395"><element-citation publication-type="other" id="sbref0340"><person-group person-group-type="author"><name><surname>GSK</surname></name></person-group><article-title>GSK Joins Xiamen Innovax Biotech to Support COVID-19 Vaccine Development &#x00026; Expands Activity to Fight War Against Pandemic. April 06</article-title><ext-link ext-link-type="uri" xlink:href="https://www.trialsitenews.com/gsk-joins-xiamen-innovax-biotech-to-support-covid-19-vaccine-development-expands-activity-to-fight-war-against-pandemic/" id="intr0520">https://www.trialsitenews.com/gsk-joins-xiamen-innovax-biotech-to-support-covid-19-vaccine-development-expands-activity-to-fight-war-against-pandemic/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0400"><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Gunn</surname><given-names>B.M.</given-names></name><name><surname>Yu</surname><given-names>W.-H.</given-names></name><name><surname>Karim</surname><given-names>M.M.</given-names></name><name><surname>Brannan</surname><given-names>J.M.</given-names></name><name><surname>Herbert</surname><given-names>A.S.</given-names></name><name><surname>Wec</surname><given-names>A.Z.</given-names></name><name><surname>Halfmann</surname><given-names>P.J.</given-names></name><name><surname>Fusco</surname><given-names>M.L.</given-names></name><name><surname>Schendel</surname><given-names>S.L.</given-names></name><name><surname>Gangavarapu</surname><given-names>K.</given-names></name><name><surname>Krause</surname><given-names>T.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><name><surname>Das</surname><given-names>J.</given-names></name><name><surname>Suscovich</surname><given-names>T.J.</given-names></name><name><surname>Lai</surname><given-names>J.</given-names></name><name><surname>Chandran</surname><given-names>K.</given-names></name><name><surname>Zeitlin</surname><given-names>L.</given-names></name><name><surname>Crowe</surname><given-names>J.E.</given-names></name><name><surname>Lauffenburger</surname><given-names>D.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name><name><surname>Kobinger</surname><given-names>G.P.</given-names></name><name><surname>Andersen</surname><given-names>K.G.</given-names></name><name><surname>Dye</surname><given-names>J.M.</given-names></name><name><surname>Saphire</surname><given-names>E.O.</given-names></name><name><surname>Alter</surname><given-names>G.</given-names></name></person-group><article-title>A role for fc function in therapeutic monoclonal antibody-mediated protection against ebola virus</article-title><source>Cell Host Microbe</source><volume>24</volume><year>2018</year><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.07.009</pub-id><comment>e5</comment><pub-id pub-id-type="pmid">30092199</pub-id></element-citation></ref><ref id="bib0405"><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Hambach</surname><given-names>J.</given-names></name><name><surname>Riecken</surname><given-names>K.</given-names></name><name><surname>Cichutek</surname><given-names>S.</given-names></name><name><surname>Sch&#x000fc;tze</surname><given-names>K.</given-names></name><name><surname>Albrecht</surname><given-names>B.</given-names></name><name><surname>Petry</surname><given-names>K.</given-names></name></person-group><article-title>Targeting CD38-Expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs)</article-title><source>Cells</source><volume>9</volume><year>2020</year><pub-id pub-id-type="doi">10.3390/cells9020321</pub-id></element-citation></ref><ref id="bib0410"><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Hamers-Casterman</surname><given-names>C.</given-names></name><name><surname>Atarhouch</surname><given-names>T.</given-names></name><name><surname>Muyldermans</surname><given-names>S.</given-names></name><name><surname>Robinson</surname><given-names>G.</given-names></name><name><surname>Hammers</surname><given-names>C.</given-names></name><name><surname>Songa</surname><given-names>E.B.</given-names></name><name><surname>Bendahman</surname><given-names>N.</given-names></name><name><surname>Hammers</surname><given-names>R.</given-names></name></person-group><article-title>Naturally occurring antibodies devoid of light chains</article-title><source>Nature</source><volume>363</volume><year>1993</year><fpage>446</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/363446a0</pub-id><pub-id pub-id-type="pmid">8502296</pub-id></element-citation></ref><ref id="bib0415"><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Han</surname><given-names>D.P.</given-names></name><name><surname>Penn-Nicholson</surname><given-names>A.</given-names></name><name><surname>Cho</surname><given-names>M.W.</given-names></name></person-group><article-title>Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor</article-title><source>Virology</source><volume>350</volume><year>2006</year><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.01.029</pub-id><pub-id pub-id-type="pmid">16510163</pub-id></element-citation></ref><ref id="bib0420"><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Hanlon</surname><given-names>A.</given-names></name><name><surname>Metjian</surname><given-names>A.</given-names></name></person-group><article-title>Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura</article-title><source>Ther. Adv. Hematol.</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">2040620720902904</object-id><pub-id pub-id-type="doi">10.1177/2040620720902904</pub-id></element-citation></ref><ref id="bib0425"><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>Q.M.</given-names></name><name><surname>Wilson</surname><given-names>K.M.</given-names></name><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Itkin</surname><given-names>Z.</given-names></name><name><surname>Eastman</surname><given-names>R.T.</given-names></name><name><surname>Shinn</surname><given-names>P.</given-names></name><name><surname>Hall</surname><given-names>M.D.</given-names></name></person-group><article-title>Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: development and drug repurposing screen of an AlphaLISA proximity assay</article-title><source>bioRxiv.</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.16.154708</pub-id></element-citation></ref><ref id="bib0430"><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name><surname>Harmsen</surname><given-names>M.M.</given-names></name><name><surname>Van Solt</surname><given-names>C.B.</given-names></name><name><surname>Fijten</surname><given-names>H.P.D.</given-names></name><name><surname>Van Setten</surname><given-names>M.C.</given-names></name></person-group><article-title>Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins</article-title><source>Vaccine</source><volume>23</volume><year>2005</year><fpage>4926</fpage><lpage>4934</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.05.017</pub-id><pub-id pub-id-type="pmid">15992972</pub-id></element-citation></ref><ref id="bib0435"><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>B.F.</given-names></name><name><surname>Gilbert</surname><given-names>P.B.</given-names></name><name><surname>McElrath</surname><given-names>M.J.</given-names></name><name><surname>Zolla-Pazner</surname><given-names>S.</given-names></name><name><surname>Tomaras</surname><given-names>G.D.</given-names></name><name><surname>Alam</surname><given-names>S.M.</given-names></name><name><surname>Evans</surname><given-names>D.T.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Karnasuta</surname><given-names>C.</given-names></name><name><surname>Sutthent</surname><given-names>R.</given-names></name><name><surname>Liao</surname><given-names>H.-X.</given-names></name><name><surname>DeVico</surname><given-names>A.L.</given-names></name><name><surname>Lewis</surname><given-names>G.K.</given-names></name><name><surname>Williams</surname><given-names>C.</given-names></name><name><surname>Pinter</surname><given-names>A.</given-names></name><name><surname>Fong</surname><given-names>Y.</given-names></name><name><surname>Janes</surname><given-names>H.</given-names></name><name><surname>DeCamp</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Billings</surname><given-names>E.</given-names></name><name><surname>Karasavvas</surname><given-names>N.</given-names></name><name><surname>Robb</surname><given-names>M.L.</given-names></name><name><surname>Ngauy</surname><given-names>V.</given-names></name><name><surname>de Souza</surname><given-names>M.S.</given-names></name><name><surname>Paris</surname><given-names>R.</given-names></name><name><surname>Ferrari</surname><given-names>G.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Soderberg</surname><given-names>K.A.</given-names></name><name><surname>Andrews</surname><given-names>C.</given-names></name><name><surname>Berman</surname><given-names>P.W.</given-names></name><name><surname>Frahm</surname><given-names>N.</given-names></name><name><surname>De Rosa</surname><given-names>S.C.</given-names></name><name><surname>Alpert</surname><given-names>M.D.</given-names></name><name><surname>Yates</surname><given-names>N.L.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name><name><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name><surname>Kaewkungwal</surname><given-names>J.</given-names></name><name><surname>Nitayaphan</surname><given-names>S.</given-names></name><name><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name><name><surname>Michael</surname><given-names>N.L.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Immune-correlates analysis of an HIV-1 vaccine efficacy trial</article-title><source>N. Engl. J. Med.</source><volume>366</volume><year>2012</year><fpage>1275</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113425</pub-id><pub-id pub-id-type="pmid">22475592</pub-id></element-citation></ref><ref id="bib0440"><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Kou</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>324</volume><year>2004</year><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.106</pub-id><pub-id pub-id-type="pmid">15474494</pub-id></element-citation></ref><ref id="bib0445"><element-citation publication-type="other" id="sbref0390"><person-group person-group-type="author"><name><surname>Heat Biologics</surname></name></person-group><article-title>Heat Biologics Announces Research Collaboration With University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus. Match 05</article-title><ext-link ext-link-type="uri" xlink:href="https://www.heatbio.com/news-media/news-releases/detail/649/heat-biologics-announces-research-collaboration-with" id="intr0525">https://www.heatbio.com/news-media/news-releases/detail/649/heat-biologics-announces-research-collaboration-with</ext-link><year>2020</year><comment>May 21, 2020., n.d.</comment></element-citation></ref><ref id="bib0450"><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.-H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><comment>e8</comment><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib0455"><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>H.</given-names></name><name><surname>Hattermann</surname><given-names>K.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Gramberg</surname><given-names>T.</given-names></name><name><surname>Geier</surname><given-names>M.</given-names></name><name><surname>Krumbiegel</surname><given-names>M.</given-names></name><name><surname>Kuate</surname><given-names>S.</given-names></name><name><surname>Uberla</surname><given-names>K.</given-names></name><name><surname>Niedrig</surname><given-names>M.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><fpage>6134</fpage><lpage>6142</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.12.6134-6142.2004</pub-id><pub-id pub-id-type="pmid">15163706</pub-id></element-citation></ref><ref id="bib0460"><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>H.</given-names></name><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Hoek</surname><given-names>Lvander</given-names></name><name><surname>Geier</surname><given-names>M.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry</article-title><source>PNAS</source><volume>102</volume><year>2005</year><fpage>7988</fpage><lpage>7993</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409465102</pub-id><pub-id pub-id-type="pmid">15897467</pub-id></element-citation></ref><ref id="bib0465"><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Houser</surname><given-names>K.V.</given-names></name></person-group><article-title>Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody</article-title><source>PLoS Pathog.</source><volume>13</volume><year>2017</year><object-id pub-id-type="publisher-id">e1006565</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006565</pub-id><comment>PPATHOGENS-D-17-00350 [pii]</comment></element-citation></ref><ref id="bib0470"><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Kou</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library</article-title><source>J. Comb. Chem.</source><volume>7</volume><year>2005</year><fpage>648</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1021/cc0500607</pub-id><pub-id pub-id-type="pmid">16153058</pub-id></element-citation></ref><ref id="bib0475"><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Bu</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>6981</fpage><lpage>6991</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.047</pub-id><pub-id pub-id-type="pmid">17709158</pub-id></element-citation></ref><ref id="bib0480"><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Huentelman Matthew</surname><given-names>J.</given-names></name><name><surname>Zubcevic</surname><given-names>Jasenka</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>Prada</given-names></name><name><surname>Jose</surname><given-names>A.</given-names></name><name><surname>Xiaodong</surname><given-names>Xiao</given-names></name><name><surname>Dimitrov Dimiter</surname><given-names>S.</given-names></name><name><surname>Raizada Mohan</surname><given-names>K.</given-names></name><name><surname>Ostrov David</surname><given-names>A.</given-names></name></person-group><article-title>Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor</article-title><source>Hypertension</source><volume>44</volume><year>2004</year><fpage>903</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000146120.29648.36</pub-id><pub-id pub-id-type="pmid">15492138</pub-id></element-citation></ref><ref id="bib0485"><element-citation publication-type="book" id="sbref0430"><person-group person-group-type="author"><name><surname>Hulswit</surname><given-names>R.J.G.</given-names></name><name><surname>de Haan</surname><given-names>C.A.M.</given-names></name><name><surname>Bosch</surname><given-names>B.-J.</given-names></name></person-group><chapter-title>Chapter Two - coronavirus spike protein and tropism changes</chapter-title><person-group person-group-type="editor"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><source>Advances in Virus Research, Coronaviruses.</source><year>2016</year><publisher-name>Academic Press</publisher-name><fpage>29</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.004</pub-id></element-citation></ref><ref id="bib0490"><mixed-citation publication-type="other" id="oref0060">IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines:<ext-link ext-link-type="uri" xlink:href="https://www.iavi.org/newsroom/press-releases/2020/" id="intr0530">https://www.iavi.org/newsroom/press-releases/2020/</ext-link>iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines. March 5, 2020., n.d.</mixed-citation></ref><ref id="bib0495"><mixed-citation publication-type="other" id="oref0065">Imperial College London. <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsarena.com/news/imperial-college-covid-vaccine/" id="intr0535">https://www.clinicaltrialsarena.com/news/imperial-college-covid-vaccine/</ext-link>. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0500"><mixed-citation publication-type="other" id="oref0070">Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo. - PubMed - NCBI [WWW Document], n.d. URL <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/" id="intr0540">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link>28827692 (accessed 5.6.20).</mixed-citation></ref><ref id="bib0505"><element-citation publication-type="other" id="sbref0435"><person-group person-group-type="author"><name><surname>IMV</surname></name></person-group><article-title>DPX-COVID-19 at a glance. April 15</article-title><ext-link ext-link-type="uri" xlink:href="https://imv-inc.com/clinical-trials/dpx-covid-19/" id="intr0545">https://imv-inc.com/clinical-trials/dpx-covid-19/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0510"><mixed-citation publication-type="other" id="oref0075">Inovio Pharmaceuticals/International Vaccine Institute. <ext-link ext-link-type="uri" xlink:href="http://ir.inovio.com/news-releases/news-releases-details/2020/I" id="intr0550">http://ir.inovio.com/news-releases/news-releases-details/2020/I</ext-link>NOVIO-and-IVI-Partner-with-Seoul-National-University-Hospital-to-Start-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-INO-4800-in-South-Korea/default.aspx. Accessed July 29, 2020, n.d.</mixed-citation></ref><ref id="bib0515"><mixed-citation publication-type="other" id="oref0080">Institute of Medical Biology, Chinesee Academy of Medical Sciences. <ext-link ext-link-type="uri" xlink:href="http://english.nmpa.gov.cn/2020-06/22/c" id="intr0555">http://english.nmpa.gov.cn/2020-06/22/c</ext-link>_502093.htm. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0520"><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmid">32317716</pub-id></element-citation></ref><ref id="bib0525"><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name><surname>Peter</surname><given-names>L.</given-names></name><name><surname>Mercado</surname><given-names>N.B.</given-names></name><name><surname>McMahan</surname><given-names>K.</given-names></name><name><surname>Mahrokhian</surname><given-names>S.H.</given-names></name></person-group><article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title><source>Science.</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abc6284</pub-id></element-citation></ref><ref id="bib0530"><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>L.A.</given-names></name><name><surname>Anderson</surname><given-names>E.J.</given-names></name><name><surname>Rouphael</surname><given-names>N.G.</given-names></name><name><surname>Roberts</surname><given-names>P.C.</given-names></name><name><surname>Makhene</surname><given-names>M.</given-names></name><name><surname>Coler</surname><given-names>R.N.</given-names></name></person-group><article-title>An mRNA vaccine against SARS-CoV-2 &#x02014; preliminary report</article-title><source>N. Engl. J. Med.</source><volume>0</volume><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id><comment>null</comment></element-citation></ref><ref id="bib0535"><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name><surname>Jaume</surname><given-names>M.</given-names></name><name><surname>Yip</surname><given-names>M.S.</given-names></name><name><surname>Cheung</surname><given-names>C.Y.</given-names></name><name><surname>Leung</surname><given-names>H.L.</given-names></name><name><surname>Li</surname><given-names>P.H.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Dutry</surname><given-names>I.</given-names></name><name><surname>Callendret</surname><given-names>B.</given-names></name><name><surname>Escriou</surname><given-names>N.</given-names></name><name><surname>Altmeyer</surname><given-names>R.</given-names></name><name><surname>Nal</surname><given-names>B.</given-names></name><name><surname>Da&#x000eb;ron</surname><given-names>M.</given-names></name><name><surname>Bruzzone</surname><given-names>R.</given-names></name><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name></person-group><article-title>Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc&#x003b3;R pathway</article-title><source>J. Virol.</source><volume>85</volume><year>2011</year><fpage>10582</fpage><lpage>10597</lpage><pub-id pub-id-type="doi">10.1128/JVI.00671-11</pub-id><pub-id pub-id-type="pmid">21775467</pub-id></element-citation></ref><ref id="bib0540"><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name><surname>Jegaskanda</surname><given-names>S.</given-names></name><name><surname>Reading</surname><given-names>P.C.</given-names></name><name><surname>Kent</surname><given-names>S.J.</given-names></name></person-group><article-title>Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine</article-title><source>J. Immunol.</source><volume>193</volume><year>2014</year><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400432</pub-id><pub-id pub-id-type="pmid">24994909</pub-id></element-citation></ref><ref id="bib0545"><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Fan</surname><given-names>R.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>A high affinity nanobody against endothelin receptor type B: a new approach to the treatment of melanoma</article-title><source>Mol. Biol. Rep.</source><volume>47</volume><year>2020</year><fpage>2137</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1007/s11033-020-05313-w</pub-id><pub-id pub-id-type="pmid">32080807</pub-id></element-citation></ref><ref id="bib0550"><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name></person-group><article-title>An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>275</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1723441</pub-id><pub-id pub-id-type="pmid">32005086</pub-id></element-citation></ref><ref id="bib0555"><element-citation publication-type="journal" id="sbref0475"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Hillyer</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title><source>Trends in Immunology S1471490620300570.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.it.2020.03.007</pub-id></element-citation></ref><ref id="bib0560"><mixed-citation publication-type="other" id="oref0085">Johns Hopkins University: <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/" id="intr0560">https://coronavirus.jhu.edu/</ext-link>map.html. Accessed on August 19, 2020., n.d.</mixed-citation></ref><ref id="bib0565"><element-citation publication-type="other" id="sbref0480"><person-group person-group-type="author"><name><surname>Johnson &#x00026; Johnson</surname></name></person-group><article-title>Johnson &#x00026; Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership With U.S. Department of Health &#x00026; Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. March 30</article-title><ext-link ext-link-type="uri" xlink:href="https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use" id="intr0565">https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use</ext-link><year>2020</year><comment>Accessed on May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0570"><element-citation publication-type="journal" id="sbref0485"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Tsui</surname><given-names>W.H.W.</given-names></name><name><surname>Lee</surname><given-names>T.S.W.</given-names></name><name><surname>Tanner</surname><given-names>J.A.</given-names></name><name><surname>Watt</surname><given-names>R.M.</given-names></name><name><surname>Huang</surname><given-names>J.-D.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Chan</surname><given-names>K.-H.</given-names></name><name><surname>Tse</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>A.P.C.</given-names></name><name><surname>Ng</surname><given-names>L.W.Y.</given-names></name><name><surname>Wong</surname><given-names>B.C.W.</given-names></name><name><surname>Tsoi</surname><given-names>H.-W.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Ho</surname><given-names>D.D.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics</article-title><source>Chem. Biol.</source><volume>11</volume><year>2004</year><fpage>1293</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2004.07.013</pub-id><pub-id pub-id-type="pmid">15380189</pub-id></element-citation></ref><ref id="bib0575"><element-citation publication-type="journal" id="sbref0490"><person-group person-group-type="author"><name><surname>Katzelnick</surname><given-names>L.C.</given-names></name><name><surname>Gresh</surname><given-names>L.</given-names></name><name><surname>Halloran</surname><given-names>M.E.</given-names></name><name><surname>Mercado</surname><given-names>J.C.</given-names></name><name><surname>Kuan</surname><given-names>G.</given-names></name><name><surname>Gordon</surname><given-names>A.</given-names></name><name><surname>Balmaseda</surname><given-names>A.</given-names></name><name><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Antibody-dependent enhancement of severe dengue disease in humans</article-title><source>Science</source><volume>358</volume><year>2017</year><fpage>929</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1126/science.aan6836</pub-id><pub-id pub-id-type="pmid">29097492</pub-id></element-citation></ref><ref id="bib0580"><mixed-citation publication-type="other" id="oref0090">Kentucky Bioprocessing, Inc. <ext-link ext-link-type="uri" xlink:href="https://www.kentucky.com/news/coronavirus/" id="intr0570">https://www.kentucky.com/news/coronavirus/</ext-link>article241709386.html. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0585"><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name><surname>Khandia</surname><given-names>R.</given-names></name><name><surname>Munjal</surname><given-names>A.</given-names></name><name><surname>Dhama</surname><given-names>K.</given-names></name><name><surname>Karthik</surname><given-names>K.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Malik</surname><given-names>Y.S.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Chaicumpa</surname><given-names>W.</given-names></name></person-group><article-title>Modulation of Dengue/Zika virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in zika virus infection</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><pub-id pub-id-type="doi">10.3389/fimmu.2018.00597</pub-id></element-citation></ref><ref id="bib0590"><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.W.</given-names></name><name><surname>Canchola</surname><given-names>J.G.</given-names></name><name><surname>Brandt</surname><given-names>C.D.</given-names></name><name><surname>Pyles</surname><given-names>G.</given-names></name><name><surname>Chanock</surname><given-names>R.M.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Parrott</surname><given-names>R.H.</given-names></name></person-group><article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title><source>Am. J. Epidemiol.</source><volume>89</volume><year>1969</year><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120955</pub-id><pub-id pub-id-type="pmid">4305198</pub-id></element-citation></ref><ref id="bib0595"><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Erdos</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Kenniston</surname><given-names>T.W.</given-names></name><name><surname>Balmert</surname><given-names>S.C.</given-names></name><name><surname>Carey</surname><given-names>C.D.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Klimstra</surname><given-names>W.B.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Korkmaz</surname><given-names>E.</given-names></name><name><surname>Falo</surname><given-names>L.D.</given-names></name><name><surname>Gambotto</surname><given-names>A.</given-names></name></person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><year>2020</year><fpage>102743</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmid">32249203</pub-id></element-citation></ref><ref id="bib0600"><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name><surname>Kobinger</surname><given-names>G.P.</given-names></name><name><surname>Figueredo</surname><given-names>J.M.</given-names></name><name><surname>Rowe</surname><given-names>T.</given-names></name><name><surname>Zhi</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Sanmiguel</surname><given-names>J.C.</given-names></name><name><surname>Bell</surname><given-names>P.</given-names></name><name><surname>Wivel</surname><given-names>N.A.</given-names></name><name><surname>Zitzow</surname><given-names>L.A.</given-names></name><name><surname>Flieder</surname><given-names>D.B.</given-names></name><name><surname>Hogan</surname><given-names>R.J.</given-names></name><name><surname>Wilson</surname><given-names>J.M.</given-names></name></person-group><article-title>Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>5220</fpage><lpage>5231</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.065</pub-id><pub-id pub-id-type="pmid">17559989</pub-id></element-citation></ref><ref id="bib0605"><element-citation publication-type="journal" id="sbref0515"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>S.</given-names></name><name><surname>Loo</surname><given-names>L.S.</given-names></name></person-group><article-title>Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity</article-title><source>J. Immunol.</source><volume>129</volume><year>1982</year><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">6282968</pub-id></element-citation></ref><ref id="bib0610"><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>S.</given-names></name><name><surname>Charlebois</surname><given-names>E.D.</given-names></name><name><surname>Sigouroudinia</surname><given-names>M.</given-names></name><name><surname>Goldbeck</surname><given-names>C.</given-names></name><name><surname>Hartog</surname><given-names>K.</given-names></name><name><surname>Sekulovich</surname><given-names>R.E.</given-names></name><name><surname>Langenberg</surname><given-names>A.G.M.</given-names></name><name><surname>Burke</surname><given-names>R.L.</given-names></name></person-group><article-title>Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine</article-title><source>J. Infect. Dis.</source><volume>181</volume><year>2000</year><fpage>335</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1086/315208</pub-id><pub-id pub-id-type="pmid">10608784</pub-id></element-citation></ref><ref id="bib0615"><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B.</given-names></name><name><surname>Fischer</surname><given-names>W.M.</given-names></name><name><surname>Gnanakaran</surname><given-names>S.</given-names></name><name><surname>Yoon</surname><given-names>H.</given-names></name><name><surname>Theiler</surname><given-names>J.</given-names></name><name><surname>Abfalterer</surname><given-names>W.</given-names></name><name><surname>Hengartner</surname><given-names>N.</given-names></name><name><surname>Giorgi</surname><given-names>E.E.</given-names></name><name><surname>Bhattacharya</surname><given-names>T.</given-names></name><name><surname>Foley</surname><given-names>B.</given-names></name><name><surname>Hastie</surname><given-names>K.M.</given-names></name><name><surname>Parker</surname><given-names>M.D.</given-names></name><name><surname>Partridge</surname><given-names>D.G.</given-names></name><name><surname>Evans</surname><given-names>C.M.</given-names></name><name><surname>Freeman</surname><given-names>T.M.</given-names></name><name><surname>de Silva</surname><given-names>T.I.</given-names></name><name><surname>McDanal</surname><given-names>C.</given-names></name><name><surname>Perez</surname><given-names>L.G.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Moon-Walker</surname><given-names>A.</given-names></name><name><surname>Whelan</surname><given-names>S.P.</given-names></name><name><surname>LaBranche</surname><given-names>C.C.</given-names></name><name><surname>Saphire</surname><given-names>E.O.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Angyal</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>R.L.</given-names></name><name><surname>Carrilero</surname><given-names>L.</given-names></name><name><surname>Green</surname><given-names>L.R.</given-names></name><name><surname>Groves</surname><given-names>D.C.</given-names></name><name><surname>Johnson</surname><given-names>K.J.</given-names></name><name><surname>Keeley</surname><given-names>A.J.</given-names></name><name><surname>Lindsey</surname><given-names>B.B.</given-names></name><name><surname>Parsons</surname><given-names>P.J.</given-names></name><name><surname>Raza</surname><given-names>M.</given-names></name><name><surname>Rowland-Jones</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>N.</given-names></name><name><surname>Tucker</surname><given-names>R.M.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wyles</surname><given-names>M.D.</given-names></name></person-group><article-title>Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><comment>S0092867420308205</comment></element-citation></ref><ref id="bib0620"><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name><surname>Krempl</surname><given-names>C.</given-names></name><name><surname>Schultze</surname><given-names>B.</given-names></name><name><surname>Laude</surname><given-names>H.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name></person-group><article-title>Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus</article-title><source>J. Virol.</source><volume>71</volume><year>1997</year><fpage>3285</fpage><lpage>3287</lpage><pub-id pub-id-type="pmid">9060696</pub-id></element-citation></ref><ref id="bib0625"><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Teng</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Preparation and characterization of Anti-GPC3 nanobody against hepatocellular carcinoma</article-title><source>Int. J. Nanomedicine</source><volume>15</volume><year>2020</year><fpage>2197</fpage><lpage>2205</lpage><pub-id pub-id-type="doi">10.2147/IJN.S235058</pub-id><pub-id pub-id-type="pmid">32280214</pub-id></element-citation></ref><ref id="bib0630"><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Jackson</surname><given-names>C.B.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Ojha</surname><given-names>A.</given-names></name><name><surname>Rangarajan</surname><given-names>E.S.</given-names></name><name><surname>Izard</surname><given-names>T.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name></person-group><article-title>The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity</article-title><source>bioRxiv</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.12.148726</pub-id><comment>06.12.148726</comment></element-citation></ref><ref id="bib0635"><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Recombinant receptor binding domain protein induces partial protective immunity in Rhesus macaques against middle east respiratory syndrome coronavirus challenge</article-title><source>EBioMedicine</source><volume>2</volume><year>2015</year><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.031</pub-id><pub-id pub-id-type="pmid">26629538</pub-id></element-citation></ref><ref id="bib0640"><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Shan</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id></element-citation></ref><ref id="bib0645"><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>S.A.</given-names></name><name><surname>Grantz</surname><given-names>K.H.</given-names></name><name><surname>Bi</surname><given-names>Q.</given-names></name><name><surname>Jones</surname><given-names>F.K.</given-names></name><name><surname>Zheng</surname><given-names>Q.</given-names></name><name><surname>Meredith</surname><given-names>H.R.</given-names></name><name><surname>Azman</surname><given-names>A.S.</given-names></name><name><surname>Reich</surname><given-names>N.G.</given-names></name><name><surname>Lessler</surname><given-names>J.</given-names></name></person-group><article-title>The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</article-title><source>Ann. Intern. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.7326/M20-0504</pub-id></element-citation></ref><ref id="bib0650"><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name><surname>Laursen</surname><given-names>N.S.</given-names></name><name><surname>Friesen</surname><given-names>R.H.E.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Jongeneelen</surname><given-names>M.</given-names></name><name><surname>Blokland</surname><given-names>S.</given-names></name><name><surname>Vermond</surname><given-names>J.</given-names></name></person-group><article-title>Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin</article-title><source>Science</source><volume>362</volume><year>2018</year><fpage>598</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1126/science.aaq0620</pub-id><pub-id pub-id-type="pmid">30385580</pub-id></element-citation></ref><ref id="bib0655"><element-citation publication-type="journal" id="sbref0565"><person-group person-group-type="author"><name><surname>Ledwith</surname><given-names>B.J.</given-names></name><name><surname>Manam</surname><given-names>S.</given-names></name><name><surname>Troilo</surname><given-names>P.J.</given-names></name><name><surname>Barnum</surname><given-names>A.B.</given-names></name><name><surname>Pauley</surname><given-names>C.J.</given-names></name><name><surname>Griffiths</surname><given-names>T.G.</given-names></name><name><surname>Harper</surname><given-names>L.B.</given-names></name><name><surname>Schock</surname><given-names>H.B.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Faris</surname><given-names>J.E.</given-names></name><name><surname>Way</surname><given-names>P.A.</given-names></name><name><surname>Beare</surname><given-names>C.M.</given-names></name><name><surname>Bagdon</surname><given-names>W.J.</given-names></name><name><surname>Nichols</surname><given-names>W.W.</given-names></name></person-group><article-title>Plasmid DNA vaccines: assay for integration into host genomic DNA</article-title><source>Dev. Biol. (Basel)</source><volume>104</volume><year>2000</year><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11713822</pub-id></element-citation></ref><ref id="bib0660"><element-citation publication-type="journal" id="sbref0570"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Hui</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Cameron</surname><given-names>P.</given-names></name><name><surname>Joynt</surname><given-names>G.M.</given-names></name><name><surname>Ahuja</surname><given-names>A.</given-names></name><name><surname>Yung</surname><given-names>M.Y.</given-names></name><name><surname>Leung</surname><given-names>C.B.</given-names></name><name><surname>To</surname><given-names>K.F.</given-names></name><name><surname>Lui</surname><given-names>S.F.</given-names></name><name><surname>Szeto</surname><given-names>C.C.</given-names></name><name><surname>Chung</surname><given-names>S.</given-names></name><name><surname>Sung</surname><given-names>J.J.Y.</given-names></name></person-group><article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title><source>N. Engl. J. Med.</source><volume>348</volume><year>2003</year><fpage>1986</fpage><lpage>1994</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030685</pub-id><pub-id pub-id-type="pmid">12682352</pub-id></element-citation></ref><ref id="bib0665"><element-citation publication-type="journal" id="sbref0575"><person-group person-group-type="author"><name><surname>Letko</surname><given-names>M.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Munster</surname><given-names>V.</given-names></name></person-group><article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title><source>Nat. Microbiol.</source><volume>5</volume><year>2020</year><fpage>562</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0688-y</pub-id><pub-id pub-id-type="pmid">32094589</pub-id></element-citation></ref><ref id="bib0670"><element-citation publication-type="journal" id="sbref0580"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition mechanisms of coronaviruses: a decade of structural studies</article-title><source>J. Virol.</source><volume>89</volume><year>2015</year><fpage>1954</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1128/JVI.02615-14</pub-id><pub-id pub-id-type="pmid">25428871</pub-id></element-citation></ref><ref id="bib0675"><element-citation publication-type="journal" id="sbref0585"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annu. Rev. Virol.</source><volume>3</volume><year>2016</year><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id></element-citation></ref><ref id="bib0680"><element-citation publication-type="journal" id="sbref0590"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Berne</surname><given-names>M.A.</given-names></name><name><surname>Somasundaran</surname><given-names>M.</given-names></name><name><surname>Sullivan</surname><given-names>J.L.</given-names></name><name><surname>Luzuriaga</surname><given-names>K.</given-names></name><name><surname>Greenough</surname><given-names>T.C.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="bib0685"><element-citation publication-type="journal" id="sbref0595"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Selection and characterization of specific nanobody against bovine virus diarrhea virus (BVDV) E2 protein</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><object-id pub-id-type="publisher-id">e0178469</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0178469</pub-id></element-citation></ref><ref id="bib0690"><element-citation publication-type="journal" id="sbref0600"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>K.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Hua</surname><given-names>Z.</given-names></name></person-group><article-title>Nanobody against the E7 oncoprotein of human papillomavirus 16</article-title><source>Mol. Immunol.</source><volume>109</volume><year>2019</year><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2019.02.022</pub-id><pub-id pub-id-type="pmid">30849663</pub-id></element-citation></ref><ref id="bib0695"><element-citation publication-type="journal" id="sbref0605"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Hua</surname><given-names>Z.</given-names></name></person-group><article-title>Nanobody against PDL1</article-title><source>Biotechnol. Lett.</source><volume>42</volume><year>2020</year><fpage>727</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1007/s10529-020-02823-2</pub-id><pub-id pub-id-type="pmid">32006351</pub-id></element-citation></ref><ref id="bib0700"><element-citation publication-type="journal" id="sbref0610"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H.-X.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Smaill</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD&#x02013;ACE2 receptor interaction</article-title><source>J. Gen. Virol.</source><volume>89</volume><year>2008</year><fpage>1015</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1099/vir.0.83331-0</pub-id><pub-id pub-id-type="pmid">18343844</pub-id></element-citation></ref><ref id="bib0705"><element-citation publication-type="journal" id="sbref0615"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>N.M.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Akhmetzhanov</surname><given-names>A.R.</given-names></name><name><surname>Jung</surname><given-names>S.-M.</given-names></name><name><surname>Yuan</surname><given-names>B.</given-names></name><name><surname>Kinoshita</surname><given-names>R.</given-names></name><name><surname>Nishiura</surname><given-names>H.</given-names></name></person-group><article-title>Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data</article-title><source>J. Clin. Med.</source><volume>9</volume><year>2020</year><pub-id pub-id-type="doi">10.3390/jcm9020538</pub-id></element-citation></ref><ref id="bib0710"><element-citation publication-type="journal" id="sbref0620"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>A comparison of plasmid DNA and mRNA as vaccine technologies</article-title><source>Vaccines (Basel)</source><volume>7</volume><year>2019</year><pub-id pub-id-type="doi">10.3390/vaccines7020037</pub-id></element-citation></ref><ref id="bib0715"><element-citation publication-type="journal" id="sbref0625"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.-Y.</given-names></name><name><surname>Wu</surname><given-names>L.-Z.</given-names></name><name><surname>Huang</surname><given-names>B.-J.</given-names></name><name><surname>Huang</surname><given-names>J.-L.</given-names></name><name><surname>Zhang</surname><given-names>Y.-L.</given-names></name><name><surname>Ke</surname><given-names>M.-L.</given-names></name><name><surname>Wang</surname><given-names>J.-M.</given-names></name><name><surname>Tan</surname><given-names>W.-P.</given-names></name><name><surname>Zhang</surname><given-names>R.-H.</given-names></name><name><surname>Chen</surname><given-names>H.-K.</given-names></name><name><surname>Zeng</surname><given-names>Y.-X.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name></person-group><article-title>Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats</article-title><source>Virus Res.</source><volume>112</volume><year>2005</year><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2005.02.009</pub-id><pub-id pub-id-type="pmid">16022898</pub-id></element-citation></ref><ref id="bib0720"><element-citation publication-type="journal" id="sbref0630"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Kwok</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Nishiura</surname><given-names>K.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Cheung</surname><given-names>K.-W.</given-names></name><name><surname>Chan</surname><given-names>K.-H.</given-names></name><name><surname>Alvarez</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Lackner</surname><given-names>A.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Anti&#x02013;spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title><source>JCI Insight</source><volume>4</volume><year>2019</year><pub-id pub-id-type="doi">10.1172/jci.insight.123158</pub-id></element-citation></ref><ref id="bib0725"><element-citation publication-type="journal" id="sbref0635"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title><source>JCI Insight</source><volume>4</volume><year>2019</year><pub-id pub-id-type="doi">10.1172/jci.insight.123158</pub-id><comment>123158 [pii]</comment></element-citation></ref><ref id="bib0730"><element-citation publication-type="journal" id="sbref0640"><person-group person-group-type="author"><name><surname>Long</surname><given-names>Q.-X.</given-names></name><name><surname>Tang</surname><given-names>X.-J.</given-names></name><name><surname>Shi</surname><given-names>Q.-L.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Deng</surname><given-names>H.-J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>J.-L.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>F.-J.</given-names></name><name><surname>Su</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>X.-M.</given-names></name><name><surname>Li</surname><given-names>J.-J.</given-names></name><name><surname>Qiu</surname><given-names>J.-F.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>A.-L.</given-names></name></person-group><article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>1200</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0965-6</pub-id><pub-id pub-id-type="pmid">32555424</pub-id></element-citation></ref><ref id="bib0735"><element-citation publication-type="journal" id="sbref0645"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="bib0740"><element-citation publication-type="journal" id="sbref0650"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>N.C.</given-names></name><name><surname>Tsang</surname><given-names>O.T.-Y.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Perera</surname><given-names>R.A.P.M.</given-names></name><name><surname>Leung</surname><given-names>W.S.</given-names></name><name><surname>So</surname><given-names>R.T.Y.</given-names></name><name><surname>Chan</surname><given-names>J.M.C.</given-names></name><name><surname>Yip</surname><given-names>G.K.</given-names></name><name><surname>Chik</surname><given-names>T.S.H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Choi</surname><given-names>C.Y.C.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Ng</surname><given-names>W.W.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Poon</surname><given-names>L.L.M.</given-names></name><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name><name><surname>Mok</surname><given-names>C.K.P.</given-names></name></person-group><article-title>Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.15.993097</pub-id><comment>2020.03.15.993097</comment></element-citation></ref><ref id="bib0745"><element-citation publication-type="journal" id="sbref0655"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.E.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name><name><surname>Holman</surname><given-names>L.A.</given-names></name><name><surname>Gordon</surname><given-names>I.J.</given-names></name><name><surname>Enama</surname><given-names>M.E.</given-names></name><name><surname>Larkin</surname><given-names>B.D.</given-names></name><name><surname>Andrews</surname><given-names>C.A.</given-names></name><name><surname>Vogel</surname><given-names>L.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name><name><surname>Roederer</surname><given-names>M.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Gomez</surname><given-names>P.L.</given-names></name><name><surname>Nason</surname><given-names>M.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>VRC 301 Study Team</surname></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.09.026</pub-id><pub-id pub-id-type="pmid">18824060</pub-id></element-citation></ref><ref id="bib0750"><element-citation publication-type="journal" id="sbref0660"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>M.A.</given-names></name></person-group><article-title>Compounds with therapeutic potential against novel respiratory 2019 coronavirus</article-title><source>Antimicrob. Agents Chemother.</source><volume>64</volume><year>2020</year><pub-id pub-id-type="doi">10.1128/AAC.00399-20</pub-id></element-citation></ref><ref id="bib0755"><element-citation publication-type="book" id="sbref0665"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P.S.</given-names></name></person-group><chapter-title>The molecular biology of coronaviruses</chapter-title><source>Advances in Virus Research</source><year>2006</year><publisher-name>Academic Press</publisher-name><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(06)66005-3</pub-id></element-citation></ref><ref id="bib0760"><element-citation publication-type="journal" id="sbref0670"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Taguchi</surname><given-names>F.</given-names></name></person-group><article-title>Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2</article-title><source>J. Virol.</source><volume>84</volume><year>2010</year><fpage>12658</fpage><lpage>12664</lpage><pub-id pub-id-type="doi">10.1128/JVI.01542-10</pub-id><pub-id pub-id-type="pmid">20926566</pub-id></element-citation></ref><ref id="bib0765"><element-citation publication-type="journal" id="sbref0675"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>T.</given-names></name><name><surname>Cao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Gong</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS</article-title><source>bioRxiv</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.08.926006</pub-id><comment>02.08.926006</comment></element-citation></ref><ref id="bib0770"><element-citation publication-type="journal" id="sbref0680"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>K.</given-names></name><name><surname>Ait-Goughoulte</surname><given-names>M.</given-names></name><name><surname>Keck</surname><given-names>Z.-Y.</given-names></name><name><surname>Foung</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>R.</given-names></name></person-group><article-title>Antibody-dependent enhancement of hepatitis C virus infection</article-title><source>J. Virol.</source><volume>82</volume><year>2008</year><fpage>2140</fpage><lpage>2149</lpage><pub-id pub-id-type="doi">10.1128/JVI.01867-07</pub-id><pub-id pub-id-type="pmid">18094180</pub-id></element-citation></ref><ref id="bib0775"><mixed-citation publication-type="other" id="oref0095">MIGAL&#x02019;s Coronavirus Vaccine Project:<ext-link ext-link-type="uri" xlink:href="https://www.migal.org.il/en/node/" id="intr0575">https://www.migal.org.il/en/node/</ext-link>7010. Accessed May 21, 2020., n.d.</mixed-citation></ref><ref id="bib0780"><element-citation publication-type="journal" id="sbref0685"><person-group person-group-type="author"><name><surname>Moradi-Kalbolandi</surname><given-names>S.</given-names></name><name><surname>Sharifi-K</surname><given-names>A.</given-names></name><name><surname>Darvishi</surname><given-names>B.</given-names></name><name><surname>Majidzadeh-A</surname><given-names>K.</given-names></name><name><surname>Jalili</surname><given-names>N.</given-names></name><name><surname>Sadeghi</surname><given-names>S.</given-names></name><name><surname>Mosayebzadeh</surname><given-names>M.</given-names></name><name><surname>Sanati</surname><given-names>H.</given-names></name><name><surname>Salehi</surname><given-names>M.</given-names></name><name><surname>Farahmand</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function</article-title><source>Mol. Immunol.</source><volume>118</volume><year>2020</year><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2019.12.017</pub-id><pub-id pub-id-type="pmid">31884389</pub-id></element-citation></ref><ref id="bib0785"><element-citation publication-type="journal" id="sbref0690"><person-group person-group-type="author"><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>van Kuppeveld</surname><given-names>F.J.M.</given-names></name><name><surname>Rottier</surname><given-names>P.J.M.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Bosch</surname><given-names>B.J.</given-names></name></person-group><article-title>The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.</article-title><source>J. Virol.</source><volume>87</volume><year>2013</year><fpage>9379</fpage><lpage>9383</lpage><pub-id pub-id-type="doi">10.1128/JVI.01277-13</pub-id><pub-id pub-id-type="pmid">23785207</pub-id></element-citation></ref><ref id="bib0790"><element-citation publication-type="journal" id="sbref0695"><person-group person-group-type="author"><name><surname>Neuman</surname><given-names>B.W.</given-names></name><name><surname>Adair</surname><given-names>B.D.</given-names></name><name><surname>Yoshioka</surname><given-names>C.</given-names></name><name><surname>Quispe</surname><given-names>J.D.</given-names></name><name><surname>Orca</surname><given-names>G.</given-names></name><name><surname>Kuhn</surname><given-names>P.</given-names></name><name><surname>Milligan</surname><given-names>R.A.</given-names></name><name><surname>Yeager</surname><given-names>M.</given-names></name><name><surname>Buchmeier</surname><given-names>M.J.</given-names></name></person-group><article-title>Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy</article-title><source>J. Virol.</source><volume>80</volume><year>2006</year><fpage>7918</fpage><lpage>7928</lpage><pub-id pub-id-type="doi">10.1128/JVI.00645-06</pub-id><pub-id pub-id-type="pmid">16873249</pub-id></element-citation></ref><ref id="bib0795"><mixed-citation publication-type="other" id="oref0100">Novavax. <ext-link ext-link-type="uri" xlink:href="https://ir.novavax.com/news-releases/news-release-details/" id="intr0580">https://ir.novavax.com/news-releases/news-release-details/</ext-link>novavax-initiates-phase-12-clinical-trial-covid-19-vaccine. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib0800"><element-citation publication-type="journal" id="sbref0700"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Tonnu</surname><given-names>N.</given-names></name><name><surname>Singer</surname><given-names>O.</given-names></name><name><surname>Hunter</surname><given-names>T.</given-names></name><name><surname>Ryan</surname><given-names>A.L.</given-names><suffix>(Firth)</suffix></name><name><surname>Pao</surname><given-names>G.M.</given-names></name></person-group><article-title>The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner</article-title><source>bioRxiv</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.21.214932</pub-id><comment>07.21.214932</comment></element-citation></ref><ref id="bib0805"><mixed-citation publication-type="other" id="oref0105">OncoGen. OncoGen researchers propose personalized vaccinomics strategy for the novel China coronavirus: <ext-link ext-link-type="uri" xlink:href="https://oncogen.ro/oncogen-vaccine-design-for-coronavirus/" id="intr0585">https://oncogen.ro/oncogen-vaccine-design-for-coronavirus/</ext-link>. Accessed May 21, 2020., n.d.</mixed-citation></ref><ref id="bib0810"><mixed-citation publication-type="other" id="oref0110">Osaka University/AnGes/Takara Bio. <ext-link ext-link-type="uri" xlink:href="https://www.takarabio.com/about/bioview-blog/current-events/" id="intr0590">https://www.takarabio.com/about/bioview-blog/current-events/</ext-link>dethroning-king-coronavirus-with-novel-vaccines. Accessed July 29, 2020, n.d.</mixed-citation></ref><ref id="bib0815"><element-citation publication-type="journal" id="sbref0705"><person-group person-group-type="author"><name><surname>Pardi</surname><given-names>N.</given-names></name><name><surname>Hogan</surname><given-names>M.J.</given-names></name><name><surname>Porter</surname><given-names>F.W.</given-names></name><name><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines &#x02014; a new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><volume>17</volume><year>2018</year><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id></element-citation></ref><ref id="bib0820"><element-citation publication-type="book" id="sbref0710"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>S.</given-names></name><name><surname>Hofer</surname><given-names>J.</given-names></name><name><surname>Ballester</surname><given-names>P.J.</given-names></name><name><surname>Fattakhova</surname><given-names>E.</given-names></name><name><surname>DiFlumeri</surname><given-names>J.</given-names></name><name><surname>Campbell</surname><given-names>A.</given-names></name><name><surname>Oravic</surname><given-names>M.</given-names></name></person-group><chapter-title>Drug Repurposing for Covid-19: Discovery of Potential Small-Molecule Inhibitors of Spike Protein-ACE2 Receptor Interaction Through Virtual Screening and Consensus Scoring</chapter-title><year>2020</year><pub-id pub-id-type="doi">10.26434/chemrxiv.12482435.v1</pub-id></element-citation></ref><ref id="bib0825"><element-citation publication-type="journal" id="sbref0715"><person-group person-group-type="author"><name><surname>Paules</surname><given-names>C.I.</given-names></name><name><surname>Marston</surname><given-names>H.D.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>Coronavirus infections&#x02014;more than just the common cold</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>707</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.0757</pub-id><pub-id pub-id-type="pmid">31971553</pub-id></element-citation></ref><ref id="bib0830"><mixed-citation publication-type="other" id="oref0115">Pharmajet: Pharmajet partner with I.T.I. and EpiVax to develop and deliver COVID-10 Vaccine. April 15, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.immunomix.com/pharmajet-partners-with-iti-and-epivax-to-develop-and-deliver-covid-19-vaccine/" id="intr0595">https://www.immunomix.com/pharmajet-partners-with-iti-and-epivax-to-develop-and-deliver-covid-19-vaccine/</ext-link>. Accessed May 21, 2020., n.d.</mixed-citation></ref><ref id="bib0835"><element-citation publication-type="journal" id="sbref0720"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Niu</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Qiao</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name><name><surname>Wang</surname><given-names>Qisheng</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name></person-group><article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><comment>S009286742030338X.</comment></element-citation></ref><ref id="bib0840"><element-citation publication-type="journal" id="sbref0725"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Smits</surname><given-names>S.L.</given-names></name><name><surname>Dekkers</surname><given-names>D.H.W.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Demmers</surname><given-names>J.A.A.</given-names></name><name><surname>Zaki</surname><given-names>A.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Rottier</surname><given-names>P.J.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><volume>495</volume><year>2013</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nature12005</pub-id><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="bib0845"><element-citation publication-type="journal" id="sbref0730"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Okba</surname><given-names>N.M.A.</given-names></name><name><surname>Gutierrez-Alvarez</surname><given-names>J.</given-names></name><name><surname>Drabek</surname><given-names>D.</given-names></name><name><surname>Dieren</surname><given-names>B.</given-names></name><name><surname>van Widagdo</surname><given-names>W.</given-names></name></person-group><article-title>Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection.</article-title><source>Sci. Adv.</source><volume>4</volume><year>2018</year><pub-id pub-id-type="doi">10.1126/sciadv.aas9667</pub-id><comment>eaas9667</comment></element-citation></ref><ref id="bib0850"><element-citation publication-type="journal" id="sbref0735"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S.</given-names></name><name><surname>Jasny</surname><given-names>E.</given-names></name><name><surname>Schmidt</surname><given-names>K.E.</given-names></name><name><surname>Petsch</surname><given-names>B.</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id></element-citation></ref><ref id="bib0855"><element-citation publication-type="other" id="sbref0740"><person-group person-group-type="author"><name><surname>ReiThera</surname></name></person-group><article-title>LEUKOCARE And Univercells. ReiThera, Leukocare and Univercells Announce Fast-track Development of a COVID-19 Vaccine. APRIL 23</article-title><ext-link ext-link-type="uri" xlink:href="https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/" id="intr0600">https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/</ext-link><year>2020</year><comment>Accessed on May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0860"><element-citation publication-type="journal" id="sbref0745"><person-group person-group-type="author"><name><surname>Renner</surname><given-names>M.</given-names></name><name><surname>Flanagan</surname><given-names>A.</given-names></name><name><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name><surname>Puttikhunt</surname><given-names>C.</given-names></name><name><surname>Kasinrerk</surname><given-names>W.</given-names></name><name><surname>Supasa</surname><given-names>P.</given-names></name><name><surname>Wongwiwat</surname><given-names>W.</given-names></name><name><surname>Chawansuntati</surname><given-names>K.</given-names></name><name><surname>Duangchinda</surname><given-names>T.</given-names></name><name><surname>Cowper</surname><given-names>A.</given-names></name><name><surname>Midgley</surname><given-names>C.M.</given-names></name><name><surname>Malasit</surname><given-names>P.</given-names></name><name><surname>Huiskonen</surname><given-names>J.T.</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J.</given-names></name><name><surname>Screaton</surname><given-names>G.R.</given-names></name><name><surname>Grimes</surname><given-names>J.M.</given-names></name></person-group><article-title>Characterization of a potent and highly unusual minimally-enhancing antibody directed against dengue virus</article-title><source>Nat. Immunol.</source><volume>19</volume><year>2018</year><fpage>1248</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0227-7</pub-id><pub-id pub-id-type="pmid">30323338</pub-id></element-citation></ref><ref id="bib0865"><element-citation publication-type="journal" id="sbref0750"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Lan</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name></person-group><article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id><pub-id pub-id-type="pmid">32231345</pub-id></element-citation></ref><ref id="bib0870"><mixed-citation publication-type="other" id="oref0120">Saiba Biotech. Saiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept. <ext-link ext-link-type="uri" xlink:href="https://www.saiba-biotech.com/" id="intr0605">https://www.saiba-biotech.com/</ext-link>. Accessed May 21, 2020., n.d.</mixed-citation></ref><ref id="bib0875"><mixed-citation publication-type="other" id="oref0125">Saint-Petersburg scientific research institute of vaccines and serums. May22, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/" id="intr0610">https://www.who.int/who-documents-detail/</ext-link>draft-landscape-of-covid-19-candidate-vaccines. Accessed May 25, 2020., n.d.</mixed-citation></ref><ref id="bib0880"><element-citation publication-type="journal" id="sbref0755"><person-group person-group-type="author"><name><surname>Sanche</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>Y.T.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Romero-Severson</surname><given-names>E.</given-names></name><name><surname>Hengartner</surname><given-names>N.</given-names></name><name><surname>Ke</surname><given-names>R.</given-names></name></person-group><article-title>The novel coronavirus, 2019-nCoV, is highly contagious and more infectious than initially estimated (preprint)</article-title><source>Epidemiology.</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.07.20021154</pub-id></element-citation></ref><ref id="bib0885"><element-citation publication-type="other" id="sbref0760"><person-group person-group-type="author"><name><surname>Sanofi and GSK</surname></name></person-group><article-title>Sanofi and GSK to Join Forces in Unprecedented Vaccine Collaboration to Fight COVID-19. April 14</article-title><ext-link ext-link-type="uri" xlink:href="https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00" id="intr0615">https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0890"><element-citation publication-type="journal" id="sbref0765"><person-group person-group-type="author"><name><surname>Saphire</surname><given-names>E.O.</given-names></name><name><surname>Schendel</surname><given-names>S.L.</given-names></name><name><surname>Fusco</surname><given-names>M.L.</given-names></name><name><surname>Gangavarapu</surname><given-names>K.</given-names></name><name><surname>Gunn</surname><given-names>B.M.</given-names></name><name><surname>Wec</surname><given-names>A.Z.</given-names></name></person-group><article-title>Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection</article-title><source>Cell</source><volume>174</volume><year>2018</year><fpage>938</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.033</pub-id><comment>e13</comment><pub-id pub-id-type="pmid">30096313</pub-id></element-citation></ref><ref id="bib0895"><mixed-citation publication-type="other" id="oref0130">SARS-CoV-2: DZIF scientists and the development of vaccines <ext-link ext-link-type="uri" xlink:href="https://www.dzif.de/en/s" id="intr0620">https://www.dzif.de/en/s</ext-link>ars-cov-2-dzif-scientists-and-development-vaccines Mar 9 2020., n.d.</mixed-citation></ref><ref id="bib0900"><element-citation publication-type="journal" id="sbref0770"><person-group person-group-type="author"><name><surname>Schriewer</surname><given-names>L.</given-names></name><name><surname>Sch&#x000fc;tze</surname><given-names>K.</given-names></name><name><surname>Petry</surname><given-names>K.</given-names></name><name><surname>Hambach</surname><given-names>J.</given-names></name><name><surname>Fumey</surname><given-names>W.</given-names></name><name><surname>Koenigsdorf</surname><given-names>J.</given-names></name></person-group><article-title>Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies</article-title><source>Theranostics</source><volume>10</volume><year>2020</year><fpage>2645</fpage><lpage>2658</lpage><pub-id pub-id-type="doi">10.7150/thno.38533</pub-id><pub-id pub-id-type="pmid">32194826</pub-id></element-citation></ref><ref id="bib0905"><element-citation publication-type="journal" id="sbref0775"><person-group person-group-type="author"><name><surname>Schultze</surname><given-names>B.</given-names></name><name><surname>Gross</surname><given-names>H.J.</given-names></name><name><surname>Brossmer</surname><given-names>R.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name></person-group><article-title>The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant</article-title><source>J. Virol.</source><volume>65</volume><year>1991</year><fpage>6232</fpage><lpage>6237</lpage><pub-id pub-id-type="pmid">1920630</pub-id></element-citation></ref><ref id="bib0910"><element-citation publication-type="journal" id="sbref0780"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>M.</given-names></name><name><surname>Cataland</surname><given-names>S.R.</given-names></name><name><surname>Peyvandi</surname><given-names>F.</given-names></name><name><surname>Coppo</surname><given-names>P.</given-names></name><name><surname>Kn&#x000f6;bl</surname><given-names>P.</given-names></name><name><surname>Hovinga</surname><given-names>J.A.K.</given-names></name><name><surname>Metjian</surname><given-names>A.</given-names></name><name><surname>Rubia</surname><given-names>J.</given-names></name><name><surname>de la, Pavenski</surname><given-names>K.</given-names></name><name><surname>Callewaert</surname><given-names>F.</given-names></name><name><surname>Biswas</surname><given-names>D.</given-names></name><name><surname>Winter</surname><given-names>H.D.</given-names></name><name><surname>Zeldin</surname><given-names>R.K.</given-names></name></person-group><article-title>Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura</article-title><source>N. Engl. J. Med.</source><year>2019</year><pub-id pub-id-type="doi">10.1056/NEJMoa1806311</pub-id></element-citation></ref><ref id="bib0915"><element-citation publication-type="journal" id="sbref0785"><person-group person-group-type="author"><name><surname>Seow</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>C.</given-names></name><name><surname>Merrick</surname><given-names>B.</given-names></name><name><surname>Acors</surname><given-names>S.</given-names></name><name><surname>Steel</surname><given-names>K.J.A.</given-names></name><name><surname>Hemmings</surname><given-names>O.</given-names></name></person-group><article-title>Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection (preprint)</article-title><source>Infectious Diseases (except HIV/AIDS).</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.09.20148429</pub-id></element-citation></ref><ref id="bib0920"><element-citation publication-type="journal" id="sbref0790"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Ye</surname><given-names>G.</given-names></name><name><surname>Geng</surname><given-names>Q.</given-names></name><name><surname>Auerbach</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>PNAS.</source><year>2020</year><pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id></element-citation></ref><ref id="bib0925"><element-citation publication-type="journal" id="sbref0795"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>B.-S.</given-names></name><name><surname>Stadler</surname><given-names>K.</given-names></name><name><surname>Nguyen</surname><given-names>H.H.</given-names></name><name><surname>Yun</surname><given-names>C.-H.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Czerkinsky</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>M.K.</given-names></name></person-group><article-title>Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain</article-title><source>Virol. J.</source><volume>9</volume><year>2012</year><fpage>215</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-9-215</pub-id><pub-id pub-id-type="pmid">22995185</pub-id></element-citation></ref><ref id="bib0930"><element-citation publication-type="other" id="sbref0800"><person-group person-group-type="author"><name><surname>Shionogi Inc</surname></name></person-group><article-title>Shionogi Accelerates Development of Potential COVID-19 Treatments and Vaccine. April 28</article-title><ext-link ext-link-type="uri" xlink:href="https://www.shionogi.com/us/en/news/2020/4/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine.html" id="intr0625">https://www.shionogi.com/us/en/news/2020/4/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine.html</ext-link><year>2020</year><comment>Accessed May21, 2020., n.d</comment></element-citation></ref><ref id="bib0935"><element-citation publication-type="journal" id="sbref0805"><person-group person-group-type="author"><name><surname>Shulla</surname><given-names>A.</given-names></name><name><surname>Heald-Sargent</surname><given-names>T.</given-names></name><name><surname>Subramanya</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Gallagher</surname><given-names>T.</given-names></name></person-group><article-title>A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry</article-title><source>J. Virol.</source><volume>85</volume><year>2011</year><fpage>873</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1128/JVI.02062-10</pub-id><pub-id pub-id-type="pmid">21068237</pub-id></element-citation></ref><ref id="bib0940"><element-citation publication-type="journal" id="sbref0810"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>Y.L.</given-names></name><name><surname>Teoh</surname><given-names>K.T.</given-names></name><name><surname>Lo</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>C.M.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Escriou</surname><given-names>N.</given-names></name><name><surname>Tsao</surname><given-names>S.W.</given-names></name><name><surname>Nicholls</surname><given-names>J.M.</given-names></name><name><surname>Altmeyer</surname><given-names>R.</given-names></name><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name><surname>Bruzzone</surname><given-names>R.</given-names></name><name><surname>Nal</surname><given-names>B.</given-names></name></person-group><article-title>The M, E, and N Structural Proteins of the Severe Acute Respiratory Syndrome Coronavirus Are Required for Efficient Assembly, Trafficking, and Release of Virus-Like Particles</article-title><source>J. Virol.</source><volume>82</volume><year>2008</year><fpage>11318</fpage><lpage>11330</lpage><pub-id pub-id-type="doi">10.1128/JVI.01052-08</pub-id><pub-id pub-id-type="pmid">18753196</pub-id></element-citation></ref><ref id="bib0945"><element-citation publication-type="journal" id="sbref0815"><person-group person-group-type="author"><name><surname>Struck</surname><given-names>A.-W.</given-names></name><name><surname>Axmann</surname><given-names>M.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name></person-group><article-title>A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2</article-title><source>Antiviral Res.</source><volume>94</volume><year>2012</year><fpage>288</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.12.012</pub-id><pub-id pub-id-type="pmid">22265858</pub-id></element-citation></ref><ref id="bib0950"><element-citation publication-type="journal" id="sbref0820"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>A.C.K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol.</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="bib0955"><element-citation publication-type="journal" id="sbref0825"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Murakami</surname><given-names>A.</given-names></name><name><surname>Tamin</surname><given-names>A.</given-names></name><name><surname>Matthews</surname><given-names>L.J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Tallarico</surname><given-names>A.S.C.</given-names></name><name><surname>Olurinde</surname><given-names>M.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name><name><surname>Bellini</surname><given-names>W.J.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Marasco</surname><given-names>W.A.</given-names></name></person-group><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>101</volume><year>2004</year><fpage>2536</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307140101</pub-id><pub-id pub-id-type="pmid">14983044</pub-id></element-citation></ref><ref id="bib0960"><element-citation publication-type="other" id="sbref0830"><person-group person-group-type="author"><name><surname>Symvivo Corporation</surname></name></person-group><article-title>Evaluating the Safety, Tolerability, and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. April 6</article-title><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04334980" id="intr0630">https://clinicaltrials.gov/ct2/show/NCT04334980</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0965"><element-citation publication-type="journal" id="sbref0835"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title><source>Virology</source><volume>499</volume><year>2016</year><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmid">27750111</pub-id></element-citation></ref><ref id="bib0970"><element-citation publication-type="journal" id="sbref0840"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Pu</surname><given-names>J.</given-names></name><name><surname>Voronin</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41423-020-0400-4</pub-id></element-citation></ref><ref id="bib0975"><element-citation publication-type="journal" id="sbref0845"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>A.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name><name><surname>Okazaki</surname><given-names>K.</given-names></name><name><surname>Kida</surname><given-names>H.</given-names></name><name><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>Infectivity-enhancing antibodies to ebola virus glycoprotein</article-title><source>J. Virol.</source><volume>75</volume><year>2001</year><fpage>2324</fpage><lpage>2330</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.5.2324-2330.2001</pub-id><pub-id pub-id-type="pmid">11160735</pub-id></element-citation></ref><ref id="bib0980"><element-citation publication-type="journal" id="sbref0850"><person-group person-group-type="author"><name><surname>Takashima</surname><given-names>Y.</given-names></name><name><surname>Osaki</surname><given-names>M.</given-names></name><name><surname>Ishimaru</surname><given-names>Y.</given-names></name><name><surname>Yamaguchi</surname><given-names>H.</given-names></name><name><surname>Harada</surname><given-names>A.</given-names></name></person-group><article-title>Artificial molecular clamp: a novel device for synthetic polymerases</article-title><source>Angew. Chemie Int. Ed.</source><volume>50</volume><year>2011</year><fpage>7524</fpage><lpage>7528</lpage><pub-id pub-id-type="doi">10.1002/anie.201102834</pub-id></element-citation></ref><ref id="bib0985"><element-citation publication-type="other" id="sbref0855"><person-group person-group-type="author"><name><surname>Takis</surname></name></person-group><article-title>Takis, a Biotech Company in Castel Romano, Rome, Announces That It Is Ready to Test Its Covid-19 Vaccine on Pre-clinical Models. 17 March</article-title><ext-link ext-link-type="uri" xlink:href="http://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-announces-that-it-is-ready-to-test-its-covid-19-vaccine-on-pre-clinical-models" id="intr0635">http://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-announces-that-it-is-ready-to-test-its-covid-19-vaccine-on-pre-clinical-models</ext-link><year>2020</year><comment>Accessed on May 21, 2020., n.d</comment></element-citation></ref><ref id="bib0990"><element-citation publication-type="journal" id="sbref0860"><person-group person-group-type="author"><name><surname>Tarr</surname><given-names>A.W.</given-names></name><name><surname>Lafaye</surname><given-names>P.</given-names></name><name><surname>Meredith</surname><given-names>L.</given-names></name><name><surname>Damier-Piolle</surname><given-names>L.</given-names></name><name><surname>Urbanowicz</surname><given-names>R.A.</given-names></name><name><surname>Meola</surname><given-names>A.</given-names></name><name><surname>Jestin</surname><given-names>J.-L.</given-names></name><name><surname>Brown</surname><given-names>R.J.P.</given-names></name><name><surname>McKeating</surname><given-names>J.A.</given-names></name><name><surname>Rey</surname><given-names>F.A.</given-names></name><name><surname>Ball</surname><given-names>J.K.</given-names></name><name><surname>Krey</surname><given-names>T.</given-names></name></person-group><article-title>An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission</article-title><source>Hepatology</source><volume>58</volume><year>2013</year><fpage>932</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1002/hep.26430</pub-id><pub-id pub-id-type="pmid">23553604</pub-id></element-citation></ref><ref id="bib0995"><element-citation publication-type="journal" id="sbref0865"><person-group person-group-type="author"><name><surname>ter Meulen</surname><given-names>J.</given-names></name><name><surname>Bakker</surname><given-names>A.B.H.</given-names></name><name><surname>van den Brink</surname><given-names>E.N.</given-names></name><name><surname>Weverling</surname><given-names>G.J.</given-names></name><name><surname>Martina</surname><given-names>B.E.E.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>2139</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16506-9</pub-id><pub-id pub-id-type="pmid">15220038</pub-id></element-citation></ref><ref id="bib1000"><element-citation publication-type="journal" id="sbref0870"><person-group person-group-type="author"><name><surname>ter Meulen</surname><given-names>J.</given-names></name><name><surname>van den Brink</surname><given-names>E.N.</given-names></name><name><surname>Poon</surname><given-names>L.L.M.</given-names></name><name><surname>Marissen</surname><given-names>W.E.</given-names></name><name><surname>Leung</surname><given-names>C.S.W.</given-names></name><name><surname>Cox</surname><given-names>F.</given-names></name></person-group><article-title>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants</article-title><source>PLoS Med.</source><volume>3</volume><year>2006</year><fpage>e237</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030237</pub-id><pub-id pub-id-type="pmid">16796401</pub-id></element-citation></ref><ref id="bib1005"><element-citation publication-type="journal" id="sbref0875"><person-group person-group-type="author"><name><surname>Tetro</surname><given-names>J.A.</given-names></name></person-group><article-title>Is COVID-19 receiving ADE from other coronaviruses? Microbes and infection</article-title><source>Special issue on the new coronavirus causing the COVID-19 outbreak</source><volume>22</volume><year>2020</year><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2020.02.006</pub-id></element-citation></ref><ref id="bib1010"><element-citation publication-type="journal" id="sbref0880"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Ying</surname><given-names>T.</given-names></name></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>382</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1729069</pub-id><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="bib1015"><element-citation publication-type="other" id="sbref0885"><person-group person-group-type="author"><name><surname>Tonix Pharma</surname></name></person-group><article-title>TNX-1800 Horsepox Vector for S Protein. April 26</article-title><ext-link ext-link-type="uri" xlink:href="https://covidvax.org/covid19-vaccine/Tonix/TNX-1800-Horsepox-vector-for-S-protein-Tonix-Pharma-Southern-Research" id="intr0640">https://covidvax.org/covid19-vaccine/Tonix/TNX-1800-Horsepox-vector-for-S-protein-Tonix-Pharma-Southern-Research</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1020"><element-citation publication-type="journal" id="sbref0890"><person-group person-group-type="author"><name><surname>Traggiai</surname><given-names>E.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Kolesnikova</surname><given-names>L.</given-names></name><name><surname>Uematsu</surname><given-names>Y.</given-names></name><name><surname>Gismondo</surname><given-names>M.R.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Rappuoli</surname><given-names>R.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</article-title><source>Nat. Med.</source><volume>10</volume><year>2004</year><fpage>871</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nm1080</pub-id><pub-id pub-id-type="pmid">15247913</pub-id></element-citation></ref><ref id="bib1025"><element-citation publication-type="journal" id="sbref0895"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>K.W.</given-names></name><name><surname>Ho</surname><given-names>P.L.</given-names></name><name><surname>Ooi</surname><given-names>G.C.</given-names></name><name><surname>Yee</surname><given-names>W.K.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chan-Yeung</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>W.K.</given-names></name><name><surname>Seto</surname><given-names>W.H.</given-names></name><name><surname>Yam</surname><given-names>L.Y.</given-names></name><name><surname>Cheung</surname><given-names>T.M.</given-names></name><name><surname>Wong</surname><given-names>P.C.</given-names></name><name><surname>Lam</surname><given-names>B.</given-names></name><name><surname>Ip</surname><given-names>M.S.</given-names></name><name><surname>Chan</surname><given-names>J.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Lai</surname><given-names>K.N.</given-names></name></person-group><article-title>A cluster of cases of severe acute respiratory syndrome in Hong Kong</article-title><source>N. Engl. J. Med.</source><volume>348</volume><year>2003</year><fpage>1977</fpage><lpage>1985</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030666</pub-id><pub-id pub-id-type="pmid">12671062</pub-id></element-citation></ref><ref id="bib1030"><element-citation publication-type="journal" id="sbref0900"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>L.V.</given-names></name><name><surname>Meganck</surname><given-names>R.M.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses</article-title><source>Front. Microbiol.</source><volume>11</volume><year>2020</year><fpage>658</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.00658</pub-id><pub-id pub-id-type="pmid">32390971</pub-id></element-citation></ref><ref id="bib1035"><element-citation publication-type="journal" id="sbref0905"><person-group person-group-type="author"><name><surname>Ulrich</surname><given-names>H.</given-names></name><name><surname>Pillat</surname><given-names>M.M.</given-names></name><name><surname>T&#x000e1;rnok</surname><given-names>A.</given-names></name></person-group><article-title>Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective</article-title><source>Cytom. Part A</source><volume>97</volume><year>2020</year><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.24047</pub-id></element-citation></ref><ref id="bib1040"><element-citation publication-type="other" id="sbref0910"><person-group person-group-type="author"><name><surname>University of Hong Kong</surname></name></person-group><article-title>CEPI Partners With University of Hong Kong to Develop COVID-19 Vaccine. March 18</article-title><ext-link ext-link-type="uri" xlink:href="https://cepi.net/news_cepi/cepi-partners-with-university-of-hong-kong-to-develop-covid-19-vaccine/" id="intr0645">https://cepi.net/news_cepi/cepi-partners-with-university-of-hong-kong-to-develop-covid-19-vaccine/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1045"><element-citation publication-type="other" id="sbref0915"><person-group person-group-type="author"><name><surname>University of Ontario</surname></name></person-group><article-title>Ontario Leading COVID-19 Research in Canada Province Announces First Phase of Research Projects to Fight COVID-19. May 21</article-title><ext-link ext-link-type="uri" xlink:href="https://news.ontario.ca/opo/en/2020/05/ontario-leading-covid-19-research-in-canada.html" id="intr0650">https://news.ontario.ca/opo/en/2020/05/ontario-leading-covid-19-research-in-canada.html</ext-link><year>2020</year><comment>Accessed May 21, 2020, n.d</comment></element-citation></ref><ref id="bib1050"><mixed-citation publication-type="other" id="oref0135">University of Queensland /GSK/Dynavax. <ext-link ext-link-type="uri" xlink:href="https://advance.qld.gov.au/" id="intr0655">https://advance.qld.gov.au/</ext-link>covid-19-fast-facts. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib1055"><mixed-citation publication-type="other" id="oref0140">University of Tokoyo and Daiichi Sankyo. Our Company&#x02019;s Efforts to Limit the Spread of the Virus that Causes COVID-19 Accessed May 21, 2020., n.d.</mixed-citation></ref><ref id="bib1060"><element-citation publication-type="other" id="sbref0920"><person-group person-group-type="author"><name><surname>University of Waterloo</surname></name></person-group><article-title>University of Waterloo Developing DNA-based COVID-19 Vaccine. April 16</article-title><ext-link ext-link-type="uri" xlink:href="https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine" id="intr0660">https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1065"><element-citation publication-type="other" id="sbref0925"><person-group person-group-type="author"><name><surname>USask</surname></name></person-group><article-title>USask VIDO-InterVac Awarded $23M for COVID-19 Vaccine Research. April 23</article-title><ext-link ext-link-type="uri" xlink:href="https://news.usask.ca/articles/research/2020/usask-vido-intervac-awarded-23m-for-covid-19-vaccine-research.php" id="intr0665">https://news.usask.ca/articles/research/2020/usask-vido-intervac-awarded-23m-for-covid-19-vaccine-research.php</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1070"><element-citation publication-type="journal" id="sbref0930"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Lambe</surname><given-names>T.</given-names></name><name><surname>Spencer</surname><given-names>A.</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><name><surname>Purushotham</surname><given-names>J.N.</given-names></name><name><surname>Port</surname><given-names>J.R.</given-names></name><name><surname>Avanzato</surname><given-names>V.</given-names></name><name><surname>Bushmaker</surname><given-names>T.</given-names></name><name><surname>Flaxman</surname><given-names>A.</given-names></name><name><surname>Ulaszewska</surname><given-names>M.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Allen</surname><given-names>E.R.</given-names></name><name><surname>Sharpe</surname><given-names>H.</given-names></name><name><surname>Schulz</surname><given-names>J.</given-names></name><name><surname>Holbrook</surname><given-names>M.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Meade-White</surname><given-names>K.</given-names></name><name><surname>P&#x000e9;rez-P&#x000e9;rez</surname><given-names>L.</given-names></name><name><surname>Bissett</surname><given-names>C.</given-names></name><name><surname>Gilbride</surname><given-names>C.</given-names></name><name><surname>Williamson</surname><given-names>B.N.</given-names></name><name><surname>Rosenke</surname><given-names>R.</given-names></name><name><surname>Long</surname><given-names>D.</given-names></name><name><surname>Ishwarbhai</surname><given-names>A.</given-names></name><name><surname>Kailath</surname><given-names>R.</given-names></name><name><surname>Rose</surname><given-names>L.</given-names></name><name><surname>Morris</surname><given-names>S.</given-names></name><name><surname>Powers</surname><given-names>C.</given-names></name><name><surname>Lovaglio</surname><given-names>J.</given-names></name><name><surname>Hanley</surname><given-names>P.W.</given-names></name><name><surname>Scott</surname><given-names>D.</given-names></name><name><surname>Saturday</surname><given-names>G.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Gilbert</surname><given-names>S.C.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques (preprint)</article-title><source>Microbiology.</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.13.093195</pub-id></element-citation></ref><ref id="bib1075"><element-citation publication-type="other" id="sbref0935"><person-group person-group-type="author"><name><surname>Vaxart</surname></name></person-group><article-title>Vaxart Announces Additional Positive Pre-clinical Data for Its Oral COVID-19 Vaccine Program. April 30</article-title><ext-link ext-link-type="uri" xlink:href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-additional-positive-pre-clinical-data-its-oral/" id="intr0670">https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-additional-positive-pre-clinical-data-its-oral/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1080"><element-citation publication-type="other" id="sbref0940"><person-group person-group-type="author"><name><surname>Vaxil</surname></name></person-group><article-title>Vaxil Commences Preclinical COVID-19 Vaccine Trial and Files an Additional COVD-19 Patent. March 27</article-title><ext-link ext-link-type="uri" xlink:href="https://vaxil-bio.com/vaxil-commences-preclinical-covid-19-vaccine-trial-and-files-an-additional-covid-19-patent/" id="intr0675">https://vaxil-bio.com/vaxil-commences-preclinical-covid-19-vaccine-trial-and-files-an-additional-covid-19-patent/</ext-link><year>2020</year><comment>Accessed May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1085"><mixed-citation publication-type="other" id="oref0145">Vaxine Pty Ltd/Medytox. <ext-link ext-link-type="uri" xlink:href="https://www.biospectrumasia.com/news/37/16000/" id="intr0680">https://www.biospectrumasia.com/news/37/16000/</ext-link>vaxine-announces-covid-19-vaccine-collaboration-with-medytox.html. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib1090"><element-citation publication-type="journal" id="sbref0945"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name></person-group><article-title>Unexpected receptor functional mimicry elucidates activation of coronavirus fusion</article-title><source>Cell</source><volume>176</volume><year>2019</year><fpage>1026</fpage><lpage>1039</lpage><comment>e1015, doi:S0092-8674(18)31642-31648 [pii] 10.1016/j.cell.2018.12.028</comment><pub-id pub-id-type="pmid">30712865</pub-id></element-citation></ref><ref id="bib1095"><element-citation publication-type="journal" id="sbref0950"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.-J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, function, and Antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><comment>e6</comment><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib1100"><element-citation publication-type="journal" id="sbref0955"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>J.D.</given-names></name><name><surname>Hutter</surname><given-names>C.A.J.</given-names></name><name><surname>Zimmermann</surname><given-names>I.</given-names></name><name><surname>Earp</surname><given-names>J.</given-names></name><name><surname>Egloff</surname><given-names>P.</given-names></name><name><surname>Sorgenfrei</surname><given-names>M.</given-names></name><name><surname>H&#x000fc;rlimann</surname><given-names>L.M.</given-names></name><name><surname>Gonda</surname><given-names>I.</given-names></name><name><surname>Meier</surname><given-names>G.</given-names></name><name><surname>Remm</surname><given-names>S.</given-names></name><name><surname>Thavarasah</surname><given-names>S.</given-names></name><name><surname>Plattet</surname><given-names>P.</given-names></name><name><surname>Seeger</surname><given-names>M.A.</given-names></name></person-group><article-title>Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain</article-title><source>bioRxiv</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.16.045419</pub-id><comment>04.16.045419</comment></element-citation></ref><ref id="bib1105"><element-citation publication-type="journal" id="sbref0960"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Geng</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>J. Virol.</source><volume>94</volume><year>2019</year><fpage>e02015</fpage><lpage>02019</lpage><pub-id pub-id-type="doi">10.1128/JVI.02015-19</pub-id><comment>/jvi/94/5/JVI.02015-02019.atom</comment></element-citation></ref><ref id="bib1110"><element-citation publication-type="journal" id="sbref0965"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.-F.</given-names></name><name><surname>Tseng</surname><given-names>S.-P.</given-names></name><name><surname>Yen</surname><given-names>C.-H.</given-names></name><name><surname>Yang</surname><given-names>J.-Y.</given-names></name><name><surname>Tsao</surname><given-names>C.-H.</given-names></name><name><surname>Shen</surname><given-names>C.-W.</given-names></name><name><surname>Chen</surname><given-names>K.-H.</given-names></name><name><surname>Liu</surname><given-names>F.-T.</given-names></name><name><surname>Liu</surname><given-names>W.-T.</given-names></name><name><surname>Chen</surname><given-names>Y.-M.A.</given-names></name><name><surname>Huang</surname><given-names>J.C.</given-names></name></person-group><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>451</volume><year>2014</year><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.07.090</pub-id><pub-id pub-id-type="pmid">25073113</pub-id></element-citation></ref><ref id="bib1115"><element-citation publication-type="journal" id="sbref0970"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection</article-title><source>Hum. Vaccin. Immunother.</source><volume>13</volume><year>2017</year><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1296994</pub-id><pub-id pub-id-type="pmid">28277821</pub-id></element-citation></ref><ref id="bib1120"><element-citation publication-type="journal" id="sbref0975"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Hou</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Nan</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>T.</given-names></name><name><surname>Mu</surname><given-names>Y.</given-names></name><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>E.-M.</given-names></name></person-group><article-title>A nanobody targeting viral nonstructural protein 9 inhibits porcine reproductive and respiratory syndrome virus replication</article-title><source>J. Virol.</source><volume>93</volume><year>2019</year><pub-id pub-id-type="doi">10.1128/JVI.01888-18</pub-id></element-citation></ref><ref id="bib1125"><element-citation publication-type="other" id="sbref0980"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>Middle East Respiratory Syndrome Coronavirus (MERS-CoV). August 2</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intr0685">https://www.who.int/emergencies/mers-cov/en/</ext-link><year>2019</year><comment>Accessed on May 27, 2020., n.d</comment></element-citation></ref><ref id="bib1130"><element-citation publication-type="other" id="sbref0985"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>Draft Landscape of COVID-19 Candidate Vaccines. May 30</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" id="intr0690">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</ext-link><year>2020</year><comment>Accessed May 30, 2020., n.d</comment></element-citation></ref><ref id="bib1135"><element-citation publication-type="other" id="sbref0990"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>Novel Coronavirus(2019-nCoV) Situation Report &#x02013; 22. February 11</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf" id="intr0695">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf</ext-link><year>2020</year><comment>Accessed May27, 2020., n.d</comment></element-citation></ref><ref id="bib1140"><element-citation publication-type="journal" id="sbref0995"><person-group person-group-type="author"><name><surname>Willey</surname><given-names>S.</given-names></name><name><surname>Aasa-Chapman</surname><given-names>M.M.</given-names></name><name><surname>O&#x02019;Farrell</surname><given-names>S.</given-names></name><name><surname>Pellegrino</surname><given-names>P.</given-names></name><name><surname>Williams</surname><given-names>I.</given-names></name><name><surname>Weiss</surname><given-names>R.A.</given-names></name><name><surname>Neil</surname><given-names>S.J.</given-names></name></person-group><article-title>Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection</article-title><source>Retrovirology</source><volume>8</volume><year>2011</year><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-8-16</pub-id><pub-id pub-id-type="pmid">21401915</pub-id></element-citation></ref><ref id="bib1145"><element-citation publication-type="journal" id="sbref1000"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>R.K.</given-names></name><name><surname>Jiang</surname><given-names>G.S.</given-names></name><name><surname>Holmes</surname><given-names>K.V.</given-names></name></person-group><article-title>Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins</article-title><source>PNAS</source><volume>88</volume><year>1991</year><fpage>5533</fpage><lpage>5536</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.13.5533</pub-id><pub-id pub-id-type="pmid">1648219</pub-id></element-citation></ref><ref id="bib1150"><element-citation publication-type="journal" id="sbref1005"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>De Vlieger</surname><given-names>D.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Torres</surname><given-names>G.M.</given-names></name><name><surname>Van Breedam</surname><given-names>W.</given-names></name><name><surname>Roose</surname><given-names>K.</given-names></name></person-group><article-title>Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies (preprint)</article-title><source>Microbiology</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.26.010165</pub-id></element-citation></ref><ref id="bib1155"><element-citation publication-type="journal" id="sbref1010"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib1160"><mixed-citation publication-type="other" id="oref0150">Wuhan Institue of Biological Products/Snopharm.<ext-link ext-link-type="uri" xlink:href="https://www.fiercepharma.com/pharma-asia/" id="intr0700">https://www.fiercepharma.com/pharma-asia/</ext-link>china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving. Accessed on July 29, 2020., n.d.</mixed-citation></ref><ref id="bib1165"><element-citation publication-type="journal" id="sbref1015"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Gu</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Tu</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Ying</surname><given-names>T.</given-names></name></person-group><article-title>Identification of human single-domain antibodies against SARS-CoV-2</article-title><source>Cell Host Microbe</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.023</pub-id></element-citation></ref><ref id="bib1170"><element-citation publication-type="journal" id="sbref1020"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>F.</given-names></name><name><surname>Kohara</surname><given-names>M.</given-names></name><name><surname>Kitabatake</surname><given-names>M.</given-names></name><name><surname>Nishiwaki</surname><given-names>T.</given-names></name><name><surname>Fujii</surname><given-names>H.</given-names></name><name><surname>Tateno</surname><given-names>C.</given-names></name><name><surname>Yoneda</surname><given-names>M.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Matsushima</surname><given-names>K.</given-names></name><name><surname>Koyasu</surname><given-names>S.</given-names></name><name><surname>Kai</surname><given-names>C.</given-names></name></person-group><article-title>Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus</article-title><source>Virology</source><volume>454&#x02013;455</volume><year>2014</year><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2014.02.005</pub-id></element-citation></ref><ref id="bib1175"><element-citation publication-type="journal" id="sbref1025"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>M.S.</given-names></name><name><surname>Leung</surname><given-names>H.L.</given-names></name><name><surname>Li</surname><given-names>P.H.</given-names></name><name><surname>Cheung</surname><given-names>C.Y.</given-names></name><name><surname>Dutry</surname><given-names>I.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Da&#x000eb;ron</surname><given-names>M.</given-names></name><name><surname>Bruzzone</surname><given-names>R.</given-names></name><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Jaume</surname><given-names>M.</given-names></name></person-group><article-title>Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS</article-title><source>Hong Kong Med. J.</source><volume>22</volume><year>2016</year><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">27390007</pub-id></element-citation></ref><ref id="bib1180"><element-citation publication-type="journal" id="sbref1030"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>S.</given-names></name><name><surname>Ning</surname><given-names>W.</given-names></name><name><surname>Quanming</surname><given-names>Z.</given-names></name></person-group><article-title>Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)</article-title><source>Chinese Journal of Preventive Medicine</source><volume>54</volume><year>2020</year><pub-id pub-id-type="doi">10.3760/cma.j.cn112150-20200317-00366</pub-id><comment>E029&#x02013;E029</comment></element-citation></ref><ref id="bib1185"><element-citation publication-type="journal" id="sbref1035"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Garron</surname><given-names>T.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Tasneem</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell. Mol. Immunol.</source><volume>13</volume><year>2016</year><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmid">25640653</pub-id></element-citation></ref><ref id="bib1190"><element-citation publication-type="journal" id="sbref1040"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Ke</surname><given-names>J.-S.</given-names></name><name><surname>Qin</surname><given-names>Z.-L.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>L.-J.</given-names></name><name><surname>Yu</surname><given-names>J.-G.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>S.-Y.</given-names></name><name><surname>Qi</surname><given-names>Z.-T.</given-names></name></person-group><article-title>DNA vaccine of SARS-Cov S gene induces antibody response in mice</article-title><source>Acta Biochim. Biophys. Sin. (Shanghai)</source><volume>36</volume><year>2004</year><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1093/abbs/36.1.37</pub-id><pub-id pub-id-type="pmid">14732873</pub-id></element-citation></ref><ref id="bib1195"><element-citation publication-type="journal" id="sbref1045"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Qiu</surname><given-names>H.</given-names></name><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>A novel nanobody targeting middle east respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV</article-title><source>J. Virol.</source><volume>92</volume><year>2018</year><pub-id pub-id-type="doi">10.1128/JVI.00837-18</pub-id><comment>e00837-18, /jvi/92/18/e00837-18.atom</comment></element-citation></ref><ref id="bib1200"><element-citation publication-type="journal" id="sbref1050"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>N.S.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Li</surname><given-names>Y.M.</given-names></name><name><surname>Poon</surname><given-names>L.L.M.</given-names></name><name><surname>Xie</surname><given-names>Z.H.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Li</surname><given-names>P.H.</given-names></name><name><surname>Tan</surname><given-names>S.Y.</given-names></name><name><surname>Chang</surname><given-names>Q.</given-names></name><name><surname>Xie</surname><given-names>J.P.</given-names></name><name><surname>Liu</surname><given-names>X.Q.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.X.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People&#x02019;s Republic of China, in February, 2003</article-title><source>Lancet</source><volume>362</volume><year>2003</year><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14630-2</pub-id><pub-id pub-id-type="pmid">14585636</pub-id></element-citation></ref><ref id="bib1205"><element-citation publication-type="journal" id="sbref1055"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.-L.</given-names></name><name><surname>Wang</surname><given-names>X.-G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="bib1210"><element-citation publication-type="journal" id="sbref1060"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chakraborti</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Sheahan</surname><given-names>T.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Prabakaran</surname><given-names>P.</given-names></name><name><surname>Rockx</surname><given-names>B.</given-names></name><name><surname>Sidorov</surname><given-names>I.A.</given-names></name><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Vogel</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.-O.</given-names></name><name><surname>Wang</surname><given-names>L.-F.</given-names></name><name><surname>Baric</surname><given-names>R.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name><surname>Curtis</surname><given-names>K.M.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Dimitrov</surname><given-names>D.S.</given-names></name></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>PNAS</source><volume>104</volume><year>2007</year><fpage>12123</fpage><lpage>12128</lpage><pub-id pub-id-type="doi">10.1073/pnas.0701000104</pub-id><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref><ref id="bib1215"><element-citation publication-type="journal" id="sbref1065"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F.-C.</given-names></name><name><surname>Li</surname><given-names>Y.-H.</given-names></name><name><surname>Guan</surname><given-names>X.-H.</given-names></name><name><surname>Hou</surname><given-names>L.-H.</given-names></name><name><surname>Wang</surname><given-names>W.-J.</given-names></name><name><surname>Li</surname><given-names>J.-X.</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmid">32450106</pub-id></element-citation></ref><ref id="bib1220"><element-citation publication-type="other" id="sbref1070"><person-group person-group-type="author"><name><surname>Zydus Cadila</surname></name></person-group><article-title>Zydus Cadila Accelerates COVID-19 Vaccine Research. 8 April</article-title><ext-link ext-link-type="uri" xlink:href="https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research" id="intr0705">https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research</ext-link><year>2020</year><comment>Accessed on May 21, 2020., n.d</comment></element-citation></ref><ref id="bib1225"><element-citation publication-type="other" id="sbref1075"><person-group person-group-type="author"><name><surname>Zydus Cadila</surname></name></person-group><article-title>Zydus Cadila Looks to Expedite Covid-19 Vaccine Development February 17</article-title><ext-link ext-link-type="uri" xlink:href="https://www.pharmaceutical-technology.com/news/zydus-cadila-covid-19-vaccine/" id="intr0710">https://www.pharmaceutical-technology.com/news/zydus-cadila-covid-19-vaccine/</ext-link><year>2020</year><comment>May 21, 2020., n.d.</comment></element-citation></ref><ref id="bib1230"><mixed-citation publication-type="other" id="oref0155">Hannah Balfour: Biotech and academia collaborate on intranasal COVID-19 vaccine development:<ext-link ext-link-type="uri" xlink:href="https://www.drugtargetreview.com/news/59182/" id="intr0715">https://www.drugtargetreview.com/news/59182/</ext-link>biotech-and-academia-collaborate-on-intranasal-covid-19-vaccine-development/ 2 April 2020, n.d.</mixed-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>We thank Dr. McClive-Reed of Heath Research, Inc. for helpful suggestions. HL was partially supported by <funding-source id="gs0005">NIH</funding-source> grants AI131669, AI133219, AI140491, AI134568, AI140406, AI141178, and AI140726.</p></ack></back></article>